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Abstract
The physical properties of the multiple forms of y-glutamyltransferase in
human bile and serum have been studied and compared with those of the
enzyme present in human liver. Leucine aminopeptidase and alkaline
phosphatase were included, where appropriate, in the study to see whether the
findings were applicable on a wider basis. y-Glutamyltransferase is present in
human bile and serum mainly as hydrophobic forms, together with small
amounts of a low molecular mass hydrophilic form. The hydrophobic enzyme
in serum is of both high and intermediate molecular mass, whereas in bile it is
of high molecular mass only. In the presence of an adequate concentration of
bile salts, the hydrophobic forms in liver, bile and serum are converted to a
low molecular mass, hydrophobic form which reaggregates in the absence of
bile salts. When treated with papain, the hydrophobic form of the enzyme in
liver, bile and serum is converted to a low molecular mass hydrophiiic form
with identical physical properties to the hydrophilic form present in small
amounts in native bile and serum. Detailed study of the
y-glutamyltransferase fraction of intermediate molecular mass in serum from
patients with a variety of liver diseases showed it to consist of a complex
between y-giutamyltransferase and high density lipoprotein.
In a clinical study it was shown that the amount of high molecular mass
y-glutamyltransferase in serum, particularly when expressed as a percentage
of the total y-glutamyltransferase activity, was raised to a greater extent in
patients with extrahepatic biliary obstruction than in those with other liver
diseases. It was also shown that y-glutamyltransferase in serum could be
separated into several bands of intermediate molecular mass by
electrophoresis. One of these bands predominated in patients with
extrahepatic biliary obstruction but not in patients with other forms of liver
disease. Although either of these observations could be of value as a clinical
test to distinguish extrahepatic from intrahepatic jaundice, it was concluded
that the electrophoresis of serum y-glutamyltransferase was likely to be a
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The abbreviations in this thesis are those used by the Biochemical Journal
1983; 209: 1 - 27.
The following abbreviations has also been used:




y-Glutamyltranferase (yGT, EC 2-3.2.2), first described by Dakin and Dudley
(1913) as antiglyoxylase and investigated further by Woodward et ai. (1935), is
a dimeric glycoprotein widely distributed in many human tissues and body
fluids.
1.1 GENERAL PROPERTIES OF y-GLUTAMYLTRAN5FERASE
1.1.1 Catalytic actions
yGT catalyses 3 types of reaction:
1. The transfer reaction
This involves the transfer of the y-glutamyl residue from glutathione
and other y-glutamyl peptides to amino: acids or small peptides,
forming the y-giutamyl-amino acid and cysteinyl-glycine:
y-glutamyl-cysteinyl-glycine + amino acid (peptide)
A
V
y-glutamyl-amino acid (peptide) + cysteinyl-glycine.
In most biological systems glutathione is the y-glutamyl donor but any
y-glutamyl residue attached to a peptide, amino acid or even an
artificial chromogen can serve this purpose.
2
2. The autotransfer reaction
In this reaction, the y-glutamyl residue can be transferred from one





R may be an amino acid, a peptide or an artificial chromogen. The
reaction is blocked by the presence of an a-methyl group attached to
the y-glutamyl residue of the substrate itself.
3. Hydrolysis
Hydrolysis occurs with the formation of free glutamic acid and either





glutamic acid + N^R
1.1.2 Measurement of y-qlutamyltransferase activity
The earliest methods for the determination of yGT activity utilized
glutathione as substrate, were only semi-quantitative and were very time
consuming (Hanes et al., 1950, 1952; Ball et al., 1956; Hird and Springwell,
1954). Significant improvements came with the introduction of substrates
whose product could be determined colorimetrically. Szewczuk and Orlowski
(1960) used a-(N-y-DL-glutamyl)-aminoproprionitrile, the liberated a-
aminoproprionitrile being determined by reaction with bromine and coupling
with benzene-pyridine. Goidbarg et al. (1960, 1963) used N-(DL-y-glutamyl)
3
aniline and measured the liberated aniline by the Bratton-Marshall (1939)
reaction.
Further development came with the introduction of the a-and 3-isomers of
y-L-glutamyl naphthylamide as substrates (Albert et al., 1961; Orlowski and
Szewczuk, 1962; Glenner et al., 1962). Again, the Bratton-Marshall (1939)
reaction was used to measure the liberated a-or 3-naphthylamine, but this was
later improved by direct coupling with the diazonium salt Fast Blue B
(Kulhanek and Dimov, 1966).
The reactions described so far involve two-stage procedures - an enzyme
reaction followed by a reaction between one of the products and a chromogen.
The reaction was greatly simplified by Orlowski and Meister (1963) who used a
chromogenic substrate y-L-glutamyl-p-nitroanilide, thus eliminating the need
for the second part of the reaction sequence. They were able to monitor the
liberation of p-nitroaniline by measuring the rate of increase of absorbance at
410 nm. The procedure was modified by Orlowski (1965) for use as a two point
assay using the autotransfer reaction described in section 1.1.1. Further
improvements came with the introduction of glycylglycine as an acceptor, thus
increasing the rate of reaction (Rosalki et al., 1970; Jacobs, 1971; Beck and
Sammons, 1975; Tamaoki, 1975).
The general acceptance, however, that kinetic methods are better than two
point assays (Moss, 1972) led to the introduction of a kinetic assay at 25°C
using this substrate (Szasz, 1969). This was later optimised at 37°C by Rosalki
and Tarlow (1974) who overcame the poor solubility of the substrate by
dissolving it in acid. They recommended, however, that owing to acid
hydrolysis of the substrate occurring, each batch of substrate solution be used
within two hours.
The problem of poor solubility of y-L-glutamyl-p-nitroanilide was overcome by
the introduction of the 3-carboxy derivative (Szasz, 1974). At present, one or
other of these two substrates are now used in the vast majority of laboratories
measuring serum yGT activity.
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1.1.3 Enzyme mechanism
The y-glutamyl reaction follows a ping pong bi bi mechanism (Theodorsen and
Stromme, 1976; Tate et al., 1976; London, 1976; Shaw et al., 1977). The active
centre consists of 3 subsites (Tate and Meister, 1981); a donor site for y-
glutamyl binding and 2 acceptor subsites, one for cysteinyl and the other for
glycine moieties. Whereas the donor subsite can bind either L-or D-y-
glutamyl residues, the acceptor subsites are stereo-specific for L-amino acids
and dipeptides (Tate and Meister, 1974; Thompson and Meister, 1977). Kinetic
studies are consistent with the ping pong mechanism involving a y-glutamyl-
enzyme intermediate (Tate and Meister, 1974; Thompson and Meister, 1977).
glutathione + enzyme ^ y-glutamyl-enzyme
+ cysteinyl-glycine
y-glutamyl-enzyme + acceptor ^ y-glutamyl-acceptor
^ + enzyme
1.1.4 Inhibition
L-serine, in the presence of borate, has been shown to inhibit yGT from a
variety of sources (Revel and Ball, 1959; Tate and Meister, 1981). This pattern
of inhibition may be used as a test for the specificity of the enzyme since
neither compound alone inhibits it. Serine appears to occupy the active site
region that accepts the a-amino and a-carboxyl groups of glutathione, whilst
the borate anion forms a bridge complex between the hydroxyl group of serine
and an active site hydroxyl group (Tate and Meister, 1978). Glycine and
alanine have also been shown to inhibit the enzyme (Stromme and Theodorsen,
1976).
The concentrations of these amino acids in serum are too low to influence the
results of yGT measurements. However, the authors noted that alanine
inhibition may present a practical problem due to contamination with alanine,
if the same enzyme analyser, with automatic pipetting of the second
substrate, is used to measure both yGT and alanine aminotransferase
(EC 2.6.1.2, ALT).
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1.2 FUNCTIONS QF y-GLUTAMYLTRANSFERASE
1.2.1 The y-qlutamyl cycle
This cycle was first postulated and developed by Meister (1973, 1974) following
his own observations and the earlier work of Hanes et al. (1930, 1952, 1954)
and of Connel and Hanes (1956). According to the idea, yGT catalyses the
formation of y-glutamyl amino acids, using glutathione as y-glutamyl donor.
The y-glutamyl amino acids are then translocated into the cell where the free
amino acids are released. There then follows a series of reactions ending in
the re-synthesis of glutathione which may then be used again in the cycle.
This theory is consistent with the fact that yGT is localised at anatomic sites
where there is substantial amino acid transport. The cycle has been shown to
function in the renal tubule and is believed to be a major component of the
mechanism responsible for the reabsorption of all amino acids except proline
from the glomerular fitrate. It is also thought to be involved in the transport
of amino acids across the blood-brain barrier and to function in all cells
capable of transporting amino acids from body fluids.
1.2.2 Glutathione metabolism
The interaction between yGT and glutathione in the y-glutamyl cycle has
implied a possible role for the enzyme in regulating tissue glutathione levels.
After studying the enzyme from human liver, Shaw and Newman (1979)
suggested that yGT played a key role in glutathione catabolism.
1.2.3 Immunoglobulin secretion
yGT preparations obtained from mucous secretions and colostral milk have
been shown to contain secretory IgA (Binkley et al., 1975a, 1975b; Binkley and
Wiesmann, 1975). These authors suggested that yGT may be the secretory
component of IgA. This hypothesis is supported by the fact that high activities
of yGT have been demonstrated in cells that are rich in secretory IgA (Albert
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et al., 1964; Ross et al., 1973). The evidence, however, is inconclusive and it
may be that the function of IgA and yGT, which are distinct from one another,
both happen to be associated with secretion and absorption from common
surfaces.
1.3 DISTRIBUTION OF y-GLUTAMYLTRANSFERASE IN TISSUES
yGT has been shown to be present in many of the body tissues and there is
general agreement that the highest activity is in the kidney, followed by the
pancreas, liver and spleen (Goldbarg et al., 1960; Szczeklik et al., 1961;
Orlowski and Meister, 1970). In most other tissues the activity of the enzyme
is of the same order of magnitude as that in the plasma that supplies them
(Rosalki, 1973).
The earliest investigation into the intracellular location of yGT appears to
have been made by Szewczuk (1966). Using high speed centrifugation he
fractionated yGT obtained from human liver and kidney into soluble and
microsomal fractions comprising 10 and 90% respectively of total tissue
activity. The membrane-bound microsomal fraction can be solubilised by the
use of detergents such as Triton X-100 and deoxycholate or by treatment with
papain (Hughey and Curthoys, 1976).
The enzyme has been purified and extensively characterised from various
tissues, in particular liver and kidney (Miller et al., 1976; Hughey and
Curthoys, 1976; Huseby, 1977; Tate and Ross, 1977; Masuiki et al., 1982). In
all of these studies it was shown to consist of a heavy subunit, relative
molecular mass (M ) 40 000 - 60 000 and a light subunit, M 20 000 - 25 000.
—r 3 —r
The papain-solubilised yGT from rat kidney is soluble in aqueous solutions
whereas the Triton-solubilised is soluble only in the presence of detergents
(Hughey and Curthoys, 1976; Hughey et al., 1979). Papain treatment of the
Triton-solubilised enzyme produces a form identical to the papain-solubilised
enzyme. The light subunits of the papain and Triton-solubilised enzymes each
have an identical whereas the heavy subunit of the latter is about 52 amino
acid residues larger than the heavy subunit of the former. From these findings
it has been suggested that the papain-sensitive amino terminal sequence of
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amino acids of the large subunit is responsible for the membrane-association
of yGT (Tate and Meister, 1981).
1.4 y-GLUTAMYLTRANSFERASE IN FLUIDS
1.4.1 Seminal fluid
Very high levels of yGT are present in seminal fluid and the activity is thought
to arise more from spermatozoa than from prostate (Rosalki and Rowe, 1973).
1.4.2 Urine
Urine contains yGT with activities being 2-6 times the levels seen in plasma.
It is thought not to originate from plasma but from the normal aging of the
renal tract cells (Rosalki, 1975).
1.4.3 Bile
High values of yGT activity have also been reported to be present in hepatic
bile (Szczeklik et al., 1961; Orlowski, 1963; Rutenburg et al., 1963; Wenham,
1976). It is thought to originate from the cells of the liver by a process of
wear and tear.
1.5 SERUM y-GLUTAMYLTRAN5FERASE IN HEALTH AND DISEASE
It is now generally believed that yGT was the agent responsible for the
breakdown of glutathione by serum described by Woodward (1939). yGT
activity per se was first demonstrated in 1960 by two independent groups of
workers (Goldbarg et al., 1960; Szewczuk and Orlowski, 1960). Most studies
have shown that serum yGT activity is higher in males than in females
(Goldberg, 1980).
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Serum yGT activity is raised in a large number of diseases. However, despite
the relative activity of yGT in kidney being over 25 times the activity in liver
(Orlowski and Meister, 1970), elevations of serum yGT activity are usually
associated with liver disease and not kidney disease (Lum and Gambino, 1972).
Serum yGT activity is often increased in patients receiving enzyme-inducing
drugs in circumstances where liver damage is unlikely (Ewen and Griffiths,
1973; Bartels et al., 1975a; Skilien and Pierides, 1976). The increase is
believed to be due to microsomal enzyme induction and a good correlation has
been shown between the urinary excretion of D-glucaric acid (an established
index of microsomal enzyme induction) and serum yGT activity in this type of
patient (Bartels et al., 1975a). Other drugs are also thought to induce yGT
activity. Whitfield et al. (1973) noted an elevated serum yGT activity in a
patient receiving warfarin, a recognised enzyme inducing drug (Goldberg,
1980). Similarly, Bartels et al. (1975b), demonstrated that serum yGT
activities were elevated in children receiving the anti-inflammatory drug
aminopyrine.
The largest increases in serum yGT activity are observed in obstructive liver
disease, with values averaging 12 times the upper limit of the reference range
(Szczeklik et al., 1961; Rutenburg et al., 1963). In an extensive study of
patients with varying degrees of biliary obstruction, Lukasik and Richterich
(1965) found that the observed elevations of serum yGT and alkaline
phosphatase (orthophosphoric monoester phosphohydrolase, EC 3.1.3.1, ALP)
correlated with one another to a significant extent. Similar findings were
reported by Whitfield et al. (1972). Serum levels of yGT activity correlate to
some extent with the degree of cholestasis, being higher in complete than in
partial obstruction (Rutenburg et al., 1963; Kokot and Kuska, 1968).
Serum yGT activity is also often raised in patients with primary and
metastatic carcinoma of the liver (Szczeklik et al., 1961; Rutenburg et al.,
1963; Boone et al., 1974) and may be the only abnormal finding in some
patients with these conditions (Goldberg, 1980). Several authors have reported
that serum yGT levels show a similar behaviour to those of 5 1 nucleotidase (5'-
nucleotide phospholydrolase, EC 3.1.3.5, 5'NT) in patients with metastatic
liver disease. Korstein et al. (1974), after studying serum levels of both
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enzymes sequentially, reported that they paralleled one another. Kolaric et
al. (1975) in a series of 30 patients with histologically proven metastatic liver
disease showed serum yGT and 5'NT activities to be elevated in all 30 patients
whereas positive liver scans were evident in only 20 out of the 30. In another
study of 79 patients, Chaimoff et ai. (1975) showed an increased serum yGT
activity in all but 2 of the patients where liver metastases were proven. In
contrast, some workers (Baden et al., 197 1; Kim et al., 1977) have concluded
that measurement of serum yGT activity was too non-specific in the diagnosis
of liver secondaries, with too many false positives. It has been suggested
(Goldberg, 1980) that the measurement of serum yGT activity may be of
greater value in excluding liver secondaries rather than detecting their
presence.
Serum yGT activity is elevated in diseases associated with liver cell damage,
as well as those associated with partial or complete biliary obstruction. Villa
et _al. (1966) and Keane et al. (1973) showed that almost all patients with viral
hepatitis had a raised serum yGT activity. However, the degree of elevation
did not correlate with that of ALT or asparate aminotransferase (EC 2.6.1.1,
A5T) (Whitfield et al., 1972). The measurement of yGT may be of prognostic
value since it has been suggested that if yGT activity fails to return to normal
after viral hepatitis, then the patient is more likely to develop cirrhosis or
chronic active hepatitis (Villa et al., 1966; Ideo and Dioguardi, 1970; Jacobs,
1972).
Perhaps the clinical value of serum yGT is greatest in screening patients for
alcoholic liver disease or in monitoring whether they abstain from alcohol
(Rosalki et al., 1970; Rosalki and Rau, 1972; Rollason et al., 1972). In a study
of 146 patients, Whitehead et al. (1978) found that serum yGT activities
reflected alcohol consumption. In general, yGT levels return to normal when
drinking ceases as long as there is no histological evidence of liver damage
(Rosalki et al., 1970; Rosalki and Rau, 1972; Wu et al., 1976).
Serum yGT activities may also be raised in non-hepatic disorders. Patients
with extensive burns tend to show greater increases in serum yGT than those
with small burns (Coombes et al., 1978). The authors suggested that the
increase was due to increased protein catabolism associated with renal failure.
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After myocardial infarction, serum yGT activity rises slowly, compared with
the activities of other enzymes, to reach a peak at about the 10th day after
the onset of the episode (Agostini et al., 1965; Hedworth-Whitty et al., 1967;
Ravens et al., 1969; Rosalki at al., 1970; Szczeklik et al., 1972). The
mechanism is not known with certainty but Agostini et al. (1965) suggested,
and this has been supported by others (Ewen and Griffiths, 1971; Szczeklik et
al., 1972) that it is due to an increased rate of yGT synthesis. This occurs due
to the repair of the myocardium and, in particular, the vascular endothelium
which is rich in yGT (Ravens et al., 1969). However, others have suggested it
to be due to liver damage secondary to congestive cardiac failure (Betro et al.,
1973; Cooke and Carter, 1973; Connell, 1973).
In summary, serum yGT activity is elevated in ail forms of liver disease, but
its measurement is of little discriminatory value. However, yGT is probably
the most sensitive overall index of liver disease presently available.
1.6 THE CONCEPT OF ISOENZYMES AND MULTIPLE ENZYME FORMS
It has for a long time been known that certain enzymes occur in different
forms in different tissues; for example, prostatic acid phosphatase may be
distinguished from the erythrocytic enzyme by its marked inhibition by L-(+)-
tartrate. From the middle 1950's onwards there was considerable
improvement of separative technigues using net molecular charge. Interest
was particularly stimulated by the application of zone electrophoresis using
starch and later polyacrylamide gel as the supporting medium together with
the adaptation of histochemical methods to visualise the separated enzyme
forms within the gel (Hunter and Markert, 1957). In 1959, Markert and Moller
introduced the term 'isozyme' to denote the different molecular forms in
which proteins with similar enzyme specificity may exist. Some authors
preferred the term 'isoenzyme' and conseguently the 2 terms have been used
interchangeably. The Commission on Biological Nomenclature of the
International Union of Biochemistry Commission on Biochemical Nomenclature
(1977) has approved both terms but has recommended that their use be
restricted to those enzymes whose occurrence as multiple forms arises from
genetically determined differences in the primary structure, due to the
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presence of more than one structural gene. Those enzymes variants that arise
by post-transcriptional modification, due to association with variable amounts
of charged moieties or polymerisation, are not considered to be isoenzymes
and the term 'multiple forms' is considered appropriate. The Commission
recommended labelling these multiple forms on the basis of their
electrophoretic mobility. For these reasons the multiple forms of yGT
described and studied further in this thesis will be referred to as multiple
forms. At present there is no evidence to suggest that they arise from
different structural genes and so the term isoenzyme is considered
inappropriate.
1.7 MULTIPLE FORMS OF y-GLUTAMYLTRAN5FERASE IN HEALTH AND
DISEASE
1.7.1 Electrophoresis in different media
Many different electrophoretic media have been used to separate the multiple
forms of yGT present in serum. Broadly speaking, they are of two types;
(a) those that separate mainly on the basis of charge differences; (b) those
which combine charge differences with molecular sieving effects. Paper,
cellulose acetate, agar and agarose come into the first category and starch gel
and polyacrylamide gel are included in the second.
Serum from healthy individuals: Using electrophoresis on paper, Kokot and
Kuska (1965) first demonstrated that in healthy subjects most of the serum
yGT activity is present as two bands, one in the a^- and the other in the a
globulin region. Subsequent studies, using a variety of media have reported
similar findings (Jacyszyn and Laursen, 1968; Miyazaki and Okumura, 1972;
Patel and O'Gorman, 1973; Azzopardi and Jayle, 1973; Hetland £t al., 1975;
Kok et al., 1978; Burlina, 1978; Wenham et al., 1979).
Serum from patients with liver disease: In contrast to the situation in healthy
individuals, much confusion exists as to the number of bands present in the
serum of patients with liver disease. The confusion is made worse because few
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studies have attempted to relate the bands obtained using different media to
one another. The only common findings appear to be that; (a) the two bands
present in normal sera are also present in liver disease but usually in increased
amounts; (b) bands of additional mobility are also present (Kokot and Kuska,
1965; Orlowski and Szczeklik, 1967; Kokot and Kuska, 1968; Rutenburg et al.,
1967; Rosalki at al., 1970; Lehmann et al., 1970; Miyazaki and Okumura, 1972;
Patel and O'Gorman, 1973; Hetland et al., 1975; Degenaar et al., 1976; Kok et
al., 1978; Burlina , 1978; Wenham et al., 1979).
Bile: In comparison to serum, few electrophoretic studies have been carried
out on human bile and the literature is somewhat less confusing. Using
agarose, Jacyszyn and Laursen (1968) demonstrated activity in the 8-globulin
position following electrophoresis of hepatic bile obtained from 'T' tube
drainage. Wenham et al. (1978a) also detected a band in this position, as well as
two additional bands in the albumin-a^- and o^-globulin regions.
Polyacrylamide gel electrophoresis of hepatic bile results in most yGT activity
remaining at the origin together with a minor zone with mobility between 70
and 80% of that of albumin (Huseby, 1978; Wenham et al., 1978a).
1.7.2 Gel filtration chromatography
Serum: Gel chromatography of serum with normal yGT activity on Sephadex
G200 (Orlowski et al., 1965; Orlowski and Szczeklik, 1967) shows three peaks
of activity of high, intermediate and low (greater then 600 000, 250 000 -
450 000 and about 100 000 respectively). In liver disease, most workers also
find three peaks of high, intermediate and low (Orlowski et al., 1965; Kokot
and Kuska, 1968; Wenham et al., 1979). However, Ideo and co-workers (Ideo
and Ronchi, 1972; Ideo et al., 1972) found only one peak, which eluted in the
void volume on Sephadex G200 and whose they estimated to be 200 000.
Their findings seem difficult to interpret since proteins that elute in the void
volume of Sephadex G200 have an of at least 600 000. In obstructive liver
disease the elevation in serum yGT activity appears to be associated mainly
with an increase in the peak of high (high Mr yGT) (Orlowski et al., 1965;
Orlowski and Szczeklik, 1967; Kokot and Kuska, 1968; Wenham at al., 1979).
However, no clinical evaluations appear to have been made of the
measurement of this fraction as an aid in the differential diagnosis of liver
disease.
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In patients with viral hepatitis the increase in serum yGT activity was found
to be evenly distributed between the high and intermediate peaks (Orlowski
et al., 1965) although Kokot and Kuska (1968) found it to be associated only
with the high yGT peak.
Bile: Fewer studies have been made on hepatic bile but all confirm that the
vast majority of the enzyme is present as high yGT (Indirani and Hill, 1977;
Huseby, 1978; Wenham et al., 1978a).
1.7.3 Relationship between the fractions obtained by electrophoresis and gel
chromatography
Serum: In contrast to the large number of studies using one or other
technique, few attempts have been made to relate the fractions obtained by
gel chromatography to the bands seen on electrophoresis. Of the few studies
made, the main conclusion appears to be, (1) that the high peak remains at
the origin after polyacrylamide or starch gel electrophoresis, (2) the
intermediate M peak travels in the a ^-globulin region, and (3) the low
peak travels in the a^-globulin region (Orlowski and Szczeklik, 1967; Wenham et
al., 1979).
1.8 WHY DOES SERUM yGT ACTIVITY RISE IN LIVER DISEASE?
Enzymes such as ALT, that are present in the soluble cytoplasm of the liver
cell, are believed to be released into the circulation by simple leakage of the
cell contents following hepatocellular injury. In contrast, yGT is largely
membrane-bound and so this simple explanation is not applicable. Several
alternative theories have been proposed to explain the release of yGT into the
circulation in liver disease. For clarity they have been categorised in terms of
the physical processes that are thought to occur:
(1) The retention theory (Rutenburg et al., 1963). This proposed that
the increase in serum yGT activity in liver and biliary-tract disease
was due to the failure of the normal excretion of the enzyme in the
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bile. However, the earlier suggestions that biliary excretion was a
factor in the clearance of plasma enzymes such as ALP have not been
supported by recent work. For example, injection of purified human
placental ALP (measured by utilising its heat stability) into normal
subjects and patients with biliary obstruction resulted in decay curves
in serum that did not differ from those of other plasma proteins and
which were similar in the two groups (Clubb et ai., 1965). It is,
therefore, unlikely that accumulation of yGT from either hepatic or
non-hepatic sources occurs due to biliary stasis, and so to a large
extent the retention theory has been abandoned.
(2) The hepatogenic theory (Orlowski, 1963). This proposes that
hepatic yGT synthesis (and subsequent release) can be induced by
certain liver diseases.
(3) The membrane fragment theory (Shinkai and Akedo, 1972;
De Broe et al., 1975). This suggests that in liver disease, fragments of
liver cell membranes to which yGT, ALP, adenosine triphosphatase
(EC 3.6.1.4, ATPase) and other proteins are attached, may break off
the main membrane. These particulate fragments may then, by a
process which remains rather obscure, find their way into the
circulation.
(4) The theory of elution (Moss, 1980). This proposes that if yGT is
an enzyme of the outer surface of cellular membranes, it may be
eluted from the cellular surface into the plasma in certain disease
states. At present however, the mechanism behind such an elution
process remains unknown.
None of these 4 theories, however, has yet gained widespread acceptance
and so the mechanisms behind the rise in serum yGT activity in liver disease
are unknown.
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1.9 OTHER ENZYMES SHOWING INCREASED SERUM ACTIVITY IN LIVER.
DISEASE
Leucine aminopeptidase (aminopeptidase (microsomal), EC 3.4.11.2, LAP) and
ALP are two other enzymes, whose serum activities are elevated in liver
disease. Like yGT they not only show particularly high levels of activity in
obstructive liver disease but also originate from the hepatocyte plasma
membrane.
1.9.1 Leucine aminopeptidase
Leucine aminopeptidase catalyses the reaction:
R may be a peptide or an amino acid and the leucine moiety may be replaced
by other amino acids although the enzyme is not as efficient at hydrolysing
these. Although the recommended name for the enzyme is aminopeptidase
(Enzyme Commission recommendations, 1972), leucine derivatives are the
commoner substrates in its determination and leucine aminopeptidase is the
term used most frequently in the literature. For these reasons the term
leucine aminopeptidase is used throughout this thesis.
Leucine aminopeptidase is present in most human tissues, particularly the cells
of the liver and biliary tract (Nachlas et al., 1957; Kowlessar et al., 1960) and
it is located mainly on the plasma membrane (Emmelot et al., 1968).
Like yGT, LAP is present in serum. Serum activities are raised in a wide
variety of liver diseases (Harkness £t al., 1960; Pineda et al., 1960; Kowlessar
et al., 196 1; Batsakis et al., 1968). The highest values occur in extrahepatic
biliary obstruction (Horky et al., 1967, Batsakis et al., 1968).
RNH- leucine + -— leucine + RNH^
Leucine aminopeptidase occurs in multiple forms in serum and bile but it is not
known whether these represent true isoenzymes (see section 1.6).
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Electrophoresis of normal serum on paper or cellulose acetate gives rise to a
single band of LAP activity in the a ^-globulin region (Smith et al., 1962;
Meade and Rosalki, 1964). Extra bands appear in the albumin, and 3-
globulin region in liver disease.
In a study of patients receiving anticonvulsant drug therapy, Rundle and Sudell
(1973) obtained up to 5 types of LAP pattern after performing serum
electrophoresis on cellulose acetate. They concluded that LAP electrophoresis
was of little clinical value. After electrophoresis on starch gel, large amounts
of LAP activity are obtained at the origin in patients with liver disease, and
this is especially so in patients with obstructive jaundice (Kowlessar et al.,
I960; Kowlessar et ai., 196 1).
Electrophoresis of hepatic bile gives rise to a single LAP band, coincident with
the band observed in normal serum (Kowlessar et al., 1960; Kowlessar et al.,
After gel chromatography on Sephadex G200 2 peaks of LAP activity are
obtained, eluting with the 19S and 7S protein peaks (Ideo and Ronchi, 1972).
The 19S peak appears to contribute a greater proportion towards total activity
in lesions involving cholestasis. LAP activity is also obtained in the void
volume after gel chromatography of sera from patients with hepatic cancer on
Sepharose 4B (Shinkai and Akedo, 1972).
1.9.2 Alkaline phosphatase
Alkaline phosphatase catalyses the reaction:
R may be any aliphatic, aromatic or heterocyclic grouping or even an artificial
chromogen.
Alkaline phosphatase is present in many human tissues with large amounts
being found in liver, intestine, bone, spleen and placenta. Normal serum also
196 1)
ROHPQ3H2 + H20 ROH + HOPO^
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contains ALP activity, and this is raised in liver disease, especially
extrahepatic biliary obstruction and liver metastases, and in bone disease, e.g.
Paget's disease and osteomalacia.
There are three isoenzymes of ALP, as defined in section 1.6, namely those
from liver/bone, intestinal and placental sources (McKenna at al., 1979).
Multiple forms of the liver band may be present in serum.
Electrophoresis of normal serum usually shows a predominant liver ALP band,
a minor bone band and sometimes one of intestinal origin (see below). The
liver isoenzyme has the same mobility as the a^-globulins following
electrophoresis of normal serum on paper, cellulose acetate or agar (Baker and
Pellagrino, 1954; Wieme and Demeulanaere, 1970; Price and Sammons, 1974).
After electrophoresis on starch or polyacrylamide gel it forms a narrow band
with about half of the mobility of albumin (Moss et al., 196 1; Hodson et al.,
1962; Hill and Sammons, 1967; Price and Sammons, 1974).
In patients with liver disease, the liver band is increased in intensity and
another fraction is usually present. This fraction travels ahead of the normal
liver band on cellulose acetate and agar, and remains at the origin on
poiyacrylamide and starch gel (Kowlessar et al., 1959; Hill and Sammons, 1967;
Wieme and Demeulenaere, 1970; Price and Sammons, 1974).
The bone band may usually be seen as a diffuse zone running immediately
behind the liver band on the different media. In healthy individuals and in
patients with liver disease it is usually present as a minor band but is usually
the main fraction present in patients with bone disease. When present, the
intestinal band runs well behind the liver and bone bands on the different
media.
Electrophoresis of hepatic bile shows a main ALP band remaining at the origin
on polyacrylamide gel but travelling ahead of the liver band, in the a ^-globulin
region on cellulose acetate (Price and Sammons, 1974; Fritch and Adams-Park,
1972).
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After gel chromatography of normal serum a main peak of ALP activity is
observed eluting with the 7S proteins with an estimated to be 200 000
(Estborn, 1964; Price and Sammons, 1974). In patients with liver disease this
fraction is increased, along with a fraction of high and which is present in
large amounts, that elutes in the void volume on Sepharose 4B or Sephadex
G200 (Fennelly et al., 1969; Shinkai and Akedo, 1972; Price and Sammons,
1974; Fritch and Adams-Park, 1974). In hepatic bile nearly all of the ALP
activity is of high M , eluting in the void volume after gel chromatography on
Sephadex G200 (Price and Sammons, 1974).
1.10 AIMS QF THE STUDY
In broad terms, the aims of the study were two-fold. Firstly, an investigation
of the physical properties of yGT in bile and serum and secondly, a clinical
assessment of the measurement of the multiple forms of yGT in patients with
liver disease. The other hepatocyte plasma membrane enzymes LAP and ALP
were included in the study, where it was considered appropriate, to see
whether the findings for yGT were applicable on a wider basis.
The multiple forms of yGT present in serum might a) represent true
isoenzymes, b) consist of aggregates of low yGT with lipid and protein
(Huseby, 1978) or c) consist of membrane fragments (De Broe et al., 1975).
Experiments were designed involving electrophoretic, chromatographic,
immunochemical and other physico-chemical techniques to investigate the
physical properties of yGT in serum and in bile. It was hoped that the results
obtained might provide evidence for or against the above theories.
The details of the study were as follows:
1. To investigate the nature of yGT in hepatic bile.
2. To investigate the nature of serum yGT in health and disease.
3. To undertake a clinical evaluation of the multiple forms of serum yGT
in liver disease.
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4. To compare the physical properties of yGT in human liver, with the
enzyme in bile and serum and to undertake preliminary in vitro elution
studies in an attempt to test the elution theory.
The results of the above investigations each form a complete chapter of this
thesis. At the end of each of these chapters I have discussed my findings in
relation to the results of similar investigations carried out by other workers.
In the final chapter under the heading 'General Discussion' I have attempted to
tie the results of each of the chapters together on a more general basis, and




This chapter describes the general methods used throughout the work
presented in this thesis. The validation and verification of methods is
included, where appropriate, in this section to ease the flow of the text in
subsequent sections. Where a method is used only once, for a particular
experiment, it is described at the appropriate point in the text.
2.1 MATERIALS
2.1.1 Measurement of enzyme activities
y-Glutamyltransferase: y-Glutamyl-p-nitroanilide from Boehringer, Lewes,
Sussex, U.K. (Boehringer). Tris (hydroxymethyl) methylamine (Analar grade)
from British Drug Houses Chemicals Ltd., Poole, Dorset, U.K. (B.D.H.).
Glycylglycine from Koch Light, Colnbrook, Bucks, U.K. (Koch Light).
Leucine aminopeptidase: L-Leucine-p-nitroanilide from Sigma Chemical Co.,
Poole, Dorset, U.K. (Sigma).
Alkaline phosphatase: p-Nitrophenyl phosphate from Boehringer. 2-Amino-2-
methyl-propan-l-ol, diethanolamine and magnesium chloride from B.D.H..
2.1.2 Fractionation of multimolecular enzyme forms
Electrophoretic media: Acrylamide, N:N'-methylene-bis-acrylamide from
Eastman Kodak, Liverpool, U.K. (Kodak). 4-30% Polyacrylamide gradient gels
from Pharmacia, Uppsala, Sweden (Pharmacia).
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Enzyme staining reagents: y-L-Glutamyl-a-naphthylamide, L-leucyl-8-
naphthylamide-HCl from Koch Light. a-Naphthyl acid phosphate (potassium
salt), Fast Blue B and 4-aminodiphenylamine diazonium sulphate from Sigma.
Glacial acetic acid (Analar grade) from B.D.H..
Gel Chromatography; Sephadex G200 and Sephacryl S300 from Pharmacia.
2.1.3 Physical and biochemical properties
Thyroglobulin, ferritin, catalase, aldolase and lactate dehydrogenase from
Pharmacia. Papain (twice crystallised), sodium deoxycholate, sodium
glycocholate, sodium glycochenodeoxycholate, 2,5-diphenyl oxazole and 1,4 -di
(2-(5-phenyl oxazoyD-benzene from Sigma. Triton X-100 from B.D.H.. Bacto-
agar from Difco laboratories, Detroit, Michigan, U.S.A.. Agarose E.F. from
LKB, Croydon, U.K.. Antisera to apolipoprotein A and apolipoprotein B from
Hoechst, Hounslow, Middlesex, U.K.. Naphthalene black from George Gurr
Ltd., London. Fat Red 3 from Corning AC1, Palo Alto, California, U.S.A.
(Corning). Dextran sulphate (M = 13 000) from Sochibo, Boulogne, France. All
other chemicals were of analytical grade from B.D.H..
2.1.4 Equipment
8600 Reaction rate analyser, chromatography columns, Uvicord II
absorptiometer and recorder, 2070 Ultrorac II fraction collector, 1200
Varioperpex peristaltic pump and 2103 electrophoresis power supply from LKB,
Bromma, Sweden. Sequential Multiple Analyser plus Computer (S.M.A.C.)
from Technicon, Basingstoke, U.K.. Electrophoresis tank for polyacrylamide
vertical gel slabs from Raven Scientific, Haverhill, Suffolk, U.K..
Electrophoresis tank for polyacrylamide gradient gels from Universal
Scientific Ltd., London, U.K.. SP800 spectrophotometer from Pye-Unicam,
Cambridge, UK.. Prepspeed 65 ultracentrifuge from M.S.E., Fisons Scientific,
Loughborough, Leicestershire, U.K.. Sorvail RC 2B superspeed centrifuge
from Dupont Instruments, Newtown, Connecticut, U.S.A..
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2.2 MEASUREMENT OF ENZYME ACTIVITIES
2.2.1 y-Glutamyltransferase
Principle of method: yGT catalyses the following reaction:
y-L-glutamyl-p-nitroaniiide p-nitroaniline
glycylglycine y-L-glutamyl-glycylglycine
This was measured in serum and bile using the method of Rosalki and Tarlow
(1974).
50 p. 1 of serum or bile was mixed with 1.0 ml of Tris (115 mmol/1) -
glycylglycine (138 mmol/1) buffer, pH 8.5. The reaction was initiated by the
addition of 100 p.1 of y-L-glutamyl-p-nitroanilide (104 mmol/1) dissolved in





The formation of p-nitroaniline was monitored at 410 nm using an LKB
reaction rate analyser. A molar extinction coefficient of 8500 for
p-nitroanaline was used in the calculations (Wenham, 1976).
The method was modified for the measurement of yGT activity in column
fractions. 0.5 ml of column effluent was mixed with 0.5 ml of Tris-
glycylglycine buffer pH 8.5, the composition of which had been adjusted to
give the same final reaction conditions as set out above.
Within-batch precision was determined by making 20 replicate measurements
of enzyme activity both in a commercial quality control material and also a
pool of column effluent. Between-batch precision was determined from 20
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measurements of enzyme activity in the same materials as above, each
measurement being made on a different day. The precision figures for the
assay are shown in Table 2.1.
Table 2.1
Precision of the various enzyme estimations
Enzyme Within-batch Between-batch
mean (U/l) S.D. (U/l) C.V. (%) S.D. (U/l) C.V. (%)
yGT (Serum, bile) 135 7.0 5.2 7.3 5.4
LAP (serum, bile) 185 7.2 3.9 9.1 4.9
ALP (serum) 177 3.4 1.9 3.5 2.0
ALP (bile) 112 2.7 2.4 3.4 3.0
yGT (column fractions) 7.6 0.19 2.5 0.3 4.0
LAP (column fractions) 3.8 0.22 5.7 0.3 7.9
ALP (column fractions) 1.3 0.078 6.0 0.085 6.5
2.2.2 Leucine aminopeptidase




Leucine aminopeptidase activity was measured in serum and bile using a
modification of the method of Szasz (1967).
50 pi of sample was mixed with 1.0 ml of Tris (100 mmol/l)-HCl buffer, pH 7.7.
The reaction was initiated by the addition of 50 pi of L-leucine-p-nitroanilide








The liberated p-nitroaniline was monitored at 410 nm in an LKB 8600 reaction
rate analyser. A molar extinction coefficient of 8500 for p-nitroaniline was
used in the calculations (Wenham, 1976).
The method was modified to measure enzyme activity in column fractions.
0.5 ml of effluent was mixed with 0.5 ml of Tris-HCl buffer, pH 7.7, the
composition of which had been altered so as to give the same final reaction
conditions as set out above.
The precision figures for the measurement of LAP activity in serum, bile and
column fractions are shown in Table 2.1.
2.2.3 Alkaline Phosphatase
Principle of method: The reaction catalysed by alkaline phosphatase is:
p-nitrophenylphosphate p-nitrophenol
This was measured in serum using a S.M.A.C.. The substrate was 10 mmol/1
p-nitrophenyl phosphate in 0.6 mol/1 2-amino-2-methyl- 1-propanol buffer, pH
10.2, containing 0.5 mmol/1 magnesium chloride (Bowers and McComb, 1966).
Alkaline phosphatase activity was measured in hepatic bile using the method
of McComb and Bowers (1972).
+
h2o inorganic phosphate
50 pi of bile was mixed with 1.0 ml of diethanolamine buffer (0.9 mol/1, pH
10.2) containing 0.5 mmol/1 magnesium chloride. The reaction was initiated by
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the addition of 100 (il of p-nitrophenylphosphate (154 mmol/l) dissolved in
0.9 mol/l diethanolamine, pH 10.2, containing 0.5 mmol/l magnesium chloride.
The final reaction conditions were:
The liberation of p-nitrophenol was monitored at 410 nm in an LKB 8600
reaction rate analyser. A molar extinction coefficient of 18,800 for
p-nitrophenol was used in the calculation (McComb and Bowers, 1972).
Enzyme activity in column fractions was measured after mixing 0.5 ml of
effluent with 0.5 ml of diethanolamine buffer (1.8 mol/l), pH 10.2, containing
1.0 mmol/l magnesium chloride; the final concentrations being the same as set
out above.
The precision figures for the 3 methods used to measure alkaline phosphatase
are shown in Table 2.1.
2.3 GEL CHROMATOGRAPHY
This was performed using either Sephadex G200 or Sephacryl 5300.
2.3.1 Sephadex G2Q0 gel chromatography
Reagents: Sephadex G200 was obtained as dry beads. 20 mmol/l Tris-HCl
buffer, pH 8.0, at 20°C was used, containing 50 mmol/l sodium chloride to
prevent protein trailing. The buffer was degassed prior to use. A 2.6 x 65 cm
LKB chromatography column was used.
Preparation of the gel: The dry Sephadex beads were soaked in an excess of






Packing of the column: The column was mounted vertically with the bottom
outlet leading to a beaker. A packing extension was connected to the top of
the column enabling the whole length of the main column to be packed. The
main column was then filled with buffer and any air bubbles removed by
drawing the buffer up and down through the bottom outlet with a 60 ml
syringe. The column was then tilted slightly, the packing extension filled with
the gel slurry and the column allowed to pack under gravity for 6 h.
When packing was complete, the extension was removed, the top put on the
column and the bottom outlet connected to an LKB peristaltic pump. Buffer
was then pumped upwards through the column at a flow rate of 15.6 ml/h for
24 h before use to enable complete equilibration of the gel with buffer.
Sample application: This was achieved using a syringe connected by a 'T' piece
to the input buffer line. 2.6 ml fractions were collected using an LKB 2070
Ultrorac fraction collector and the protein content monitored at 280 nm using
an LKB Uvicord II flow-through absorptiometer.
2.3.2 Sephacryl 5300 gel chromatography
This was performed in a manner similar to that described for Sephadex G200.
However, 2.6 x 65 and 2.6 x 96 cm columns were used, the upward flow rate
was 28 ml/h and 3.5 ml fractions were collected.
2.3.3 Calibration of the gel columns:
Each Sephadex and Sephacryl column was calibrated by performing gel
chromatography on proteins of known M . Calibration curves were prepared
by plotting their elution volume (linear scale) versus (logarithmic scale).
Whenever any alteration in flow rate occurred, due to suspected infection or
admission of air bubbles, the column was immediately dismantled, repacked
and recalibrated. Each time a column was repacked, a fresh calibration curve
was prepared since different columns, although ostensibly of the same
dimensions, possessed slightly different elution characteristics. Minor
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between-column variations in the elution volumes of the various peaks were
observed, but their estimated M did not differ by more than 5%. The
—r
calibration proteins and their methods of detection are listed in Table 2.2 and
typical calibration curves are shown in Figs. 2.1 and 2.2.
Table 2.2




IgM* 900 000 "In house" kinetic immuno-
turbidemetry
Thyroglobulin* 669 000 absorption at 280 nm
Ferritin 440 000 absorption at 280 nm
Catalase 232 000 absorption at 280 nm
Aldolase 158 000 absorption at 280 nm
Lactate
dehydrogenase
140 000 Pyruvate/NADH substrates;




Albumin 67 000 absorption at 280 nm
* These proteins were not used to calibrate Sephadex G200 columns.
2.3.4 Investigation into the choice of gel matrix for the chromatography of
yGT in human serum
Originally it was intended to perform gel chromatography of yGT in human
serum using Sephadex G200. This medium has a relatively small mesh size and
excludes all molecules of M greater than 600 000. However, during the
course of this study, a newer gel matrix, Sephacryl S300, became generally
available. This is an ally 1 dextran, cross-linked with N,N'-methylene-bis-
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Figure 2.1 Typical calibration curve for a 65 x 26 cm column of
K
Sephadex G200. The void volume (elution volume of blue
dextran) was approximately 105 ml.
5-




Figure 2.2 Semi-logarithmic plot of elution volume versus M in the
r

















acrylamide, giving a rigid gel with a carefully controlled pore size that
excludes all molecules of greater than 1 000 000. It was decided,
therefore, to compare the elution profiles of yGT obtained after performing
gel chromatography of human serum on both Sephadex G200 and Sephacryl
5300. It was postulated that Sephacryl S300 would give better resolution of
those yGT fractions eluting near to or with the void volume than when
Sephadex G200 was used.
Procedure: 2 ml of serum from a patient with alcoholic cirrhosis was
subjected to both Sephadex G200 and Sephacryl S300 gel chromatography.
yGT activity was measured in both eluates and the elution profiles compared.
Results: Chromatography of the serum on 2.6 x 65 cm columns of both media
gave rise to three peaks of yGT activity of high, intermediate and low M^
(Figs. 2.3 and 2.4). For reasons given in later sections of this thesis, these
were called Peak 1 (yGT), Peak 2 (yGT) and Peak 4 (yGT) respectively. Peaks
1 (yGT) and 2 (yGT) were poorly resolved following chromatography on
Sephadex G200 but were completely resolved using Sephacryl S300. Although
Peaks 2 (yGT) and 4 (yGT) were not as clearly resolved by Sephacryl S300 as
by Sephadex G200, it was thought that the resolution could be improved by
increasing the column length to 95 cm. Gel chromatography of 1 ml of serum
from another patient with alcoholic cirrhosis confirmed this to be the case
(Fig. 2.5).
Because Sephacryl S3Q0 gave greater resolution of the yGT fractions, it was
chosen as the medium for the chromatography of yGT in human serum.




This was performed in vertical 7% gel slabs (140 x 165 x 3 mm) using the
Raven IN96 electrophoresis apparatus and a modification of the method of
Azzopardi and Jayle (1973).
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Figure 2.3 Elution profile of yGT following gel chromatography on a 65











Figure 2.4 Gel chromatography on a 63 x 2.6 cm column of 5ephacryl
S300 of yGT present in serum from a patient with alcoholic
cirrhosis.
Peakl Peak 2 Peak 4
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Figure 2.5 Elution profile of yGT following gel chromatography on a 95
x 2.6 cm of Sephacryl S300, of serum from a patient with
alcoholic cirrhosis.
Peakl Peak 2 Peak 4
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Stock gel monomer: 280 g of acrylamide and 7.35 g of N,N'-methylene-bis-
acrylamide dissolved in 1 litre of distilled water.
Catalyst; 1.4 g of ammonium persulphate per litre of distilled water.
Gel buffer: Tris (720 mmol/l)-HCl, pH 8.9, containing 2.3 ml of N,N,N',N'-
tetramethyl-ethylene diamine (Temed) per litre.
Electrode Buffer (Davis 1964): Tris (50 mmoi/l)-glycine (384 mmol/l) pH 8.3,
diluted 1 in 10 (v/v) with distilled water immediately prior to use.
Preparation of gel: 1 volume of stock gel monomer, 2 volumes of catalyst
solution and 1 volume of gel buffer were mixed and the gel cast. n-Butanol
was layered on top of the solution to prevent the inhibition of the
polymerisation process by oxygen.
Electrophoresis: This was performed either for 2-3 at a constant voltage of
250 V or overnight at a constant voltage of 70 V.
Polyacrylamide gradient gel electrophoresis
This was carried out on vertical 4 - 30% polyacrylamide gradient gels, pre-
equilibrated with Tris (5.0 mmol/l) -glycine (38.4 mmol/l), pH 8.3 for 15 min at
125 V. Electrophoresis was performed for 20 min at 70 V followed by 18 h at
125 V at room temperature.
Localisation of enzyme activity
This was performed in two stages using a modification of the method of
Wenham et al. (1978b).
Preparation of substrate-buffer-acceptor solution: 165 mg of y-L-glutamyl-a-
naphthylamide were dissolved in 2 ml of 0.5 mol/1 HC1. The solution was
mixed with 30 ml of buffer-acceptor solution (Tris (220 mmol/l) - glycylglycine
(110 mmol/l), pH 7.4, at 37°C) and the pH brought back to 7.4 by the addition








Preparation of staining solution; 50 mg of Fast Blue B diazonium salt was
dissolved in 50 ml of 10% (v/v) acetic acid.
dish containing substrate-buffer-acceptor solution. The gel was washed twice
with distilled water and immersed in staining solution for 15 min at room
temperature. The gels were placed in distilled water and stored in the dark
until photographed.
2.4.2 Leucine aminopeptidase
7% Polyacrylamide gel and polyacrylamide gradient gel electrophoresis
Electrophoresis was carried out exactly as described for yGT.
Localisation of enzyme activity
This was done in 2 stages using a slight modification of the method of
Goldbarg and Rutenburg (1958).
Preparation of substrate-buffer solution: 20 mg of L-leucyl-8-naphthylamide
were dissolved in 2 ml of 10 mmol/1 HC1 and the solution added to 50 mi of
200 mmol/1 Tris-HCl buffer, pH 7.7. The final compostion of the solution was:







Staining solution: This was prepared exactly as for yGT.
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Procedure: This was exactly as for yGT.
2.4.3 Alkaline phosphatase
Polyacrylamide gel electrophoresis
This was performed in uniform vertical 7% gel slabs (140 x 165 x 3 mm) using
the Raven IN96 electrophoresis apparatus and a modification (Warwick et al.,
1972) of the method of Kaplan and Rogers (1969).
Stock gel monomer: 13.3 g of acrylamide and 0.7 g of N, N'-methylene-bis-
acrylamide per litre of distilled water.
Gel and electrode buffer: Tris (370 mmol/l)-borate, pH 9.5, containing
0.5 mmol/1 magnesium chloride.
Catalyst and accelerator: 0.07 g of ammonium persulphate and 0.4 ml of
Temed per 80 ml of gel-buffer solution.
Casting of gel: Equal volumes (40 ml) of buffer and stock gel monomer were
mixed, the appropriate amount of persulphate and Temed added and the gel
cast.
Electrophoresis: This was performed either for 2 - 3 h at a constant voltage of
250 V or overnight at a constant voltage of 70 V.
Polyacrylamide gradient gel electrophoresis
4 - 30% polyacrylamide gradient gels, pre-equilibrated with 370 mmol/l Tris-
borate buffer, pH 9.5, containing 0.5 mmol/1 magnesium chloride, for 15 min
at 125 V, were used. Electrophoresis of the samples was performed for 20 min
at 70 V, followed by 18 h at 125 V at room temperature.
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Localisation of enzyme activity
This was performed in a single stage using a-naphthyl acid phosphate as
substrate.
Substrate-staining solution: 39.2 mg of a-naphthyl acid phosphate and 100 mg
of 4-amino-diphenylamine diazonium sulphate were dissolved in 100 ml of Tris-
borate buffer. The final composition of the solution was:
a-naphthyi acid phosphate 0.75 mmol/l
4-amino diphenylamine diazonium sulphate 2mmol/l
magnesium chloride 0.5 mmoi/l
pH 9.5
Procedure: The 7% slab or gradient gel was incubated for 3 h at 37°C in a dish
containing the buffer-substrate-staining solution. The gels were then cleared
by immersion in 10% (v/v) acetic acid solution.
2.4.4 Calibration of the polyacrylamide gradient gels
Each gradient gel was calibrated by running a mixture of proteins of knowm
in one of the slots on the gel. At the end of each run, the track
corresponding to the marker proteins was sliced from the rest of the gel and
stained for protein by immersion in a solution of 1% naphthalene black in
glacial acetic acid-absolute methanol (10/90 (v/v)). The gel was then
destained in pure solvent for 24 h and the migration distance of each marker
protein measured. A calibration curve was constructed by plotting migration
distance against log M . The proteins used for calibration are listed in
Table 2.3 and a typical calibration curve is shown in Fig. 2.6. To reduce
between-gel variation to a minimum, the mixture of calibration proteins was
run with every gel.
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Bovine serum albumin •




Proteins used to calibrate polyacrylamide gradient gels
Protein M
—r
Bovine serum albumin 67 000




2.3 FRACTIONATION OF SERUM LIPOPROTEINS USING POLYANION5
This was performed using the method of Burstein et al. (1970) with either
sodium phosphotungstate-magnesium chloride, or manganese chloride-dextran
sulphate as precipitant.
2.5.1 Fractionation using sodium phosphotunqstate and magnesium chloride
Procedure: 400 pi of 4% (w/v) sodium phosphotungstate and 100 pi of 2 moi/l
magnesium chloride were added to 4 ml of serum. The final concentration of
phosphotungstate (0.36% (w/v)) and magnesium chloride (44 mmol/1) caused
immediate selective precipitation of both LDL and VLDL. The precipitate was
removed by centrifugation for 10 min at 6000 x 3, washed with 0.9% (w/v)
NaCl containing 0.36% (w/v) phosphotungstate and 44 mmol/l magnesium
chloride, and redissolved in 4 ml of 0.9% (w/v) NaCl.
1.8 ml of 4% (w/v) sodium phosphotungstate was added to 2.2 ml of the LDL-
and VLDL-free supernatant (final concentrations: sodium phosphotungstate
2% (w/v), magnesium chloride 25 mmol/l). The precipitate, consisting largely
of y-globulin was removed by centrifugation for 10 min at 6000 x £ and
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discarded. 400 pi of 2 mol/l magnesium chloride was added to the supernatant
(final concentrations: sodium phosphotungstate 1.8% (w/v), magnesium
chloride 200 mmol/1). After 2 h, when precipitation of the HDL was complete
the mixture was centrifuged for 30 min at 20 000 x g. The precipitate was
washed in 0.9% (w/v) NaCl containing 2% (w/v) sodium phosphotungstate and
200 mmol/1 magnesium chloride, and redissolved in 2.2 ml of 0.9% (w/v) NaCl.
Enzyme activities were determined on all of the fractions.
2.3.2 Fractionation using dextran sulphate and manganese chloride
20 pi of 10% (w/v) dextran sulphate and 200 pi of 1 mol/l manganese chloride
were added to 4 ml of serum. At these final concentrations (dextran sulphate
0.047% (w/v), manganese chloride 47 mmol/1) the LDL and VLDL were
completely and selectively precipitated. The precipitate of LDL and VLDL
was removed by centrifugation for 10 min at 6000 X g, and washed with 0.9%
(w/v) NaCl containing 0.047% (w/v) dextran sulphate and 47 mmol/1 manganese
chloride. The LDL and VLDL precipitate was then redissolved in 4 ml of 0.9%.
(w/v) NaCl.
300 pi of 1 mol/l manganese chloride and 120 pi of 10% dextran sulphate were
added to 1.55 ml of the LDL-and VLDL-free supernatant (final concentrations:
manganese chloride 190 mmol/1, dextran sulphate 0.65% (w/v)). Precipitation
of the HDL fraction began at once and was complete within 2 h. The mixture
was centrifuged for 30 min at 20 000 x g, the supernatant collected and the
HDL precipitate washed with 0.9% (w/v) NaCl containing 190 mmoi/1
manganese chloride and 0.65% (w/v) dextran sulphate. The HDL precipitate
was redissolved in 1.55 ml of 0.9% (w/v) NaCl. Enzyme activities were
determined on all of the fractions and the solutions kept for further study.
2.5.3 Lipoprotein electrophoresis
This was performed both upon sera and on the lipoprotein fractions obtained
after polyanion precipitation on 1% (w/v) agarose using the Corning Universal
electrophoresis apparatus. 1 to 5 pi of sample was added to the prepared wells
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in the gel (Universal Electrophoresis Film) and electrophoresis performed for
35 min at 90 V using 50 mmol/1 barbitone buffer, pH 8.6, (Martin and Franglen,
1954).
The lipoprotein fractions were made visible by staining for 5 min with a 0.2 g/l
solution of Fat Red 7B in methanol-water (80/20, v/v) then cleared in an equal
volume of methanol-water.
2.5.4 Validation of the lipoprotein fractionation method
This was done by performing lipoprotein electrophoresis (section 2.5.3) upon
the various fractions obtained after treatment of serum with polyanions. The
fractions were; i) whole serum; ii) serum after precipitation of LDL and VLDL;
iii) serum after precipitation of HDL, LDL and VLDL; iv) LDL and VLDL (8
lipoprotein); v) HDL (a-lipoprotein). Figure 2.7 confirms that the various
lipoprotein fractions were precipitated as described in sections 2.5.1 and 2.5.2.
2.6 IMMUNOELECTROPHORESIS
This was carried out using a modification (Seidel et ai., 1970) of the
Scheidegger technique (1955).
Preparation of gel; A 1% (w/v) solution of agar was prepared by heating 1 g of
agar in 100 ml of barbitone buffer, pH 8.6, in a boiling water bath for 60 min.
When the agar had completely dissolved, the solution was cooled to 60°C ready
for use.
The glass plates, 8.4 x 9.4 cm were cleaned with ethanol, pre-warmed in an
oven and placed on a level surface. 14 ml of warm fluid agar was pipetted on
to each plate and when the gels had formed, the plates were placed in a
refrigerator for 30 min to ensure firmness. Five wells, each 2 mm in diameter
and spaced 7.5 mm apart, were cut starting 4 cm from the anodal end of each
plate. Each well was filled with 4 p.1 of sample.
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Figure 2.7 Electrophoresis on agarose gei of whole serum and the
fractions obtained after polyanion precipitation, stained for
lipid. 1, whole serum; 2, supernatant after precipitation of
LDL plus VLDL; 3, supernatant after precipitation of LDL
plus VLDL, and HDL; 4, LDL plus VLDL; 5, HDL; 6, whole
serum.





Electrophoresis; The plates were placed on the cooling plate, with a layer of
water between them and the cooling plate, to provide thermal conduction.
The wicks were placed on the gels to cover 1 cm of both the anodal and
cathodal ends. Electrophoresis was performed for 2 h at 200 V.
Immunoprecipitation; Troughs 1 mm wide and 3 cm long were cut between the
wells, filled with the appropriate antiserum and left to diffuse overnight at
room temperature in a moist chamber to form any precipitin arcs. The gels
were washed for 2 days in 0.9% (w/v) NaCl and stained for protein by soaking
in 1% (w/v) naphthalene black dissolved in glacial acetic acid-methanol (10/90,
(w/v)) for 60 s, and destained in glacial acetic acid-methanol (10/90, (w/v)) for
24 h.
Alternatively the precipitin arcs were stained for yGT activity using the
method described in section 2.4.1.
2.7 MEASUREMENT OF BILE SALT CONCENTRATIONS IN BILE AND
SERA
The primary bile salts, cholate and chenodeoxycholate, are present in serum
and bile as either their taurine- or glycine-conjugates. In this study both were
measured as their total conjugates by specific radio-immunoassays (Beckett et
al., 1978; Beckett et al., 1979).
Reagents
Stripped serum: Bile salt-free serum was prepared by mixing 1 litre of pooled
normal human serum with 1 litre of Amberiite XAD2 resin. The mixture was
then stirred for 1 h at room temperature and left overnight at 4°C. The
mixture was filtered and the serum kept for further use.
Working buffer: This contained disodium hydrogen orthophosphate
(83 mmol/1), sodium dihydrogen orthophosphate (45 mmol/l), sodium azide
(15 mmol/1) and sodium chloride (16 mmol/l) adjusted to pH 7.2 with 1 mol/1
sodium hydroxide. 750 ml of stripped serum was added to 4250 ml of this
buffer and the mixture stored at room temperature.
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Wash solution: Ammonium sulphate (270 g/1).
_ 125 125
T racers; These consisted of I- glycocholate and I-
glycochenodeoxycholate - 250 pCi/10 ml. These had been prepared by the
iodination of histamine-glycocholate and histamine-glycochenodeoxycholate.
Working reagents; These were prepared by mixing either 25 pi of antiserum to
glycocholate or 50 pi of antiserum to glycochenodeoxycholate with 30 pi of
the appropriate tracer and 10 ml of working buffer.
Standard curve; A 1 mmol/l solution of both bile salts was prepared in
absolute methanol. From this stock solution, standard curves were prepared
by diluting the stock standard with working buffer. The standard values were
0, 0.5, 1.0, 2.0, 4.0, 6.0, 12.0 pmol/1.
Procedure
10 pi of sample was diluted with 200 pi of working reagent, mixed and
incubated for at least 2 h at room temperature. 3 ml of wash solution was
added to precipitate the bound fraction, mixed, and the mixture centrifuged at
3000 rpm at 4°C for 15 min. The tubes were then inverted to discard the
supernatant and the bound fraction counted in a Nuclear Enterprises 1600 y
counter.
The standard curve was fitted to a non-linear 4 parameter log-logistic model
(Healy, 1972) using an iterative least-squares technique on a Hewlett-Packard
9821 calculator.
The coefficients of variation for both methods following repeat analysis of a
serum pool 20 times, were 7.0% within-batch and 8.0% between-batch at a
mean bile salt concentration of 3.0 pmol/l.
Sera with high bile salt concentrations were diluted 1/10 or 1/100 with




PHYSICAL PROPERTIES OF y-GLUTAMYLTRANSFERASE IN HUMAN BILE
Studies using gel chromatography on Sephadex G200 or similar material appear
to show that yGT in human bile is present mainly as a high form (Wenham
et al., 1978a; Crofton and Smith, 1981a). However, if sodium deoxycholate is
included in the chromatography buffer, a low form of yGT is recovered in
the eluate (Huseby, 1978). This suggests that yGT may be present in human
bile in a low form and that the high form obtained by gel
chromatography may merely represent an artefact caused by aggregation of
the enzyme in aqueous media in which no detergent, i.e. bile salt, is present.
The normal concentration of total bile salts in hepatic bile ranges from 3 to
45 mmol/1 (Scharschmidt, 1982). Their critical micellar concentration is
estimated to be 0.9 to 2.2 mmol/1, and so most will be present in micellar form
(Tamesue and Juniper, 1967). However, bile salts are normally present in bile
as conjugates of glycine or of taurine and the conjugates of cholate and of
chenodeoxycholate are present in greater concentrations than those of
deoxycholate (Sjovall, 1960; Heaton, 1972). The detergent properties of the
bile salts, as measured by their rate of dissolution of cholesterol monohydrate,
increase inversely with their polarity, and so decrease in the order
deoxycholate, chenodeoxycholate, cholate (Carey, 1982). Experiments are
described in this chapter involving the bile salt sodium deoxycholate that are
designed to test the hypothesis that high M yGT is in fact an artefact of
reaggregation. In order to mimic physiological conditions in bile more closely,
the effects of glycocholate and glycochenodeoxycholate are also studied.
Leucine aminopeptidase and alkaline phosphatase have also been assumed to be
present in native bile as high forms since, after exclusion chromatography
on Sephadex G200 or Sepharose 6B, they also elute mainly in the void volume
(Price et al., 1972; Crofton and Smith, 1981a). These enzymes have also been
included in the study to see whether they may be present in bile in forms
comparable to those of yGT.
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3.1 SAMPLES USED IN THE STUDY
Twelve samples of hepatic bile were obtained from patients with percutaneous
or 'T' tube drainage of the common bile duct. The ranges of enzyme activities
were as follows; yGT, 100-1340 U/L; LAP 22-126 U/L; ALP, 75-1150 U/L.
3.2 EFFECT OF PAPAIN TREATMENT ON yGT IN HUMAN BILE
Papain (EC 3.4.22.2) is a non-specific proteolytic enzyme obtained from
papaya latex. Unlike the serine proteases, trypsin (EC 3.4.21.4) and
chymotrypsin (EC 3.4.21.1) it is insensitive to inhibition by
di-isopropylfluorophosphate and depends upon a highly reactive sulphydryl
group for its activity (Dixon and Webb, 1979). It has been shown to release
LAP almost completely from rat liver membrane (Emmelot et _al., 1968), and
more recently, to convert yGT in bile to a lower Mf form (Huseby, 1978). A
study of the effect of papain on yGT in human bile therefore seemed
worthwhile in an attempt to gain further insight about yGT in hepatic bile.
Samples of bile were incubated with papain (lg/lOg protein) overnight at 20°C
in the presence of 100 mmol/1 cysteine. Preliminary experiments were
performed to determine whether papain had any effect per se on yGT activity.
The results presented in Table 3.1 show that papain treatment of bile resulted
in slight decrease in the yGT activity.
Table 3.1
yGT activity after digestion of human bile with papain








3.3 EFFECT OF BILE SALTS ON yGT ACTIVITY IN HUMAN BILE
Prior to gel chromatography or electrophoresis, bile salts, equal to the
concentration used in the appropriate buffer, were added to the bile. The bile
was assayed for yGT activity before and immediately after the addition, to
see whether bile salts also had an effect upon yGT activity per se. It was then
stored for 12 h prior to further investigation. Bile salts appeared to have no
effect upon total yGT activity (Table 3.2).
Effects of different concentrations of added bile salts on yGT activity in bile
Table 3.2






















* The endogenous concentration of conjugated cholate was 2.7 mmol/1 and of
conjugated chenodeoxycholate 0.5 mmol/1.
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3.4 GEL FILTRATION CHROMATOGRAPHY ON SEPHADEX G200
3.4.1 General nomenclature used throughout this chapter
A fairly clear pattern of results emerged following these investigations. In
order to simplify the description, the peaks were named separately in order of
their elution from the gel column:
Peak 1 (yGT), Peak 1 (LAP), Peak 1 (ALP): void volume for all enzymes.
Peak 2 (yGT): a variable peak with estimated in the range 300 000 -
600 000 (this wide range may well represent partial dissociation of enzyme
complexes whilst running on the column).
Peak 2T (yGT), Peak 2T (LAP), Peak 2T (ALP): major intermediate
peaks eluting when 0.1% (w/v) Triton X-100 is present in the elution buffer.
Peak 3 (yGT), Peak 3 (LAP), Peak 3 (ALP): major low peaks eluting
when bile salts are present in the eluting buffer. These peaks reaggregate in
the absence of bile salts.
Peak 4 (yGT), Peak 4 (LAP), Peak 4 (ALP): minor peaks in bile, eluting
after the corresponding Peak 3 and found in small amounts in native bile, and
in large amounts (for yGT and LAP) in bile which has been previously treated
with papain. These peaks do not undergo reaggregation in the absence of bile
salts.
3.4.2 Gel chromatography performed in the absence of detergents
After gel chromatography of native bile, between 87 and 97% of yGT activity
eluted in the void volume, with the remainder eiuting as Peak 4 (yGT)
(Fig. 3.1). The recovery of yGT activity ranged from 80 - 100%.
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Elution profile of y^T in human bile following












3.4.3 Gel chromatography performed in the presence of sodium deoxycholate
Bile was incubated with an equal volume of 25 mmol/1 sodium deoxycholate for
1 h at room temperature and 1 - 2 ml of the mixture subjected to gel
chromatography with varying concentrations of deoxychoiate in the elution
buffer. The main peak of yGT activity changed from Peak 1 (yGT), when
there was no deoxycholate in the elution buffer, to Peak 3 (yGT), when the
deoxycholate concentration was more than 5 mmol/1. However, at
intermediate deoxycholate concentrations, a significant amount of activity
was present as Peak 2 (yGT) with little or no activity in Peak 3 (yGT)
(Fig. 3.2).
3.4.4 Gel chromatography performed in the presence of qlycocholate and
qlycochenodeoxycholate
Gel chromatography with increasing concentrations of glycocholate in the
elution buffer resulted in a decrease in the amount of yGT activity eluting in
the void volume and the appearance of a fraction eluting as Peak 3 (yGT).
Between 41 and 56% of yGT activity eluted as Peak 3 (yGT), when the elution
buffer contained 20 mmol/1 glycocholate (Fig. 3.3).
Similarly, when glycochenodeoxychoiate was included in the elution buffer at
increasing concentrations, the main peak of activity changed from Peak 1
(yGT) to Peak 3 (yGT). At a concentration of 5 mmol/1, 31 - 95% of yGT
activity eluted as Peak 3 (yGT) (Fig. 3.4). At intermediate concentrations of
glycochenodeoxychoiate, significant amounts of yGT activity eluted as Peak 2
(yGT), with little or no activity in Peak 3 (yGT).
3.4.5 Gel chromatography performed in the presence of Triton X-100
Triton X-100 (polyoxyethylene glycol (9-10) p-t-octyl-phenol) is a fairly mild
non-ionic detergent and has been used to solubilize membrane proteins (Sohn
and Marinetti, 1974; Helenius and Simons, 1975). More recently, high M ALP
in human bile has been converted by Triton X-100 to a form of lower M
51
Gel chromatography on Sephadex G200 of yGT in
deoxycholate-treated hepatic bile, with increasing
concentrations of deoxycholate in the eluting buffer. O ,
no deoxycholate; ■ , 1.2 mmol/1 deoxycholate; # ,
7 mmol/1 deoxycholate.
PEAK 1 PEAK 2 PEAK 3 PEAK A
(TGT) (TGT) (TGT) (TGT)
ELUTION VOLUME (ml)
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Figure 3.3 Gel chromatography on Sephadex G200 of yGT in human bile
with increasing concentrations of glycocholate in the elution
buffer. O , 5 mmoi/1 glychocholate; | , 10 mmol/1








Figure 3.4 Eiution profile of yGT following gel chromatography of
human bile on Sephadex G200, with increasing
concentrations of glycochenodeoxycholate in the eiution
buffer. O , 1 mmoi/1 glycochenodeoxycholate; ■ ,






(Crofton and Smith, 198 la). It therefore seemed worthwhile to study the
effects of Triton X-100 on yGT in hepatic bile.
Two volumes of bile were mixed with 1 volume of 0.3% (w/v) Triton X-100 and
stored at 4°C overnight. Gel chromatography of the treated bile (2 ml) with
0.1% (w/v) Triton X-100 in the elution buffer resulted in 90% of yGT activity
eluting as Peak 2T (yGT). Small amounts of activity still eluted as Peak 1
(yGT) with the remainder as Peak 4 (yGT) (Fig. 3.5).
3.4.6 Gel chromatography of papain-treated bile
After papain treatment, gel chromatography in the absence of detergents
resulted in a decrease in yGT activity eluting in the void volume, together
with an increase in activity eluting as Peak 4 (yGT) (Fig. 3.6).
The estimated of the various fractions obtained after gel chromatography
in the presence and absence of bile salts is shown in Table 3.3.
Table 3.3




Peak 1 > 600 000
Peak 2T 333 000
Peak 3 16 1 000*
Peak 4 115 000
* Mean value, range 157 000 - 165 000, due to between-column variation.
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Figure 3.5 Elution profile of
bile on Sephadex
the elution buffer.
yGT after gel chromatography of human
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Figure 3.6 Sephadex G2D0 gel chromatography of papain-treated yGT
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3.5 7% POLYACRYLAMIDE GEL ELECTROPHORESIS
3.5.1 Electrophoresis in the absence of detergents
After electrophoresis, untreated bile showed a major band of activity at the
origin (Band I (yGT)), with a small amount of activity present as a band with
approximately 70 - 80% of the mobility of serum albumin (Band IV (yGT))
(Fig. 3.7). Occasionally a weak additional band of intermediate mobility was
seen. Electrophoresis of concentrated pooled fractions corresponding to Peak
1 (yGT) and Peak 4 (yGT) obtained by gel chromatography, revealed that Peak
1 (yGT) gave rise to Band 1 (yGT), and that Band IV (yGT) had identical
mobility to concentrated pooled fractions corresponding to Peak 4 (yGT)
(Fig. 3.8).
3.5.2 Electrophoresis performed in the presence of detergents
Electrophoresis in 7% polyacrylamide gel, pre-equilibrated with the running
buffer containing 5 mmol/1 glycochenodeoxycholate or deoxycholate, showed
the following pattern. Both native bile and Peak 3 (yGT), which was obtained
by performing gel chromatography in the presence of bile salts, contained a
main zone of activity (Band III (yGT)), which migrated just ahead of the zone
due to Peak 4 (yGT) (Band IV (yGT)) (Fig. 3.9). This suggests that the Peak 3
form of yGT possesses a greater negative charge than the Peak 4 form.
When both the gel and running buffer had been equilibrated with 0.1% (w/v)
Triton X-100, electrophoresis of Peak 2T (yGT), obtained after gel
chromatography in the presence of 0.1% (w/v) Triton X-100, gave rise to a
single band, the mobility of which was about 10% of that of Band IV (yGT)
(Band IIT (yGT)) (Fig. 3.10).
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Figure 3.7 7% polyacrylamide slab gel electrophoresis of hepatic bile
stained for yGT activity. 1, bile A; 2, bile B.
1 2




Electrophoresis on 7% polyacrylamide gel of hepatic bile
and the fractions obtained after gel chromatography,




Figure 3.9 Polyacrylamide slab gel electrophoresis in 5 mmol/1
glycochenodeoxycholate, stained for yGT activity. 1, bile








Figure 3.10 Polyacrylamide slab gel electrophoresis in 0.1% (w/v) Triton
X-100 of the fractions obtained after gel chromatography.






3.6 POLYACRYLAMIDE GRADIENT GEL ELECTROPHORESIS
The Peak 1 form of yGT had an M of greater than 1 000 000, whereas the
Peak 3 and Peak 4 forms were both of low M . Peak 4 (yGT), obtained from
untreated bile, had a lower jv^ than Peak 3 (yGT), obtained from bile treated
with either deoxycholate or glycochenodeoxycholate. The estimated values
of the various fractions are shown in Table 3.4.
Table 3.4
Estimated IM values of the various yGT fractions obtained from hepatic




Peak 1 > 1000 000 *
Peak 3 130 000 125 000 - 135 000
Peak 4 104 000 98 000 - 110 000
* Not estimable
3.7 STUDIES ON THE FRACTIONS OBTAINED BY GEL
CHROMATOGRAPHY
3.7.1 Studies on peak 3 (yGT)
The experiments were designed to determine if Peak 3 (yGT) reaggregated in
the absence of bile salts.
A concentrated pool of Peak 3 (yGT), obtained by performing gel
chromatography in the presence of 5 mmol/1 deoxycholate, was
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rechromatographed a) in the presence of 5 mmol/1 deoxycholate and b) in the
absence of bile salts. The elution profiles (Fig. 3.11) show that, in the
presence of deoxycholate, Peak 3 (yGT) retains its low form, whereas
chromatography in the absence of deoxycholate causes complete reaggregation
of the yGT into a form with greater than 600 000.
3.7.2 Studies on Peak 4 (yGT)
These experiments were designed to determine if Peak 4 (yGT), when added to
bile, was able to form high Mr complexes of yGT.
Samples of bile, containing 0.24 U of yGT activity, were added to 0.5 ml of
concentrated Peak 4 (yGT) eluate, also containing 0.24 U of yGT activity.
The volumes were made up to 2 ml with Tris-HCl buffer, pH 8.0, and the
solutions incubated for 6 h and 30 h, before being subjected to gel
chromatography in the absence of bile salts. The elution profiles (Fig. 3.12)
show that the incubation did not alter the chromatographic behaviour of Peak
4 (yGT).
3.8 INVESTIGATION INTO POSSIBLE BILE SALT BINDING TO yGT
This was carried out in an attempt to demonstrate if bile salt binding to yGT
could account for the differences in size and charge between the yGT in
Peaks 3 and Peak 4.
3.8.1 Radioactive counting
This was performed in a Packard Tri-Carb liquid scintillation spectrometer
(model 3255) using a toluene: Triton X-100 (2:1 (v/v)) based scintillant
containing 2,5-diphenyl oxazole, 4 g/1 and 1, 4 - di (2-(5-phenyi oxazolyl)) -
benzene, 0.2 g/1. 5 ml of scintillant was mixed with 100 p.1 of aqueous sample
in polyethylene vials and counted with a standard deviation of less than 1%.
Samples were corrected for quenching by the channels ratio method. The
64
Figure 3.11 Rechromatography on Sephadex G200 of Peak 3 (yG"0 in the
presence # , or absence O » 5 mmol/i deoxycholate.
PEAK 1 PEAK 3
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Figure 3.12 Gel chromatography on Sephadex G200 of human bile
before and after incubation with Peak 4 (yGT). O , before;









counting .efficiency was determined by counting known amounts of [ CJ
deoxycholate in hexadecane and was found to be 67%.
3.8.2 Investigation into bile salt binding under non-equilibrium conditions
This was studied using gel chromatography. Neat bile (2 ml) was incubated for
1 h at room temperature with 3 pi of a solution containing lpCi [ C]
deoxycholate (19.2 nmol). This mixture was then chromatographed on
Sephadex G200 and radioactivity and yGT activity measured in the eluate.
Radioactivity was only present in the salt volume of the column and was not
associated with any of the peaks of yGT activity.
3.8.3 Investigation into bile salt binding under equilibrum conditions
To investigate the possibility that any yGT-deoxycholate complexes had
dissociated during chromatography, deoxycholate binding was also studied
using an equilibrum method. Equilibrum chromatography, introduced by
Hummel and Dreyer (1962), avoids the problem of dissociation since the
column is eluted with a constant concentration of ligand. The ligand-protein
complex is, therefore, constantly surrounded by free ligand during
chromatography. In order to increase the amount of yGT protein available for
possible binding, bile was concentrated approximately 20 times, prior to use,
using a Minicon macro solution concentrator (Amicon, London, U.K.).
p 14 i2 ml of concentrated bile was incubated for 1 h with lpCi [ C]
deoxycholate. Column chromatography of the mixture on Sephadex G200,
which had been pre-equilibrated with [^C] deoxycholate (5pCi/l), resulted in
three peaks of radioactivity. The first, Peak A, co-eluted with the void
volume and contained the majority of yGT activity. The second, Peak B,
eluted at 175 ml, corresponding to an estimated of about 70 000, and the
third, Peak C, eluted with the salt volume; there was no yGT activity
associated with these last two peaks (Fig. 3.13). The ratio of radioactivity in
Peak B to that in Peak A was 1.45:1.
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Elution profile of yGT and [^C] deoxycholate after gel
chromatography of hepatic bile on a column of Sephadex




This experiment was repeated using bile which had previously been treated
with papain. The elution pattern of radioactivity obtained was similar to that
above apart from the fact that a relatively greater amount of radioactivity
appeared in Peak B (ratio of Peak B to Peak A was 1.83:1, (Fig. 3.14). The
total amount of radioactivity in Peak B was approximately the same in both
experiments.
3.9 ULTRACENTRIFUGATIQN
If yGT in native bile is present as a low form, then significant quantities of
yGT activity should remain in the supernatant following centrifugation at high
speed. In order to determine if this is so, the following experiments were
carried out.
Samples of bile (before and after treatment with bile salts), (10 ml) were
centrifuged at 2500 x £ for 10 min. 8.5 ml of the supernatant was collected,
the pellet was washed with 1 ml of 20 mmol/1 Tris-HCl buffer, pH 8.0, and
then resuspended in 2 ml of the same buffer. yGT activity was estimated on
ail fractions.
Over 92% of yGT activity was recovered in the supernatant following
centrifugation at 2500 x £. After a further centrifugation of this supernatant
at 150 000 x £ for 1 h, the percentage of yGT activity recovered in the
supernatant ranged from 25 - 75%. Addition of increasing concentrations of
glycochenodeoxychoiate to the bile prior to centrifugation resulted in more
activity being recovered in the 150 000 x £ supernatant (Fig. 3.15). The
observed increase in recovered supernatant activity was greater in the samples
from patients in whom bile had been draining for several days before the
collection was made. These samples had a low concentration of bile salts due
to depletion of the bile salt pool.
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Figure 3.14 Elution profile of [^C] deoxycholate and yGT following
gel chromatography of papain-treated bile on Sephadex









Figure 3.15 Percentage recovery of yGT activity in the supernatant
following ultracentrifugation of hepatic bile at 150 000 x 3,
plotted against conjugated chenodeoxycholate
concentration.
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3.10 STUDIES QN LEUCINE AMINOPEPTIDASE AND ALKALINE
PHOSPHATASE
3.10.1 Effect of papain treatment
Digestion of hepatic bile with papain had a variable effect upon LAP activity,
whereas ALP activity was destroyed following this treatment (Table 3.5).
Table 3.5
Enzyme activities after digestion of human bile with papain
Sample Percentage initial activity
LAP ALP
Bile A 108 3
Bile B 74 0
Bile C 84 12
3.10.2 Effect of bile salts upon enzyme activities
Sodium glycocholate, at concentrations up to 20 mmol/1, appeared to stimulate
ALP activity slightly, whereas sodium glycochenodeoxycholate appeared to
have no effect. Both bile salts significantly inhibited LAP activity (Table 3.6).
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Table 3.6
Enzyme activities following addition of bile salts to human bile














* The endogenous concentration of conjugated cholate was 2.7 mmol/l and of
conjugated chenodeoxycholate 0.5 mmol/l.
3.10.3 Gel chromatography performed in the absence of bile salts
Both LAP and ALP eluted mainly as void volume peaks (Fig. 3.16), comprising
61 - 76% and 83 - 98% respectively of total recovered activity with the
remainder eluting as Peak 4 (LAP) and Peak 4 (ALP). Recovery of LAP ranged
from 80 -100% and of ALP from 100 - 220%. The high recovery for ALP may
possibly be due to low inhibitors of ALP present in native bile but which
become separated from the enzyme as it passes through the gel column.
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Figure 3.16 Elution profiles of LAP and ALP in human bile following gel
chromatography on Sephadex G200 before and after
treatment with papain. # , LAP before; O > LAP after;





After papain treatment, gel chromatography in the absence of detergents
resulted in a decrease in LAP activity eluting in the void volume, along with
an increase in activity eluting as Peak 4 (LAP) (Fig. 3.16).
3.10.4 Gel chromatography performed in the presence of bile salts
Gel chromatography, with increasing concentrations of glycocholate in the
elution buffer, resulted both in a decrease in the amount of ALP activity
eluting in the void volume and in the appearance of a fraction eluting as Peak
3 (ALP). At a concentration of 20 mmol/1 glycocholate, the proportion of ALP
activity eluting as Peak 3 (ALP) ranged from 32 - 45%. Results for LAP could
not be obtained because, at high concentrations of glycocholate, the enzyme
was almost completely inhibited during its passage through the column.
When glycochenodeoxycholate was included in the elution buffer, at increasing
concentrations, the main peak of activity for both LAP and ALP changed from
Peak 1 to Peak 3. When the concentration was 5 mmoi/1, 63 - 87% of LAP and
73 - 77% of ALP eluted as Peak 3 (Fig. 3.17).
3.10.5 Gel chromatography performed in the presence of Triton X-100
Bile, previously incubated with Triton X-100 (see section 3.4.5), was applied to
a Sephadex G200 column and eluted with buffer also containing Triton X-100
(0.1% w/v). The majority of LAP (71%) and ALP (84%) eluted as peaks 2T
(Fig. 3.18). Small amounts of activity (6 - 11%) still eluted as Peak 1 with the
remainder as Peak 4.
The estimated of the various fractions obtained after gel chromatography
are listed in Table 3.7.
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Figure 3.17 Elution of LAP and ALP following gel chromatography on
Sephadex G200 containing 5 mmol/1 glycochenodeoxychoiate





































Figure 3.18 Gel chromatography of LAP and ALP in human bile on
Sephadex G2Q0 equilibrated with 0.1% (w/v) Triton X-100.
• , LAP; ■ , ALP.
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Peak 1 >600 000 >600 000
Peak 2T 430 000 400 000
Peak 3 310 000 290 000
Peak 4 200 000 200 000
3.10.6 7% polyacrylamide gel electrophoresis
The electrophoresis of bile, of Peak 3 (ALP) and of Peak 4 (ALP) in 7%
polyacrylamide gel, equilibrated in both the gel and running buffer with
5 mmol/1 glychochenodeoxycholate, showed a single fast band of identical
mobility in all three samples (Fig. 3.19). The peak 4 (ALP) was obtained after
performing gel chromatography of serum from a patient with liver disease.
Results for LAP could not be obtained owing to its inhibition by bile salts.
3.10.7 Polyacrylamide gradient gel electrophoresis
The results obtained for alkaline phosphatase were analogous to those obtained
for yGT. Thus, the estimated values for the Peak 4 forms of ALP in
untreated bile, and in bile treated with papain, were less than those for the
corresponding Peak 3 forms (Table 3.8). Again, results for LAP could not be
obtained in the presence of bile salts because of inhibition.
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Figure 3.19 Polyacryiamide slab gel eletcrophoresis, in the presence of
5 mmol/1 glycochenodeoxycholate, of hepatic bile and the
fractions obtained from gel chromatography, stained for ALP.










Peak 1 > 1 000 000 > 1 000 000
Peak 3 * 280 000
Peak 4 177 000 180 000
* Not estimable
3.10.8 Ultracentrifugation
The results obtained for LAP and ALP were similar to those obtained for yGT
(see section 3.8). Over 92% of LAP and ALP activity was recovered from the
supernatant following centrifugation at 2500 x £. After further centrifugation
of this supernatant at 150 000 x £ for 1 h, between 27 and 54% of LAP and 22
and 48% of ALP activity was recovered in the supernatant. Again, when
increasing concentrations of glycochenodeoxycholate were added to the bile
prior to centrifugation, similar results to those for yGT were obtained, in that
more activity of both enzymes was recovered in the supernatant (Fig. 3.20).
3.11 SUMMARY AND DISCUSSION
1. In the absence of detergents, yGT has been shown to be present in
human bile largely as a hydrophobic, high M form, together with small
amounts of a low M^ hydrophilic form of the enzyme.
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Figure 3.20 Percentage recovery of enzyme activity in the supernatant
following ultracentrifugation of bile at 150 000 x 3 plotted
against conjugated chenodeoxycholate concentration.
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2. High yGT in human bile is converted both by deoxycholate and by
physiological concentrations of glycocholate and glycocheno-
deoxycholate to a low form. This form is hydrophobic and readily
reaggregates in the absence of detergents.
3. High yGT in human bile is converted, by treatment with the non-
ionic detergent Triton X-100, to a molecule of intermediate M .
4. Treatment of human bile with papain converts high yGT to a
hydrophilic low form. This has identical physical properties to the
low form present in small amounts in native bile and does not
reaggregate when added to, and incubated with, bile.
5. When human bile is centrifuged at 130 000 x 3, between 25 and 73% of
yGT activity is recovered in the supernatant. This proportion is
increased following prior addition of bile salts to the bile.
6 Analogous results were obtained for LAP and ALP although the results
were incomplete because bile salts inhibited LAP activity and papain
destroyed ALP activity.
These results confirm previous reports that yGT, LAP and ALP, when studied
by gel chromatography in the absence of detergents, seem to be present in
native bile mainly as high forms (Price et. al., 1972; Wenham et al., 1978a;
Huseby, 1978; Crofton and Smith, 1981a; Echetebu and Moss, 1982a).
However, if deoxycholate, Triton X-100 or physiological concentrations of
either glycocholate or glycochenodeoxycholate are included in the gel buffer,
the elution patterns of the enzymes change markedly. The void volume peak
contains less of the enzyme activity and lower forms of the enzymes appear
(Peak 3, Peak 2T). These lower M^ forms reaggregate if they are
rechromatographed in detergent-free eluting buffer. The results presented
here suggest that, in order to prevent reaggregation from occurring and to
obtain a truer picture, gel chromatography must be carried out in buffer
containing glycocholate or giycochenodeoxycholate at a concentration of at
least 20 mmoi/l or 5 mmol/l respectively. The greater efficacy of
deoxycholate and glycochenodeoxycholate in causing this change can readily
be explained in terms of the greater polarity of glycocholate, due to possession
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of an extra hydroxyl group. The results suggest that the apparent high
of biliary yGT, LAP and ALP may well be an artefact caused by reaggregation
of the enzymes when removed into a solution containing no bile salts.
The lower forms of yGT, LAP and ALP, which result from bile salt
treatment (Peak 3 forms), have been shown to be quite distinct in terms of
molecular size, charge and other properties from the low forms found in
untreated bile or obtained following treatment with papain. The Peak 4
enzymes do not tend to aggregate, show no change of properties on the
addition of bile salts and have a significantly smaller and negative charge
than the Peak 3 enzymes. By analogy with other membrane proteins, the
results support previous suggestions (Huseby, 1978) that that Peak 3 forms of
yGT (and also LAP and ALP) all contain a hydrophobic domain by which they
are normally attached to the hepatocyte or canalicular membrane. They are
consistent with explanations that have been advanced previously, namely that
bile salt or detergent treatment of yGT complexes results in the formation of
a yGT molecule possessing this hydrophobic domain to which detergents may
attach (Hughey and Curthoys, 1976). Unless an adequate concentration of
detergent is present, enzyme molecules possessing this hydrophobic region will
tend to aggregate in aqueous solution. Papain treatment may remove this
hydrophobic area, which is presumably a peptide or peptides, causing
formation of a yGT molecule which neither binds bile salts, nor reaggregates.
It is perhaps not surprising that binding of radiolabeled deoxycholate to the
hydrophobic form of yGT was not demonstrated. The approximate molar
concentration of yGT in the neat and concentrated samples of bile studied,
using the data from Huseby (1977), was estimated to be 7.2 nmol/1 and 154
nmol/1 respectively. Thus the molar amounts of yGT applied to the column
(approximately 15.4 and 308 pmoles respectively) were both several orders of
magnitude less than the amount of radiolabeled deoxychoiate added to the
bile (19.2 nmol) in order to obtain sufficient counts.
The ultracentrifugal studies showed that between 25 and 75% of yGT, LAP and
ALP activity in native bile is present in the 150 000 x 3 supernatant. In
samples in which the bile salt concentration is low, such as those obtained
after several days of biliary drainage, the proportion of each of the enzymes
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present in the 150 000 x £ supernantant also tended to be low. A similar
observation was obtained jri vitro by adding glycochenodeoxycholate to bile
and thereby increasing the amount of enzyme present in the supernatant
fraction. The simple interpretation of these findings is that the 150 000 x £
sediment contains particles or aggregated enzyme and that bile salts, whether
endogenous or exogenous, will release the enzyme from these complexes.
However, the exact nature of these complexes remains to be determined.
Chapter 4
PHYSICAL PROPERTIES OF y-GLUTAMYLTRANSFERASE IN
HUMAN SERUM
y-Glutamyltransferase in human serum has been shown, by gel chromatography
on a variety of media, to be present as three fractions of high, intermediate
and low Mr (greater than 600 000, 250 000 - 450 000, and about 100 000
respectively) (Orlowski et al., 1965; Kokot and Kuska, 1968; Huseby, 1978;
Wenham et al., 1979; Huseby, 1982a; Huseby, 1982b). Two of these fractions
have been studied by several groups of investigators. The high Mr fraction is
thought to consist of complexes in which hydrophobic yGT is associated with
lipids, lipoprotein-X and other membrane enzymes, or membrane fragments
(De Broe et al., 1975; Wenham et al., 1979; Crofton and Smith, 1981b; Huseby,
1982a; Echetebu and Moss, 1982b). In contrast, the low JM fraction is
hydrophilic and is thought to be produced by the action of neutral
endopeptidases upon the hydrophobic enzyme either before or after its release
into the circulation from the hepatobiliary tract (Huseby, 1978; Tsuji et al.,
1980; Huseby, 1982b). However, there has only been one detailed study on the
nature or physical properties of the intermediate fraction (Huseby 1982a).
This investigation suggested that such intermediate M^ forms consisted of
complexes between yGT and high density lipoprotein (HDL).
The present study was undertaken to characterise the y-glutamyltransferases
present in human serum, particularly those of intermediate Mr, and to
compare their properties in patients with a wide variety of liver diseases. The
objective was two-fold. Firstly, to ascertain if any physical differences
between the intermediate Mr forms in different patients might suggest the
basis for a useful diagnostic test of liver disease. Secondly, to gain further
insight regarding possible mechanisms for the elevation of serum yGT activity
in liver disease.
The two enzymes, leucine aminopeptidase and alkaline phosphatase, also
thought to originate from the hepatocyte plasma membrane, were included in
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the study where appropriate, to see if the findings were applicable on a wider
basis to other membrane enzymes.
4.1 SAMPLES USED IN THE STUDY
Sera were obtained from 100 patients with liver disease and 10 apparently
healthy individuals in whom there was no clinical or biochemical evidence of
hepatic damage. Further details are given in Chapter 5, section 5.1.
4.2 EFFECT OF PAPAIN ON yGT IN HUMAN SERUM
Sera were incubated with papain (1 g/10 g protein) overnight at 20°C in the
presence of 100 mmol/l cysteine. The digestion had little effect upon yGT
activity (Table 4.1).
Table 4.1
yGT activity after digestion of sera with papain




4.3 GEL CHROMATOGRAPHY ON SEPHACRYL S300
For the reasons described in section 2.3.4, Sephacryl S300 was chosen, in
preference to Sephadex G200, as the gel medium for the study of yGT in
human serum. However, in some of the studies on low M yGT where
—r
Sephacryl offered no additional advantage, Sephadex G200 was used for
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convenience, as these studies coincided with equivalent studies on bile
described in Chapter 3.
4.3.1 General nomenclature used throughout the chapter
In order to maintain the previous arbitrary nomenclature described in Chapter
3, the peaks have again been numbered in order of their elution from the gel
column. Quantitative differences were noted in the relative sizes of the peaks
but in this chapter attention is focussed on their physical properties:
Peak 1 (yGT), Peak 1 (LAP), Peak 1 (ALP): void volume for all
enzymes.
Peak 2 (yGT), Peak 2 (LAP): major peaks of intermediate M . For
yGT, Peak 2 could take two forms (see below). No corresponding peak was
present for ALP.
Peak 3 (yGT), Peak 3 (ALP): peaks of low-intermediate present in
the eluate only when bile salts are present in the eluting buffer. No
corresponding peak was present for LAP owing to its inhibition by bile salts.
Peak 4 (yGT), Peak 4 (LAP), Peak 4 (ALP): peaks of low M^
representing a small fraction of serum yGT but a major proportion of serum
LAP and ALP activity. The size of this peak (for yGT and LAP) was increased
greatly in sera that had previously been treated with papain.
4.3.2 Gel chromatography performed in the absence of bile salts
After gel chromatography of normal sera and sera from patients with liver
disease, varying amounts of yGT eluted as Peaks 1, 2 and 4 (yGT) (Table 4.2).
The recovery of yGT activity was variable; mean 101.7%, range 81 - 146%.
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Table 4.2
Distribution of yGT obtained after gel chromatography of IIP sera on
Sephacryl 5300
Fraction Percentage of total recovered activity
Mean Range
Peak 1 27.3 6 -■ 82
Peak 2 57.4 0 •- 83
Peak 4 15.3 2 -- 58
The elution profile of the second peak of yGT activity from most of the
patients with extrahepatic biliary obstruction (Peak 2B (yGT)) differed from
that of most of the other patients and normal individuals (Peak 2A (yGT))
(Figs. 4.1, 4.2 and 4.3). Peak 2B (yGT) eluted later than Peak 2A (yGT) and
was therefore of lower apparent M^ than Peak 2A (yGT). Of the 25 patients
with extrahepatic biliary obstruction who were studied, 20 exhibited Peak 2B
(yGT) activity only, three Peak 2A (yGT) only, one approximately equal
amounts of both, and one neither peak activity. All sera possessed variable
amounts of Peaks 1 and 4 (yGT). It was noted that in some jaundiced sera
from patients with pathologies other than extrahepatic biliary obstruction, a
shoulder was obtained on Peak 2A (yGT) in the position of Peak 2B (yGT).
4.3.3 Gel chromatography performed in the presence of bile salts
When gel chromatography was performed in the presence of either 12 mmol/1
glycochenodeoxycholate or 12 mmol/l deoxycholate, the amount of yGT
activity in Peaks 1 and 2 (yGT) decreased, with a corresponding appearance of
Peak 3 (yGT) (Fig. 4.4).
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Figure 4.1 Elution profile of y^T following gel chromatography










Figure 4.2 Gel chromatography on Sephacryl 5300 of yGT in serum from










Figure 4.3 Elution profile of yGT following gel chromatography on
Sephacryl S300 of serum from a patient with alcoholic
cirrhosis.
Peak 1 Peak2A Peak 4
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Figure 4.4 Gel chromatography on Sephacryl S300 of serum from a
patient with extrahepatic biliary obstruction, with and without
12 mmol/l deoxycholate in the elution buffer. O > no
deoxycholate % , 12 mmol/l deoxycholate.
Elution volume (ml)
Peak 2B Reak3 Peak 4




The fractions containing Peaks 1 and 2 (yGT) obtained from gel
chromatography were pooled, concentrated by ultrafiltration and
rechromatographed in the presence of either 12 mmol/1
glycochenodeoxycholate or 12 mmol/1 deoxycholate. Following
rechromatography, Peak 1 (yGT) and Peak 2 (yGT) disappeared, giving rise to
Peak 3 (yGT) (Fig. 4.5).
4.3.4 Gel chromatography of papain-treated sera
Following gel chromatography of papain-treated sera in the absence of bile
salts, there was a decrease in yGT activity eluting as Peaks 1 and 2 (yGT),
together with an increase in activity eluting as Peak 4 (yGT) (Fig. 4.6).
The estimated M values of all of the various fractions obtained after gel
—r
chromatography are shown in Table 4.3.
Table 4.3




Peak 1 >1 000 000
Peak 2A 325 000 - 500 000
Peak 2B 258 000 - 295 000
Peak 3 175 000
Peak 4 118 000
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Gel chromatography on Sephacryl S300 of Peak 2B (yGT)
with # , and without O > 12 mmol/1 deoxycholate in
the elution buffer.
Peak 2B Peak 3
(TGT) (TGT)
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Figure 4.6 Elution profile on Sephacryl S300 of papain-treated serum
from a patient with liver disease.
Peak 1 Peak 4
Elution volume (ml)
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4.4 7% POLYACRYLAMIDE GEL ELECTROPHORESIS
4.4.1 Electrophoresis in the absence of bile salts
Two fairly distinct patterns of yGT activity, according to the type of liver
disease, were obtained following electrophoresis on 7% polyacrylamide gel. In
sera from patients with extrahepatic biliary obstruction, two main bands of
activity were seen, one at the origin (Band 1 (yGT)), and another of a mobility
45 - 55% of that of albumin (Band IIB (yGT)). Occasionally, smaller, minor
zones of slower mobility were seen. The sera from other groups of patients
and the normal sera showed a smaller zone of activity at the origin, with
significant activity occurring in various zones (Bands IIA (yGT)), with
mobilities between 8 and 40% of that of albumin. Minor zones were often
present, corresponding to Band IIB (yGT), in abnormal but not In normal sera.
Sera from all patients showed a less intense zone of activity (Band IV (yGT)),
of mobility between 70 and 80% of that of albumin. This zone was also
present in normal sera but seemed to contribute a greater proportion of the
total activity. Typical electrophoretic patterns are shown in Fig. 4.7. The
positions of the various bands are shown schematically in Fig. 4.8.
Electrophoresis was performed on concentrated pooled fractions of Peak 1
(yGT), Peak 2A (yGT), Peak 2B (yGT) and Peak 4 (yGT) obtained after gel
chromatography. This showed that Peak 2A (yGT) was heterogenous, giving
rise to several zones (Bands IIA (yGT)). On the other hand, Peak 1 (yGT), Peak
2B (yGT) and Peak 4 (yGT) each gave rise to an electrophoretically discrete
band (Band I (yGT)), Band IIB (yGT) and Band IV (yGT) respectively) (Fig. 4.9).
4.4.2 Electrophoresis performed in the presence of bile salts
Electrophoresis, in the presence of a concentration of sodium deoxycholate
greater than or equal to 5 mmol/l, gave rise to two bands of activity. The
faster one (Band III (yGT)), was the main band obtained after electrophoresis
of either serum, or of a concentrated pool of Peak 3 (yGT) obtained after gel
chromatography. The other band (Band IV (yGT)) was the main band obtained
following electrophoresis of a concentrated pool of Peak 4 (yGT) (Fig. 4.10).
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Figure 4.7 7% polyacrylamide gel electrophoresis of yGT in sera from
patients with liver disease. 1, extrahepatic biliary
obstruction; 2, blank; 3-7, alcoholic cirrhosis.
1 2 3 4 5 6 7





Figure 4.8 Schematic representation of the positions of the various
zones of yGT activity obtained after electrophoresis of sera
in polyacrylamide gel. 1 - 7, sera from patients with 1,
extrahepatic biliary obstruction; 2, alcoholic cirrhosis; 3,
chronic active hepatitis; 4, primary biliary cirrhosis; 5,
haemochromatosis; 6, alcoholic cirrhosis; 7, liver metastases;
8, normal serum.
1 2 3 4 5 6 7 8
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; 4.9 Polyacrylamide gel electrophoresis of serum and the fractions
obtained after gel chromatography, stained for yGT
activity. 1, Peak 1 (yGT); 2, Peak 2B (yGT); 3, Peak 2A
(yGT); 4, Peak 4 (yGT); 5, serum. Track 4 contains slight
contamination in the position of Band IIA (yGT) due to
overflow of staining from an adjacent track. Unfortunately,
the zone corresponding to Band IV (yGT) in track 4 did not
show up very clearly after photography.










Figure 4.10 Electrophoresis on 7% polyacrylamide gel of sera and the
fractions obtained after performing gel chromatography.
Both the gel and running buffer were equilibrated with 5
mmol/1 sodium deoxycholate. 1, 3, sera; 2, 4, Peak 4 (yGT);
5, Peak 3 (yGT).
origin—*





4.5 PGLYACRYLAMIDE GRADIENT GEL ELECTROPHORESIS
Electrophoresis, carried out in the absence of bile salts demonstrated the
heterogeneity of Peak 2 (yGT). In the presence of 12 mmol/1 deoxycholate,
the technique confirmed that Peak 3 (yGT) was of higher than Peak 4
(yGT) (Table 4.4).
Table 4.4




Peak 1 >1 000 000
Peak 2A 300 000 - 710 000
Peak 2B 180 000 - 220 000
Peak 3 135 000
Peak 4 98 000
4.6 POLYANION PRECIPITATION
This was performed on 14 sera, as described in section 2.5.2, using dextran
sulphate and manganese chloride. Gel chromatography was then performed on
the redissolved lipoprotein fractions of LDL plus VLDL, and HDL.
Between 40 and 75% of Peak 1 (yGT) activity co-precipitated with the LDL
and VLDL fraction, together with a much smaller proportion of Peak 2A (yGT)
(Fig. 4.11). Between 49 and 65% of Peak 2A (yGT) was precipitated with the
HDL fraction, whereas Peak 2B (yGT) did not co-precipitate with any of the
lipoprotein fractions.
Polyanion precipitation of the lipoprotein fractions was also carried out on 2
sera using sodium phosphotungstate and magnesium chloride as described in
section 2.5.1. Gel chromatography was performed on the redissolved
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Figure A. 11 Elution profile of yGT in serum and the lipoprotein fractions
from a patient with alcoholic liver disease before and after
precipitation with polyanions. O , whole serum; ■ ,
LDL, VLDL; £ , HDL; Q , supernatant after
precipitation of LDL, VLDL and HDL.
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lipoprotein fractions. Similar results were obtained to those using dextran
sulphate and manganese chloride, in that Peak 1 (yGT) co-precipitated
predominantly with LDL plus VLDL, whereas Peak 2A (yGT) mostly co-
precipitated with HDL.
The results described here for Peak 2A (yGT) provide circumstantial evidence
that this fraction is a part of HDL. However, in case the polyanion
precipitation procedure coincidently precipitates yGT protein, the following
control experiments were performed.
Firstly, the polyanion procedure using dextran sulphate and manganese
chloride was performed on a serum sample and the total protein determined in
the supernatants after each precipitation stage. Electrophoresis on cellulose
acetate, followed by protein staining, was performed on each of the
supernatants and on the original serum. The results are shown in Fig. 4.12 and
Table 4.5 and suggest that the polyanion procedure has very little effect on
the total recovered protein from either the supernatant or the various protein
fractions.
Total recovered protein in the supernatant following precipitation of the
various lipoprotein fractions
Table 4.5
Fraction Total protein Percentage initial concentration
(g/1)







Figure 4.12 Cellulose acetate electrophoresis of serum before and after
polyanion precipitation of the various lipoprotein fractions,
stained for protein. 1, whole serum; 2, serum minus LDL




Secondly, Peak 4 (yGT) was added to serum (from which HDL and LDL plus
VLDL had been removed) at a concentration of dextran sulphate and
manganese chloride suitable for HDL precipitation. The mixture was
centrifuged for 30 min at 20 000 x £ and the yGT activity determined on the
supernatant. 91% of the added yGT activity was recovered in the supernatant,
suggesting that the polyanion procedure did not precipitate significant
quantities of yGT protein.
4.7 INCUBATION OF SERA WITH ANTISERUM TO APOLIPOPROTEIN A
4.7.1 Optimisation of antiserum/serum ratio
10 pi of serum was incubated with increasing amounts of antiserum to
apolipoprotein A or with saline as a control (0 - 50 pi) overnight at room
temperature. The volumes of all of the incubations were made up to 60 pi
with saline. For each serum-apolipoprotein antiserum incubation there was an
equivalent saline-apolipoprotein antiserum incubation of the same volume
ratio in order to correct for yGT activity in the antiserum. The mixture was
centrifuged at 11 000 x ^ for 10 min and yGT activity determined on the
supernatant. The percentage of yGT activity precipitated in each incubation
was calculated according to the equation:
n/ • • i_ i_ _j /, (A - C\ x 100% yGT activity precipitated = (1 g—)
Where A = yGT activity in the supernatant of the
serum/apolipoprotein antiserum mixture.
B = yGT activity in the corresponding serum/saline control mixture.
C = yGT activity in the corresponding saline/apolipoprotein control
mixture.
The results are shown in Fig. 4.13 and suggest that a volume ratio of antiserum
to serum of 5 to 1 gives optimal precipitation of yGT activity.
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Figure 4.13 Percentage of yGT activity precipitated following
incubation of serum with increasing amounts of antiserum to
apolipoprotein A.
0 1 2 3 4 5
Volume ratio antibody to serum
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4.7.2 Effect of ammonium sulphate on the precipitation of the
antibody/yGT/HDL complex
This brief investigation was carried out to maximise the precipitation of the
antibody/yGT/HDL complex. 10 pi of another serum was incubated with 50 pi
of antiserum to apolipoprotein A and with 50 pi of saline as a control
overnight at room temperature. 10 pi of saline was also similarly incubated
with 50 pi of antiserum as an antiserum control. Increasing amounts of
ammonium sulphate (270 g/l) were then added, mixed, and the mixture
centrifuged for 10 min at 11 000 x cj. The results are shown in Fig. 4.14 and
show that maximal precipitation is obtained after the addition of 1 ml of
ammonium sulphate. Ammonium sulphate did not precipitate yGT activity in
the absence of antibody.
4.7.3 Quantitative investigation into the precipitation of serum yGT
activity with antiserum to apolipoprotein A
The following incubation tubes were set up:
A 50 pi of antiserum to apolipoprotein A + 10 pi of serum (69 patients)
or 10 pi of concentrated pool of Peak 4 (yGT).
B As above, but with saline substituted for antiserum to apolipoprotein
A.
C 50 pi of antiserum to apolipoprotein A + 10 pi of saline as a batch
control to correct for the yGT activity of the antibody.
These were incubated overnight at room temperature, 1 ml of ammonium
sulphate was added, mixed, and centrifuged for 10 min at 11 000 x The
percentage of yGT activity precipitated in each incubation was calculated as
described in section 4.7.1.
Variable amounts of yGT activity were precipitated after incubation of sera
with antiserum to apolipoprotein A (mean 59.5%; range 8 - 92%). In contrast,
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Figure 4.14 Effect of increasing the amount of ammonium sulphate upon
the percentage of yGT activity precipitated after
incubation of serum with antiserum to apolipoprotein A.
0-5 1-0 1-5
Volume of ammonium sulphate added (ml)
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no Peak 4 (yGT) activity was precipitated by the incubation procedure.
Similarly, incubation of 11 sera with antiserum to apolipoprotein B (raised in
the same animal species as the antiserum to apolipoprotein A and using the
same incubation conditions as above) did not cause precipitation of any serum
yGT activity.
4.7.4 Qualitative investigation into binding of serum yGT to antiserum to
apolipoprotein A
25 pi of serum, papain-treated serum, or concentrated Peak 4 (yGT) pool were
incubated overnight at room temperature with 125 pi of antiserum to
apolipoprotein A or with saline as a control. 25 pi of 40% (w/v) sucrose
solution containing 0.1% (w/v) bromophenol blue were added to label the
albumin and 150 pi of the mixture were subjected to electrophoresis on either
7% polyacrylamide or 4 -30% polyacrylamide gradient gels. The gels were
stained for yGT activity.
Incubation of serum with antiserum to apolipoprotein A resulted in a marked
decrease in staining associated with Bands IIA (yGT) and Band IIB (yGT) when
compared with incubation of serum with a saline control (Fig. 4.15).
Inspection of the gels also suggested an increase in intensity of staining of
yGT at the origin.
On the other hand, incubation of the papain-treated sera or Peak 4 (yGT) with
antiserum to apolipoprotein A did not alter the staining of Band IV (yGT) when
compared with incubation with a saline control (Fig. 4.16).
Immunoelectrophoresis against antiserum to apolipoprotein A was performed
on 4 patients' sera and the precipitin arcs stained for yGT activity. The
results (Fig. 4.17) show that the precipitin arcs did stain for yGT activity,
although there was significant residual background activity due to non-
precipitated enzyme, despite the two day washing procedure. In the absence
of substrate, no staining of the precipitin arcs was observed.
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Figure 4.15 Polyacrylamide slab gel electrophoresis of sera from
patients with liver disease. 1, 3, 5, 7, 9, after incubation
with saline; 2, 4, 6, 8, 10, after incubation with antiserum to
apolipoprotein A; 11, antiserum to apolipoprotein A.






Polyacrylamide slab gel electrophoresis of papain-treated
serum and Peak 4 (yGT). Papain-treated serum 2, after
incubation with saline, 1, after incubation with antiserum to
apolipoprotein A; Peak 4 (yGT) 4, after incubation with




Figure 4.17 Immunoelectrophoresis of 4 sera against antiserum to
apolipoprotein A. The precipitation arcs are stained for
yGT activity. 1, 2, sera from patients post liver transplant;





As a means of 1) validating the antiserum and 2) showing that the enzyme
staining of the precipitin arcs described above was not due to any inherent
yGT activity associated with the antiserum, immunoelectrophoresis against
antiserum to apolipoprotein A was performed on the various fractions obtained
after polyanion precipitation. Immunoelectrophoresis of the LDL plus VLDL
fraction, and of the HDL-free serum did not reveal the presence of any
precipitin arcs when stained for protein. On the other hand,
immunoelectrophoresis of the HDL fraction gave rise to a single precipitin arc
in the a^-globulin region when stained for protein (Fig. 4.18). No enzyme
activity was observed when this precipitin arc was stained for such activity.
The results of this section provide additional evidence that the yGT fractions
of intermediate ^ are a part of HDL.
4.8 INCUBATION. OF SERA WITH BILE
These investigations we re carried out in an attempt to reproduce the serum
abnormalities found in extrahepatic biliary obstruction.
Sera containing Peak 2A (yGT) activity were incubated with an equal volume
of hepatic bile for 3 h at 37°C. The mixture was then subjected to gel
chromatography on Sephacryl S300, or electrophoresis on either 7%
polyacrylamide or 4 - 30% polyacrylamide gradient gels.
Gel chromatography of the mi^ure revealed that the Peak 2A (yGT) activity
appeared to change to Peak 2B (yGT) activity (Fig. 4.19). This change was
occasionally associated with an apparent increase in total yGT activity
recovered from the sera/bile mixtures. This increase may be due to a matrix
effect of the serum proteins upon biliary yGT.
After electrophoresis of the mixture, there was a marked decrease in the
intensity of Bands IIA (yGT) along with the appearance of a zone (Band IIC
(yGT)) ahead of Band IIB (yGT) (Fig. 4.20). Similarly, electrophoresis of bile-
treated sera from patients with obstructive jaundice possessing Band IIB (yGT)
activity, resulted in the appearance of Band IIC (yGT). Usually this was
associated with a decrease in the intensity of staining of Band IIB (yGT).
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Figure 4.18 Immunoelectrophoresis against antiserum to apolipoprotein
A of whole serum and the lipoprotein fractions obtained
after the polyanion precipitation procedure. 1, whole
serum; 2, supernatant after precipitation of LDL and VLDL;
3, supernatant after precipitation of LDL, VLDL and HDL;
4, LDL and VLDL; 5, HDL; 6, Blank; 7, serum protein
fractions.
1 2 3 4 5 6
origin-






Figure 4.19 Elution profile on Sephacryl S300 of yGT in the serum of a
patient with alcoholic cirrhosis before and after incubation
with hepatic bile. O > serum before; fl| , serum and bile
mixture; % , hepatic bile.
160 180 200 220 240 260 280
ELUTION VOLUME (ml)
PEAK1 PEAK 2A PEAK 2B PEAK 4
(VGT) (/GT) (VGT) (/GT)
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Figure 4.20 Polyacrylamide slab gel electrophoresis of sera from
patients with liver disease before and after incubation with
dialysed or undialysed hepatic bile. 1, undialysed hepatic
bile; 2, dialysed hepatic bile; 3, 6, 9, sera + saline; 4, 7, 10,
sera + undialysed bile; 5, 8, 11, sera + dialysed bile.
0RIGIN-








The ability of bile to effect these changes of Peak 2A (yGT) and Bands IIA
(yGT) and IIB (yGT) was inhibited by prior dialysis of the bile against 1000
volumes of 20 mmol/l Tris-HCl buffer, pH 8.0, overnight at 4°C, and for a
further 12 h at 4°C after a change of buffer (Figs. 4.20 and 4.21).
Incubation of the various bile-sera mixtures with antiserum to apolipoprotein
A, followed by electrophoresis, resulted in a decrease in the intensity of
staining of Band IIC (yGT) when compared to mixtures that had been incubated
with a saline control (Fig. 4.22).
4.9 INCUBATION OF SERA WITH BILE SALTS
The results of section 4.8 suggest that a small dialysable molecule present in
bile was responsible for effecting the changes on Peaks 2A (yGT) and Bands
IIA (yGT) and IIB (yGT). Since bile salts were the most obvious candidates for
this role, the effect of bile salts on serum was investigated further.
Patients' sera were incubated with an equal volume of glycochenodeoxycholate
at concentrations ranging from 10 pmol/1 to 20 mmol/l for 3 h at 37°C.
Electrophoresis of the mixtures on either 7% polyacrylamide or 4 - 30%
polyacrylamide gradient gels showed that incubation with
glycochenodeoxycholate at a concentration greater than or equal to 6 mmol/l
resulted in a decrease in intensity of Bands IIA (yGT) and IIB (yGT) together
with the appearance of Band IIC (yGT) (Fig. 4.23). This phenomenon appeared
to be independent of the initial concentration of total conjugated
chenodeoxycholate in the sera studied. For the patients with extrahepatic
biliary obstruction this was: mean, 64 p.mol/1; range, 9 - 229 pmol/l. For the
others the mean was 12 pmol/1, range 0-113 pmol/l.
A sample of serum, from an alcoholic patient, containing Peak 2A (yGT)
activity was incubated with an equal volume of 20 mmol/l
glycochenodeoxycholate for 3 h at 37°C. Gel chromatography of the mixture
on Sephacryl 5300 revealed a shift in the elution profile of Peak 2A (yGT) to
that approximating to Peak 2B (yGT). No change in the elution profile of Peak
1 (yGT) was observed (Fig. 4.24).
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Figure 4.2 1 Elution profile on Sephacryl S300 of yGT in the serum of a
patient with alcoholic cirrhosis before and after incubation
with dialysed hepatic bile. O , serum before; # , serum
and bile mixture.
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Figure 4,22 Polyacrylamide gradient gel electrophoresis of various bile-
sera mixtures before and after incubation with antiserum to
apolipoprotein A. 1, serum before; 2, serum + bile before;
3, serum after; 4, serum + bile after; 5, bile after.






Figure 4.23 Polyacrylamide slab gel electrophoresis of serum from a
patient with alcoholic cirrhosis after incubation with
increasing concentrations of glycochenodeoxycholate (GC),
or with saline as a control. 1, saline; 2, 10 pmol/1 GC; 3,
50 p.mol/1 GC; 4, 100 p.mol/1 GC; 5, 250 p.mol/1 GC; 6, 500
(j.mol/1 GC; 7, 1 mmol/1 GC; 8, 2.5 mmol/1 GC; 9, 5
mmol/1 GC; 10, 10 mmol/1 GC.
1 2 3 4 5 6 7 8 9 10
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Figure 4.24 Gel chromatography on Sephacryl S300 of serum from an
alcoholic patient before and after incubation with an equal
volume of 20 mmol/1 glycochenodeoxycholate. O , before;
# , after.
121
4.10 EFFECT OF DIALYSIS UPON THE ELUTIGN PROFILE OF yGT IN
HUMAN SERUM
This investigation was carried out to see if there was some dialysable factor,
present in sera from patients with extrahepatic biliary obstruction, which was
responsible for Peak 2A (yGT) being present as Peak 2B (yGT).
A sample of serum (1 ml) was dialysed overnight at 4°C against 1000 ml of
Tris-HCl buffer, pH 8.0, and for a further 12 h at 4°C after a change of
buffer. The original and the dialysed serum were then subjected to gel
chromatography on Sephacryl S300 in the absence of bile salts. No change in
the elution profile of yGT was observed as a result of prior dialysis of the
serum (Fig. 4.25).
4.11 EFFECT OF FREEZING AND THAWING
The stability of the various yGT peaks to freezing and thawing was studied by
freezing a serum sample to -60°C, thawing at 37°C, and repeating the process
three times. Gel chromatography was performed on the original serum before
and after treatment by the freezing and thawing procedure. The elution
profile of the various fractions was unaffected by the freezing and thawing
procedure (Fig. 4.26).
4.12 STUDIES UPON THE FRACTIONS OBTAINED AFTER GEL
CHROMATOGRAPHY
4.12.1 Peak 4 (yGT)
Samples of serum containing 0.24 U of yGT activity were added to 0.5 ml of
concentrated Peak 4 (yGT) eluate, also containing 0.24 U of yGT activity.
The volumes were made up to 2 ml with Tris-HCl buffer, pH 8.0, and
incubated for 6 h at 37°C. Gel chromatography on a 65 x 26 cm column of
Sephadex G200 revealed that approximately 86% of the added Peak 4 (yGT)
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Figure 4.25 Elution profile on Sephacryl S300 of yGT in the serum of a
patient with extrahepatic biliary obstruction before and
after dialysis against 20 mmol/1 Tris-HCl buffer pH 8.0.
O , before dialysis; # , after dialysis.
Peak1 Peak 2B Ffeak4
(7GT) (7GT) (tGT)
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Figure 4.26 Elution profile on Sephacryl S300 of yGT in serum
before O , and after # , repeated freezing and
thawing.
Reakl Fteak2 Peak 4
(tGT) (TGT) hGT)
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activity was recovered as Peak 4 (yGT) (Fig. 4.27). This suggests that the
incubation procedure did not alter the chromatographic behaviour of Peak 4
(yGT).
4.12.2 Peak 3 (yGT)
Gel chromatography on Sephacryl S30D was performed on a patient's serum
containing Peak 2A (yGT) and 2B (yGT), in the presence of 12 mmol/1
deoxycholate. The Peak 3 (yGT) which was obtained was pooled, concentrated
and dialysed against 20 mmol/1 Tris-HCl buffer, pH 8.0.
Gel chromatography on Sephacryl S300 of 1 ml of this concentrated pool in the
presence or absence of bile salts, revealed that, in the absence of bile salts,
Peak 3 (yGT) reaggregates (Fig. 4.28).
The pool representing the combined Peaks 2A (yGT) and 2B (yGT) was
incubated overnight at room temperature with an equal volume of normal
serum. This mixture, the pool of Peaks 2A (yGT) and 2B (yGT), and the
original serum from which these peaks were derived were then incubated
overnight with antiserum to apolipoprotein A and with saline as a control. The
mixtures were subjected to electrophoresis on 4 - 30% polyacrylamide
gradients and stained for yGT activity. When compared to a saline control, a
decrease was observed in enzyme staining in the areas corresponding to Bands
IIA (yGT) and Band IIB (yGT) in all of the incubations (Fig. 4.29).
Similarly, the concentrated Peak 3 (yGT) pool was incubated with an equal
volume of normal serum overnight at room temperature. This mixture and the
Peak 3 (yGT) pool were incubated with antiserum to apolipoprotein A or with a
saline control, and subjected to electrophoresis. On staining for yGT activity,
a decrease in staining intensity of the zones of intermediate mobility was
observed only in the Peak 3 (yGT) - normal serum mixture, as compared to a
saline control (Fig. 4.30).
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Figure 4.27 Elution profile on Sephadex G200 of yGT in serum from a
patient with extrahepatic biliary obstruction before O ,




Figure 4.28 Rechromatography of Peak 3 (yGT) on Sephacryl S300 with




Figure 4.29 Polyacrylamide gradient gel electrophoresis of a patient's
serum, a pool of Peaks 2A and 2B (yGT) and mixture
composed of egual proportions of the pool and normal
serum, before and after incubation with antiserum to
apolipoprotein A. Serum, 1, before, 2, after; pool, 3,
before, 4 after; pool/normal serum mixture, 5, before, 6,
after.






Figure 4.30 Polyacrylamide gradient gel electrophoresis of a Peak 3
(yGT) pool and a Peak 3 (YGT)/normal serum mixture,
before and after incubation with antiserum to apolipoprotein
A. Peak 3 (yGT) pool, 1, before; 2, after; Peak 3 (yGT)
pool /normal serum mixture, 3, before; 4, after.
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4.13 CATALYTIC PROPERTIES
Since there is a distinct possibility that the yGT fractions obtained from
serum and bile (Chapter 3) might be related, a brief comparison of their
kinetic properties was undertaken.
The reaction catalysed by yGT follows a ping-pong bi-bi kinetic mechanism
(see section 1.1.3). The most accurate way of estimating the values for
each substrate is by replotting rate data obtained at several concentrations of
the second substrate. Since the objective of this brief study however, was to
compare directly the kinetic properties of the various yGT fractions in human
bile and serum, the simple experimental design of Echetebu and Moss (1982a)
using only a single, high concentration of second substrate was used.
4.13.1 Michaelis constants
In the analysis of enzyme kinetics, the estimates of K and V were1 1
—m —max
obtained by a least-squares non-linear fitting procedure of the direct velocity
versus "substrate concentration data points (Wilkinson, 1961). The calculations
were programmed on a Hewlett-Packard 9821 Desk Calculator.
y-L-Glutamyl-p-nitroanilide
The K values for the donor substrate were determined at a constant
—m
concentration of 120 mmol/l glycylglycine in the final reaction mixture, while
the concentration of donor substrate was varied from 1-9 mmol/l.
Glycylqlycine
Acceptor substrate j<m values were similarly determined at a constant
concentration of donor substrate of 9 mmol/l, while varying the concentration
of acceptor substrate from 10 to 120 mmol/l. The K values obtained in the
—m
serum and bile fractions are shown in Table 4.6. The differences observed in
the j<m values were not statistically significant.
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T able 4.6
Michaelis constants of the various yGT fractions obtained from serum and bile
Fraction (n) Michaelis Constant (+ S.D.)
Glycylglycine y-L-Glutamyl-p-nitroanilide
Serum (7) 16.39 + 2.20 1.54 + 0.22
Bile (4) 15.91 + 2.20 1.42 + 0.14
Serum Peak 1 (4) 16.00 + 3.23 1.77 + 0.38
Serum Peak 2A (5) 16.40 + 3.23 1.67 + 0.37
Serum Peak 2B (4) 16.74 + 3.80 1.42 + 0.24
Serum Peak 4 (3) 13.42 + 1.66 1.34 + 0.16
Bile Peak 1 (2) 15.81 + 3.40 1.62 + 0.37
Bile Peak 4 (5) 15.40 + 1.70 1.36 + 0.40
4.13.2 Inhibitor studies
Glycine was used for inhibitor studies. This amino acid is believed to interact
with the enzyme by behaving as a substrate analogue for both donor and
acceptor substrates, resulting in dead-end inhibition (Stromme and Theodorsen,
1976). With donor substrate the inhibition is competitive, whilst with acceptor
substrate it is uncompetitive (Stromme and Theodorsen, 1976). Replots of the
slopes and the intercepts of the Lineweaver-Burke plots obtained from the
initial kinetic data were used to determine the inhibition constants. Each
Lineweaver-Burke plot was obtained at different inhibitor concentrations in
the final reaction mixture ranging from 0 to 20 mmol/1. For the competitive
inhibition observed on the donor substrate the replot was K /V versusr —m —max
inhibitor concentration. For the uncompetetive inhibition observed on the
acceptor substrate the replot was 1/V versus inhibitor concentration.r r —max
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The fitted lines in the replots were obtained by least-squares linear regression
performed on a Hewlett-Packard 9821 Desk Calculator, which also calculated
the intercept (and standard error) of the line on the inhibitor concentration
axis, thus giving the value of the inhibitor constant. The values obtained for
the inhibitor constants of the various fractions are shown in Table 4.7. The
differences between the values of each inhibitor constant for the various
fractions were not statistically significant.
T able 4.7
Inhibitor constants for glycine of the yGT fractions obtained from serum and
bile
Fraction Inhibitor Constant + (S.E.)
Glycylglycine y-L-Glutamyl-p-nitroanilide
Serum 25.12 + 3.21 4.03 + 0.092
Bile 22.23 + 2.44 4.73 + 0.60
Serum Peak 1 22.60 + 4.73 4.51 + 0.68
Serum Peak 2A 22.47 + 2.53 4.42 + 0.40
Serum Peak 2B 27.36 + 4.12 4.33 + 0.35
Serum Peak 4 21.72 + 3.02 3.75 + 0.16
Bile Peak 1 21.64 + 3.99 4.43 + 0.95
Bile Peak 4 28.80 + 2.11 3.92 +' 0.61
The results suggest that there is no difference in the catalytic properties
studied, between the different yGT fractions obtained from serum and bile.
The significance of this finding is considered in Chapter 7 of this thesis.
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4-14 STUDIES ON LEUCINE AMINOPEPTIDASE AND ALKALINE
PHOSPHATASE
4.14.1 Effect of papain treatment
Variable amounts of LAP and ALP activity were destroyed following papain
treatment (Table 4.8).
Table 4.8
Enzyme activities after digestion of sera with papain
Sample Percentage initial enzyme activity
LAP ALP
Serum A 81 74
Serum B 91 64
Serum C 66 57
4.14.2 Gel chromatography performed in the absence of bile salts
After gel chromatography of normal sera and sera from patients with liver
disease, varying amounts of LAP eluted as Peaks 1, 2 and 4 (LAP) (Table 4.9).
In contrast to Peak 2 (yGT), no splitting of Peak 2 (LAP) was noticed although
it appeared to constitute a smaller proportion of total activity in patients with
extrahepatic biliary obstruction as compared to the rest (Figs. 4.31 and 4.32).
In contrast to both yGT and LAP, ALP showed no intermediate peaks
(Figs. 4.31 and 4.32) (Table 4.9). The recovery of enzyme activity was
variable; for LAP mean 104%, range 81 -155%; for ALP mean 105.3%, range
82 - 143%.
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Figure 4.31 Elution profiles of LAP and ALP following gel
chromatography on Sephacryl S300 of serum from a patient
with extrahepatic biliary obstruction. # , LAP; O >
ALP.
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Figure 4.32 Gel chromatography on Sephacryl S300 of LAP and ALP in
serum from a patient with alcoholic cirrhosis. # , LAP;
o , alp.





Distribution of LAP and ALP activity obtained after gel chromatography of
IIP sera on Sephacryl S3Q0
Fraction Percentage of total recovered activity
Mean Range
Peak 1 (LAP) 18.5 3 - 60
Peak 2 (LAP) 22.5 0-53
Peak 4 (LAP) 59 27-91
Peak 1 (ALP) 14.0 2-54
Peak 4 (ALP) 86 46 - 98
4.14.3 Gel chromatography performed in the presence of bile salts
When serum was chromatographed in the presence of 12 mmol/1 deoxycholate
or glyochenodeoxycholate, the amount of ALP activity eluting as Peak 1 (ALP)
decreased, together with the appearance of activity eluting as Peak 3 (ALP)
(Fig. 4.33). Although the elution volume of Peak 4 (ALP) appeared to be
unaffected, there was a suggestion of some loss of activity.
When a concentrated pool of Peak 1 (ALP) was rechromatographed in the
presence of bile salts it disappeared, giving rise to Peak 3 (ALP). No LAP
activity was ever recovered in the eluate when serum or Peak 1 (LAP) were
chromatographed in the presence of bile salts.
4.14.4 Gel chromatography of papain-treated serum
Gel chromatography of papain-treated serum in the absence of bile salts
resulted in a decrease in LAP activity eluting as Peaks 1 and 2 (LAP) together
Figure 4.33
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Elution profile on Sephacryl S300 of ALP with 0 , or
without O , 12 mmol/1 deoxycholate in the elution buffer.
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with an increase in activity eluting as Peak 4 (LAP) (Fig. 4.34). There was also
a decrease in activity of Peak 1 (ALP) but no concomitant increase in activity
associated with Peak 4 (ALP).
The estimated Mr values of the enzyme fractions obtained after gel
chromatography are shown in Table 4.10.
Table 4.10





Peak 2 400 000 - 6 10 000 **
Peak 3 * 280 000
Peak 4 190 000 200 000
* Not estimable
** Not present
4.14.5 7% polyacrylamide gel electrophoresis
Results obtained for LAP were analogous to those described for yGT. Three
main areas of activity were observed; one at the origin (Band 1 (LAP)), one of
varying mobility (between 5 and 35% of that of albumin) (Bands II (LAP)) and
two bands with mobility approximately 55 and 60% of that of albumin (Band
IVA (LAP) and Band IVB (LAP)) (Fig. 4.35). Bands IVA and IVB (LAP) were also
obtained following electrophoresis of the fraction corresponding to Peak 4
(LAP) obtained after gel chromatography.
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Figure 4.34 Gel chromatography of LAP in human serum before O >
or after # , treatment with papain.
Peakl Peak 2 Peak*.
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Figure 4.33 Polyacrylamide slab gel electrophoresis of sera from
patients with liver disease and a papain-treated serum,
stained for LAP activity. 1 - 4, primary biliary cirrhosis; 5 -
8, extrahepatic biliary obstruction; 9 - 11, chronic active
hepatitis; 12, papain-treated serum.
ongin-







Electrophoresis of papain-treated sera yielded a single band of LAP activity of
equal mobility to Band IVB (LAP) (Fig. 4.35).
4.14.6 Polyacrylamide gradient gel electrophoresis




Estimated values of the various enzyme fractions obtained after gel





Peak 2 * ***
Peak 3 ** 260 000
Peak 4 170 000 180 000
* The staining of this fraction was too faint and diffuse to allow an accurate





Results were obtained for LAP, analogous to those obtained for yGT (see
section 4.6). Peak 1 (LAP) co-precipitated with LDL and VLDL and Peak 2
(LAP) co-precipitated with HDL (Fig. 4.36). ALP activity as Peak 1 (ALP),
however, only precipitated with the VLDL and LDL fraction.
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Figure 4.36 Elution profile of LAP in serum and the lipoprotein fractions
from a patient with gallstones before and after precipitation
with polyanions. O , whole serum; ■ , LDL and VLDL;




4.14.8 Incubation with antisera
Sera were incubated with antiserum to apolipoprotein A and with saline as a
control (see section 4.7.3) and subjected to electrophoresis. On staining for
LAP activity there was a decrease in the staining intensity of the area of
intermedate mobility (Fig. 4.37).
4.14.9 Effect of dialysis and freezing and thawing
Dialysis against 20 mmol/l Tris-HCl, pH 8.0 buffer, or repeated freezing to
-60°C followed by thawing at 37°C (4 times), had no effect upon the elution
patterns of the enzymes from the Sephacryl column (Fig. 4.38).
4.15 DISCUSSION
The results presented in this chapter confirm previous reports that yGT is
present in normal sera, and in the sera of patients with liver disease as high,
intermediate and low _M forms (Orlowski et al., 1965; Kokot and Kuska, 1968;
Huseby, 1978; Wenham et al., 1979; Echetebu and Moss, 1982a). They have
also shown that another hepatocyte plasma membrane enzyme, LAP, is present
in high, intermediate and low M^ forms, unlike ALP which does not possess the
intermediate M form.
—r
The high form of yGT (and also that of LAP and of ALP) co-precipitated
with VLDL and LDL after treatment with polyanions. This is consistent with
previous reports that these high forms may consist of complexes of the
enzymes with lipoproteins or lipoprotein-X (Price and Sammons, 1974; Wenham
£tjd., 1979; Crofton and Smith, 1981b; Huseby, 1982a).
On the other hand, varying amounts of the intermediate forms of yGT (and
also of LAP), with the notable exception of Peak 2B (yGT) co-precipitated
with HDL; an observation in agreement with that of Huseby (1982a). In
contrast, all of the intermediate _M yGT (and LAP) including Peak 2B (yGT),
were shown to bind to antiserum to apolipoprotein A but not to apolipoprotein
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Figure 4.37 Polyacrylamide slab gel electrophoresis of sera from
patients with liver disease after incubation 1 and 3, with
saline; or 2 and 4, with antiserum to apolipoprotein A. 5
antiserum to apolipoprotein A.
12 3 4 5






Figure 4.38 Elution profile on Sephacryl S300 of ALP in serum before
O , and after # , repeated freezing and thawing.
Peak 1 Fteak 4
(ALP) (ALP)
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B. The amount of yGT activity precipitated by the antiserum to
apolipoprotein A was variable, a finding in agreement with that of previous
workers (Huseby, 1982a; Artur et al., 1984a, 1984b). The latter authors,
however, were also able to precipitate yGT activity using antiserum to
apolipoprotein B, a finding at variance with the results both of the present
study and those of Huseby (1982a). This apparent discrepancy could be due to
the presence of antibody directed against yGT protein, in their antiserum to
low density lipoprotein, a property that has already been ascribed to antiserum
to lipoprotein-X (Huseby, 1982a). The results described in this chapter
strongly suggest that the intermediate M forms of yGT (and of LAP) consist
of complexes of the enzyme with HDL. The of an HDL particle may range
from 175 000 to 350 000 (Lewis, 1976; Huseby, 1982a), and so the estimated
of the intermediate yGT (and LAP) is consistent with the attachment of a
single molecule of yGT (or of LAP) onto such an HDL particle. However, the
possible attachment of more than one enzyme molecule per HDL particle is
not precluded in view of the wide range of M observed, particularly in Peak
2A (yGT). As well as co-precipitating with HDL, up to 30% of the
intermediate yGT also co-precipitated with LDL and VLDL. There are two
possible explanations for this; firstly, that the very presence of yGT on the
HDL complex alters the behaviour of this complex when treated with a given
concentration of polyanions, and secondly, that yGT is associated with LDL or
VLDL or both. The latter possibility is rendered unlikely by the fact that no
yGT activity was precipitated by antiserum to apolipoprotein B. The reason
why Peak 2B (yGT) did not precipitate with polyanions is unclear. Although
there is no evidence, it is possible that the precipitation characteristics of
these particles may have been altered by the presence of high concentrations
of bile salts in the serum of these patients.
The mean bile salt concentrations of serum from patients with extrahepatic
biliary obstruction were over five times those of the other groups. An attempt
was therefore made to mimic the abnormalities found in serum in obstructive
jaundice, by incubating sera that contained Peak 2A (yGT), with hepatic bile.
This incubation resulted in the conversion of Peak 2A (yGT) to a peak with an
elution pattern similar to that of Peak 2B (yGT). The ability of bile to effect
this change was a) inhibited by prior dialysis of the bile and b) reproduced by
incubation with glycochenodeoxycholate. These results suggest that the
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conversion of Peak 2A (yGT) to Peak 2B (yGT) was caused by the bile salts
present in the bile. However, electrophoresis of the bile / bile salt / sera
mixtures showed the presence of Band IIC (yGT) which was not previously
detected in any of the sera. This suggests that bile salt concentrations are not
the only factor involved in the formation of Peak 2B (yGT) in the sera of
patients with obstructive jaundice. This hypothesis is supported by the fact
that dialysis appears to have no effect upon Peak 2B (yGT), either in terms of
its or total recovered activity.
The eiution pattern of yGT (and ALP) changed markedly when gel
chromatography was performed in the presence of bile salts, as most of the
activity eluted as the Peak 3 forms. The picture is incomplete, however, since
bile salts inhibited LAP activity. The Peak 3 forms were hydrophobic in
nature and readily reaggregated if the bile salts were removed by dilution or
dialysis. The Peak 4 form of yGT (and also of LAP and of ALP) on the other
hand, observed in untreated sera, or obtained following treatment with papain,
was hydrophilic in nature and showed no tendency to reaggregate after
incubation with serum.
The inability of antiserum to apolipoprotein A to bind Peak 3 (yGT) suggests
that the yGT-HDL complex had either been dispersed or radically altered in
its properties. In an attempt to reform the complex, Peak 3 (yGT) was
incubated with normal serum. When this had been done the antiserum
appeared to be able to bind to the yGT in the serum - Peak 3 (yGT) mixture.
This phenomenon suggests that the yGT-HDL interaction is hydrophobic in
nature and that it can form spontaneously in serum in vitro. The complex also
appears to have a stable physical configuration since freezing and thawing had
no noticeable effect.
Finally, the fact that Peak 2B (yGT) is found in large amounts only in the
serum from patients suffering form extrahepatic obstructive jaundice suggests
that measurement of this fraction might be of clinical and diagnostic value.
This hypothesis is tested and explored further in Chapter 5 of this thesis.
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Chapter 5
A CLINICAL STUDY OF THE MULTIPLE FORMS GF
y-GLUTAMYLTRANSFERASE
Although it is known that yGT activity in serum is increased in patients with
liver disease (Szczeklik et ah, 196 1; Goldbarg et al., 1963; Rosalki £t al., 1971;
Rosalki and Rau, 1972), most investigators have found that such measurements
of total activity discriminate poorly, if at all, between the different types of
liver disease. Differential measurements of the multiple forms of yGT in
serum have been made much less frequently in such patients. Furthermore, in
those instances where differential measurements have been made, they have
usually been based on electrophoretic means of separation rather than on
methods which separate the multiple forms on the basis of ^1 (Jacyszyn and
Laursen, 1968; Hetland et al., 1975; Kok et al., 1973; Burlina, 1978).
During the study of the physical properties of serum yGT (Chapter 4), three
major categories of yGT were distinguished on the basis of and
electrophoretic behaviour:
1. The first fraction, high yDT, which I have called Peak 1 (yGT), elutes
in the void volume after gel chromatography on Sephacryl 5300 and
remains at the origin after polyacrylamide gel electrophoresis. This
fraction is present in normal serum and tends to predominate in serum
from patients with obstructive liver disease.
2. The second fraction, intermediate M yGT (M 250 000 -500 000), has an
—r —r
electrophoretic mobility between 8 and 55% of that of albumin. This
fraction may be of two types, most easily distinguished from one another
by electrophoresis. The first type separates into several bands (which I
have called Bands IIA (yGT)) with mobilities between 8 and 40% of that of
albumin. In contrast, the second type moves as a discrete band (Band IIB
(yGT)) with a mobility of 45 - 55% of that of albumin. During the studies
described in Chapter 4 it was noted that although Bands IIA (yGT) are
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usually the main intermediate fractions present in liver disease, Band
IIB (yGT) predominates in patients with jaundice due to extrahepatic
obstruction.
3. The third fraction, low yGT, (M about 120 000) is a hydrophilic form
of the enzyme. This is in contrast to the two hydrophobic forms of the
enzyme mentioned above.
The present study attempts to define more precisely the physical differences
(described in Chapter 4) between the yGT found in various liver diseases. In
particular, it attempts to determine whether the use of yGT measurement can
help to distinguish jaundice due to extrahepatic obstruction and possibly
remediable by surgery, from other 'medical' causes of jaundice.
High M forms of leucine aminopeptidase and alkaline phosphatase also appear
in serum in liver disease (Ideo and Ronchi- 1972; Price and Sammons, 1974;
Crofton and Smith, 1981a). The high forms of these enzymes have also
been studied in order to compare their diagnostic efficiency with that of yGT.
It is hoped that the results might also lead to more insight into the mechanism
of release of yGT (and LAP and ALP) into the circulation.
5.1 SAMPLES USED IN THE STUDY
Sera from 100 patients with liver disease (97 of which had an elevated yGT
activity) were selected from specimens sent to the department for yGT
measurement. The selection of particular specimens was made on the basis of
diagnosis and following discussion with the clinician looking after the patient.
The diagnosis was based on clinical and laboratory findings and wherever
possible confirmed by liver scan, liver biopsy or laparotomy. Sera were also
obtained from 10 apparently healthy individuals with no clinical or biochemical
evidence of liver damage. The classification of the patient groups, together
with the abbreviations used throughout this chapter, is shown in Table 5.1.
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Table 5.1
Classification of patient groups
Patient Group No of patients
Abbreviations used
in illustrations




Metastatic liver disease 25 Liver 2°.
Primary biliary cirrhosis 9 P.B.C.




Chronic active hepatitis 7 C.A.H.
Haemochromatosis 7 H'chrom.
Post liver transplant 6 T'plant
5.2 MEASUREMENT OF HIGH M ENZYMES
r
This was carried out following gel chromatography of 1 - 2 ml of serum on a
95 x 2.6 cm column of Sephacryl S30Q (see section 2.3). The problem of
overlapping peaks, when it arose, was overcome by extrapolation of the peaks.
The enzyme activities in the high M^ peaks were summed and the activity of
the high M^ fraction calculated using the formulas-
High M enzyme (%) = -r—^ R x 100r r\ "f* D
High M^ enzyme (U/l) = —^^ ^ x serum enzyme activity (U/l)
Where A = The sum of the activities of the fractions in the high M^ enzyme
peak.
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B = The sum of all of the other recovered enzyme activity.
The recovery of enzyme activity was variable; for yGT, the mean was 10 1.7%,
with a range of 8 1 - 146%; for LAP, mean 104%, range 81 - 155%; for ALP,
mean 105.3%, range 82 - 143%. It is possible that these unexpected high
recoveries may be attributed to the presence of inhibitors in serum which were
removed or diluted during gel chromatography. The precision of the method
was assessed by performing gel chromatography on a single serum sample on
11 different days and measuring the high M^ fraction each day. Coefficients
of variation were 3.7% for high M^ yGT at a mean value of 58 U/l, 10.2% for
high M^ LAP at a mean value of 16 U/l and 7.9% for high M^ ALP at a mean
value of 22 U/l.
5.3 MEASUREMENT OF BAND IIB (yGT)
Intermediate M^ yGT was separated into its subtractions, Bands IIA (yGT) and
Band IIB (yGT) by electrophoresis on 4 - 30% polyacrylamide gradient gels (see
section 2.4). Polyacrylamide gradient gels were chosen instead of uniform 7%
polyacrylamide slabs because:
1. They were of a more convenient size to fit the scanner.
2. Up to 4 gels, i.e. 20 samples, could be set up in each run.
3. It was more convenient to use pre-cast gels.
5.3.1 Optimal staining time of gel
The time course of colour development during the first stage of the two-step
gel staining procedure was investigated to determine the optimal incubation
time. Electrophoresis was performed on equal portions of a pool of Peak 2B
(yGT) obtained after gel chromatography of serum on Sephacryl S300. After
electrophoresis, slices of the gel corresponding to each aliquot were incubated
in substrate solution for various lengths of time. At the end of each period the
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gels were immersed in a solution of Fast Blue B diazonium salt in 10% (v/v)
acetic acid for 15 min then scanned at 525 nm using an Auto Scanner Flur-Vis
(Helena Laboratories, Beaumont, Texas, USA). The results (Fig. 5.1) show that
the increase in colour development (as measured by the area under the peak)
was rectilinear with time up to 6 h. Three hours was arbitrarily chosen as a
convenient incubation time.
5.3.2 Variation of staining intensity with amount of enzyme applied to gel
Samples (0 - 40 pi) of a concentrated pool of Peak 2B (yGT) were made up to
50 pi with saline, then subjected to polyacrylamide gradient gel
electrophoresis. The gels were then incubated with substrate for 3 h, stained
for 15 min in Fast Blue B-giacial acetic acid and then scanned. The graph of
colour intensity versus amount of enzyme (volume of Peak 2B (yGT))
electrophoresed was linear up to an applied activity of 8.4 x 10"^ U (Fig. 5.2).
The yGT activity of the pool was 210 U/l.
5.3.3 Calculation and precision of the method
Band IIB (yGT) was estimated as a percentage of the total intermediate
yGT from the formula:
Band IIB (yGT) = _ C _ x 100C + D
Where C = The area of the peak corresponding to Band IIB (yGT) obtained
after scanning.
Where D = The area of the peaks corresponding to Bands IIA (yGT)
obtained after scanning.
Between-batch precision was estimated by performing electrophoresis on 10
sera on 2 different occasions, each on different days. A coefficient of
variation of 11.2% was obtained for Band IIB (yGT) at a mean of 55%
(range 0 - 100%). The mean serum yGT activity was 309 U/l
(range 28 - 625 U/l).
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Figure 5.1 Electrophoresis of Peak 2B (yGT) on polyacrylamide
gradient gei. Variation in intensity of Band IIB (yGT) with
incubation time.
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Figure 5.2 Electrophoresis of Peak 2B (yGT) on polyacrylamide
gradient gel. Variation in intensity of Band IIB (yGT) with
amount of enzyme applied.
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5.4 REFERENCE RANGES
Reference ranges for the enzyme activities in serum were as follows:- for
yGT, 6-31 U/l for females, 8-49 U/l for males; for LAP, 27 - 70 U/l and for
ALP, 30 - 140 U/l.
5.5 STATISTICAL ANALYSIS
The results of tests in different disease categories were compared using non-
parametric methods of analysis (Kruskal-Wallis one-way analysis of variance),
(Siegel 1956). Correlation analysis was performed using standard parametric
methods.
5.6 HIGH Mf yGT
The distributions of total yGT, high yGT (U/l) and high yGT (%) in the
different patient groups are shown in Figs. 5.3 - 5.5. The results from patients
with metastatic liver disease are similar, whether or not jaundice was evident
(P = 0.13), so these two groups have been considered together. In all cases
there is considerable overlap between the groups. Nevertheless it is clear that
high yGT, expressed as a percentage:-
1. Was greatest in patients with extrahepatic obstruction (p < 0.000001).
2. Was greater in patients with liver metastases than in other groups, if the
patients with extrahepatic obstruction are excluded from the analysis
(p < 0.0001).
3. Was greater in patients with extrahepatic obstruction than in those with
metastatic liver disease (p < 0.00001).
4. Was greater in patients with extrahepatic obstruction than in jaundiced
patients in other disease categories (p < 0.00001).
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Figure 5.3 Distribution of total yGT activity in the different patient
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Figure 5.4 Distribution of high Mr yGT expressed as U/l in the
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Figure 5.5 Distribution of high yGT expressed as the percentage of
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High yGT (expressed as U/l) tends to be within the reference range or only
slightly elevated in those patients receiving anticonvulsants, suffering from
haemochromatosis, or after liver transplantation.
5.7 HIGH M LAP AND HIGH M ALP
r r
The results for high LAP (Figs. 5.6 - 5.8) were very similar to those for
high yGT in patients with extrahepatic obstruction and metastatic liver
disease.
The results for high ALP (Figs. 5.9 - 5.11)~were also similar to those for
high yGT, but showed fewer differences between the different disease
categories. For example, whereas high Mr ALP (%) was greatest in
extrahepatic obstruction (p < 0.001), direct comparison between the patients
with extrahepatic obstruction and those v/ith liver secondaries or those with
jaundice from other causes showed no significant difference. The results of
the statistical analysis of the data for the high enzymes are shown in Table
5.2.
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Figure 5.6 Distribution of total LAP activity in the different patient
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Figure 5.7 Distribution of high LAP expressed as U/l in the
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Figure 5.8 Distribution of high M LAP (%) in the different patient
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Figure 5.9 Distribution of total ALP activity in the different patient
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Figure 5.10 Distribution of high ALP expressed as U/l in the
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Figure 5.11 Distribution of high M ALP expressed as the percentage of




















Result between patient groups of the comparison of high yGT (%), high M
LAP (%) and hiqh M ALP (%)
r
Patient Groups yGT LAP ALP
Ob.j. (Mj) v All other (M2) 53 18 34 13 20 10
Pa <0.000001 <0.000001 <0.001
Ob.j. (Mj) v- Liver 2° (M3) 53 27 34 19 20 18
Pa <0.00001 <0.0001 N.S.b
Ob.j. (M.) v
All jaundiced sera (M4) 53 24 34 16 20 14
Pa <0.00001 <0.00001 N.S.b
Liver 2° (M.J v
All patients minus Ob.j. (M^) 27 19 19 13 18 9
Pa <0.0001 <0.001 <0.0001
g




Mj = mean value in patients with obstructive jaundice
= mean value in all other patients
= mean value in patients with metastatic liver disease
= mean value in all jaundiced sera
= mean value in all patients without obstructive jaundice
5.8 RELATIONSHIP BETWEEN HIGH M yGT AND OTHER HIGH M
—r -i —r
ENZYMES
There was a close relationship between high yGT(%) and high M^ LAP (%),
r = 0.84 (Fig. 5.12). There was a poorer correlation between high ALP (%)
and high yGT (%), r = 0.66 (Fig. 5.13) or high LAP %, r = 0.67 (Fig. 5.14).
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Figure 5.12 Relationship between high yGT and high LAP, both
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Figure 5.13 Relationship between high yGT and high ALP, both
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Figure 5.14 Relationship between high LAP and high ALP, both


















One of the points on the yGT v LAP correlation scattergram (Fig. 5.12), which
was from a patient with primary biliary cirrhosis, appears to be obviously
discrepant. There were values of 23.9% and 50.5% for high yGT and high
M LAP respectively. However, the calculation was confirmed to be correct
and nothing else unusual was found about the patient.
Similarly, inspection of the yGT v ALP correlation scattergram (Fig. 5.13)
revealed 9 patients with a low value for high ALP (%) relative to high M^
yGT (%), i.e. all of the high ALP (%) values were less than 20%, and all of
the high yGT (%) values were greater than 43%. Although all of these
patients had extrahepatic obstructive jaundice, it was difficult to place any
great significance on this observation, due to the large scatter on the data
points.
5.9 RELATIONSHIP BETWEEN HIGH M ENZYMES AND BILE SALT
—r
CONCENTRATIONS
Since serum bile salt concentrations are widely regarded as good indices of
cholestasis, the relationship between them and the high M^ enzymes, measured
as percentages of total activity, was investigated. Bile salt concentrations
were significantly higher, in extrahepatic obstruction than in other forms of
liver disease (Table 5.3, p < 0.000001). The relationship between the bile salt
concentrations and the high enzymes is shown in Figs. 5.15 - 5.20). There
is a low but significant association between serum bile salt concentrations and




Bile salt concentrations in patients with extrahepatic biliary obstruction
compared to all other patients
p . p Total conjugated Total conjugateda len roup cholate ((imol/1) chenodeoxycholate ((j.mol/1)
Mean Range Mean Range
Ob.j. 101 12 - 296 64 9 - 229
All other patients 24 0 - 234 12 0 - 113
Table 5.4
Correlation coefficients between the high M^ enzymes and total conjugated
bile salt concentrations
High M enzyme Total conjugated Total conjugated
cholate chenodeoxycholate
r r
High Mr yGT (%) 0.47 a 0.32 b
High Mr LAP (%) 0.38 a 0.24 C








Figure 5-15 Relationship between high yGT, expressed
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Relationship between high yGT, expressed as the
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Figure 5.17 Relationship between total conjugated cholate and high

















Figure 5.18 Relationship between high LAP, expressed as the























Figure 5.19 Relationship between high ALP, expressed as the
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Figure 5.20 Relationship between high ALP, expressed as the
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5.10 QUANTITATION OF BAND IIB (yGT)
Quantitative measurement of Band IIB (yGT) was made in 64 of the patients
with liver disease, including 16 of the 25 patients with jaundice due to
extrahepatic obstruction. Typical electrophoretic patterns are shown in
Fig. 5.21 and the results plotted in relation to high yGT (%) in Fig. 5.22. In
the occasional cases where Bands IIA and IIB (yGT) were present together in
the serum and they were not completely separated, e.g. patients 5 and 8
(Fig. 5.21), the percentages were calculated by extrapolation of the individual
peaks. In 11 of the 16 patients (69%) with obstructive jaundice, all of the
intermediate yGT was present as Band IIB (yGT) as seen by visual
inspection of the gels and confirmed by densitometric scanning. In none of the
patients from any of the other groups was all of the intermediate yGT
present as Band IIB (yGT). Although the numbers are quite small, the data in
Fig. 5.22 suggest that the electrophoretic subdivision of Band II (yGT)
discriminates between the patients with extrahepatic obstruction and the rest
better than the measurement of high yGT (%). In an attempt to determine
whether the two results combined further improved discrimination, Fig. 5.22
was arbitrarily divided into 4 quadrants using cut-off values derived from the
value of the mean +2 S.D. for each variable in the patients without obstructive
jaundice (40% for high yGT, 57% for Band IIB (yGT)). A positive test for
obstructive jaundice was defined as a value in the top right quadrant (i.e. both
variables above the cut-off limit). The results obtained, compared to those
derived from using only one of the variables (with the same cut-off limits) are
shown in Table 5.5 together with equivalent results obtained by measuring high
M LAP (%) (cut-off value 32%) and high M ALP (%) (cut-off value 26%).—r —r
They suggest that little improvement in discrimination is obtained by
measuring high M yGT (%) and Band IIB (yGT) together as compared with that
obtained from electrophoretic fractionation alone. The results also show that,
whereas all three high enzymes had similar values for specificity in the
detection of extrahepatic biliary obstruction, high ALP (%) was much less
sensitive than either high M yGT (%) or high M LAP %.
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Figure 5.21 Polyacrylamide gradient gel electrophoresis of sera from
patients with liver disease. 1-4, extraheptic biliary
obstruction; 5-9, alcoholic cirrhosis.
- ongin-





Figure 5.22 Band IIB (yGT), expressed as the percentage of all
intermediate yGT, plotted in relation to high yGT,
expressed as a percentage of the total yGT activity, in
patients with liver disease. 0 , extrahepatic biliary






















Table5.5 DiagnosticvalueofhighyGT(%)andBIIB(yG )measuredsi glyt e her,higLAPand highMALP(%),inthedetectionofxtrahepaticb li ryobs ruction Sensitivity Specificity^ Predictivevaluof positivete t Predictivevaljuof negativetestNumber(and%)oft talpatients HighMrLAP fALHighyGT 11/16(69) 44/48(92) 11/15(73) 44/49(90)BandIIB 14/16(88) 46/48(96) 14/16(88) 46/48(96)Both 10/16(63) 47/48(98) 10/11(9 ) 47/53(89)9/16(56) 40/42(95) 9/11(82) 40/47(85)
3/15(20) 38/40(95) 3/6(50) 35/47(7 )
g
Proportionfatientsw thextrahepaticobs ruc iong v gpositivet ,
k Proportionfpatientswith utextrahepaticbstructiong v gnegativet . QProportionfsitivete sw hext ahepaticb ruction. ^ Proportionfnegativetestswith utextrahepaticobstruction.
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5.11 DISCUSSION
In this chapter, the discussion is limited to the relationship of the results to
diagnosis. Discussion of the results in the light of possible mechanisms for the
appearance of the enzymes in the circulation will be considered in the final
chapter (under the heading 'General Discussion').
The results confirm many previous reports that serum yGT activity is elevated
in most types of liver disease. In the present study an attempt was made to
increase its discriminatory capacity by performing more complex analysis of
serum yGT patterns in liver disease.
Despite the obvious constraints imposed upon the study by time and limitations
in patient numbers, the investigation has shown that high M^ yGT, particularly
when the results are expressed as a percentage, is (1) higher in obstructive
than non-obstructive lesions, and (2) higher in extrahepatic than in
intrahepatic obstruction. These results suggest that measurement of high M^
yGT, particularly when the results are expressed as a percentage, can help to
distinguish extrahepatic (a) from intrahepatic obstruction and (b) from almost
every other form of liver disease, whether or not the patient is jaundiced.
Moreover, a high value (greater than 50%) appears to be almost diagnostic of
extrahepatic obstructive jaundice (Fig. 5.5).
Only one systematic clinical study of high M^ yGT in patients with liver
disease appears to have been made (Moss et al., 1982). These authors found
significantly higher values in 38 patients with malignant infiltration of the
liver than in 17 patients with alcoholic liver disease. In both groups, however,
the mean total serum yGT activities were similar. These results have been
confirmed in the present study although considerable overlap occurred
between these particular groups. More recently, Selvaraj et al. (1984), in a
study of total hydrophobic yGT, were unable to distinguish between different
types of liver disease. However, their method, which involved relatively non¬
specific binding of hydrophobic yGT to phenyl-Sepharose, would also measure
intermediate yGT, as well as high M yGT.
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High Mr LAP behaved similarly to high yGT and was also present in greater
amounts in obstructive than in non-obstructive lesions.
In notable contrast to high yGT and high LAP, several clinical studies
involving the measurement of high ALP have been made (Fennelly et al.,
1969; Price and Sammons, 1976; Crofton et al., 1979; Siede and Sieffert, 1983).
These studies have also found higher levels in obstructive than in non¬
obstructive lesions. There is, however, some disagreement as to whether the
highest levels are observed in extrahepatic obstruction or metastatic liver
disease (Fennelly et al., 1969; Price and Sammons, 1976; Crofton et al., 1979).
Although the present investigation found that highest levels occurred in
extrahepatic obstruction (Fig. 5.11), there was no significant difference
between these and the values seen in patients with liver metastases (Table
5.2).
The measurement of high ALP has been advocated as having particular
value in the detection of metastatic liver disease (Viot et al., 198 1; Karmen et
al., 1984). The present study confirms that higher levels are present in
patients with secondary deposits compared to patients with liver disease other
than extrahepatic biliary obstruction. However, these results do not suggest
that the measurement of high fractions of yGT, or of LAP and ALP, is
likely to be of practical value in the diagnosis and detection of metastatic
liver disease, since the overlap with other categories of liver disease is so
great. One group of patients however was omitted from the study, namely
those with minimal abnormalities of liver function - a group in which the
detection of metastatic liver disease might be important. Such a group
however was studied by Moss et al. (1982) who concluded that measurement of
high yGT was no more sensitive in detecting such metastases than the
measurement of total serum yGT activity or total, or liver specific, alkaline
phosphatase.
The results do suggest that the measurement of Band IIB (yGT), as a
percentage of total intermediate yGT, particularly when its value is 100%,
may distinguish extrahepatic biliary obstruction from other types of liver
disease. The technique could prove especially valuable in daily practice if it
can be confirmed that visual assessment, without the need for scanning, is
adequate for distinguishing most cases.
183
The measurement of Band IIB (yGT) was combined with that of high M yGT in
an attempt to increase the discrimination between patients who did and did
not have extrahepatic obstructive jaundice. This strategy was unsuccessful
however (Table 5.5) as no greater discrimination was obtained than by
measuring Band IIB (yGT) alone.
In conclusion, the present study has shown that the measurement of high M^
yGT or of the intermediate form which has been called Band IIB (yGT),
may aid in diagnosis in liver disease. High yGT may distinguish
extrahepatic obstructive causes of jaundice from other causes, but the method
is time consuming and tedious rendering it unsuitable for obtaining a result
that could be of immediate value to patients. In contrast, estimation of
Band IIB (yGT) is relatively simple and is probably a better discriminator. It is
considered that electrophoresis of yGT on polyacrylamide gel (or possibly
other gels as well) can aid the important clinical differentiation between
extrahepatic and intrahepatic causes of jaundice. Moreover, it is sufficiently
practical for use in a service laboratory.
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Chapter 6
PHYSICAL PROPERTIES OF y-GLUTAMYLTRANSFERASE IN HUMAN
LIVER: RELATIONSHIP TO y-GLUTAMYLTRANSFERASE IN BILE
AND SERUM
y-Glutamyltransferase in serum probably originates from the liver because
increases in serum yGT activity are largely confined to liver disease (Huseby,
198 1). The results of the experiments described in Chapters 3 and 4 of this
thesis have shown that yGT is present in human bile and serum mainly as
hydrophobic forms, together with small amounts of a low ]Y hydrophilic form
(Peak 4 (yGT)). In serum, the hydrophobic yGT is of both high (Peak 1 (yGT))
and intermediate Mf (Peak 2 (yGT)), whereas in bile it is of high M only. In
the presence of an adeguate concentration of bile salts, the hydrophobic high
and intermediate M^ forms are dispersed and converted to hydrophobic low jv^
forms (Peak 3 (yGT)). These low M forms reaggregate in the absence of bile
salts.
In studies attempting to reproduce the electrophoretically separable zones of
yGT activity seen in serum, liver tissue was incubated with a normal serum
pool and various protein-free solutions (Echetebu and Moss, 1979; Moss, 1980;
Echetebu and Moss, 1982a). These authors compared the eluted fractions with
those found in a pool of abnormal sera with high yGT activities, in terms of
electrophoretic mobility and M . They noted, in particular, that a high Mr
form, produced by incubation of liver tissue in serum, resembled a form
present in the high activity serum pool. They tentatively interpreted this
fraction as corresponding to the elution of yGT, in association with
components of the membrane matrix, from liver or biliary tract cells.
The preliminary investigation described in this chapter is an attempt to
reproduce and extend their findings. Liver tissue has been incubated with
abnormal as well as normal serum, protein and protein-free solutions, bile and
bile salts, and the eluted enzyme studied. The physical properties of yGT in
liver microsomes have also been investigated and a direct comparison made
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with the physical properties of yGT in human bile and serum. The aim of the
study was to gain further insight into the mechanism behind the findings of the
raised serum yGT activity seen in liver disease.
6.1 PHYSICAL PROPERTIES QF yGT IN HUMAN LIVER
6.1.1 Samples used in study
Samples of human liver were obtained post mortem, within 24 h of death, from
patients with no evidence or history of liver disease. The liver was washed
with ice cold saline, and homogenised in ice cold 20 mmol/1 Tris-HCl buffer,
pH 8.0, containing 50 mmol/1 NaCl (9 g of tissue per 20 ml of buffer). The
liver homogenate was centrifuged for 30 min at 3000 x 5 to remove cell debris
and then the supernatant for a further 30 min at 18 000 x £ to remove
mitochondria. The microsomal fraction was obtained by centrifugation of the
supernatant at 100 000 x £ for 1 h.
6.1.2 Treatment with sodium deoxycholate
The crude microsomal preparation was incubated with an approximate 10-fold
volume of 25 mmol/1 sodium deoxycholate for 1 h at room temperature. After
centrifugation at 100 000 x 5 for 1 h, the supernatant was kept for further
study.
6.1.3 Treatment with papain
Samples of liver microsomes were incubated with an approximately equal
volume of papain (24.5 g/1) and a 10-fold volume of Tris-HCl, pH 8.0,
containing 50 mmol/1 NaCi overnight at 20°C in the presence of 100 mmol/1
cysteine. The samples were then centrifuged for 1 h at 100 000 x 3 and the
supernatant kept for further study.
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6.1.4 Gel filtration chromatography
This was carried out on a 2.6 x 65 cm column of Sephadex G200, as described
in section 2.3.1. The column was calibrated as described in section 2.3.3 and
the same nomenclature used to describe the peaks as used in section 3.4.1.
After gel chromatography of deoxycholate-treated liver microsomes, with
increasing concentrations of deoxycholate in the eluting buffer, the main peak
of yGT activity changed from Peak 1 (yGT), when there was no deoxycholate
in the elution buffer, to peak 3 (yGT) when the deoxycholate concentration
was 5 mmol/1 or greater (Fig. 6.1). When a concentrated pool of Peak 3 (yGT),
(obtained by performing gel chromatography of deoxycholate-treated liver
microsomes in the presence of 7 mmol/1 deoxycholate), was
rechromatographed in the absence of bile salts, the elution profile changed
from Peak 3 (yGT) to Peak 1 (yGT).
Gel chromatography of hepatic bile or serum in the presence of at least
5 mmol/1 sodium deoxycholate, revealed that the Peak 3 forms of yGT in bile,
serum and liver microsomes all had identical elution volumes (Fig. 6.2).
Gel chromatography of the supernatant from the papain-treated microsomes
revealed that all of the activity eluted as Peak 4 (yGT). This peak had an
identical elution volume to that of the Peak 4 (yGT) obtained following gel
chromatography of papain-treated bile (section 3.2) and of papain-treated
serum (section 4.2) (Fig. 6.3).
6.1.5 7% polyacrylamide gel electrophoresis
Electrophoresis in 7% polyacrylamide gel, equilibrated in both the gel and the
running buffer with at least 5 mmol/1 of sodium deoxycholate, showed that
deoxycholate-treated liver microsomes contained a main zone of activity
(Band III (yGT)) which migrated just ahead of Peak 4 (yGT) (Band IV (yGT)).
The Band III (yGT) and Band IV (yGT) obtained from liver microsomes had
identical electrophoretic mobilities to that of Band III (yGT) and of Band IV
(yGT) obtained from bile (section 3.5.2) and serum (section 4.4.2) (Fig. 6.4).
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Figure 6.1 Elution profile on Sephadex G200 of yGT in deoxycholate-
treated liver microsomes. There were increasing
concentrations of deoxychoiate in the eluting buffer. O ,
no deoxychoiate; Q , 1.2 mmol/1 deoxychoiate; # , 7 mmol/1
deoxychoiate.
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Figure 6.2 Elution profile on Sephadex G200 of yGT in deoxycholate-
treated hepatic bile, serum and liver microsomes. The
concentration of deoxycholate in the elution buffer was












Figure 6.3 Sephadex G200 gel chromatography of papain-treated yGT
present in hepatic bile, serum and liver microsomes. # ,
hepatic bile; O , serum; Q , liver microsomes.
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Figure 6.4 Polyacrylamide slab gel electrophoresis in 12 mmol/l sodium
deoxycholate of yGT in deoxycholate and in papain-treated
bile, liver microsomes and serum from a patient with
extrahepatic biliary obstruction. 1, 4, 5, papain-treated
bile, liver, serum; 2, 3, 6, deoxycholate-treated bile, liver
serum.




6.1.6 Polyacrylamide gradient gel electrophoresis
The gradient gels were calibrated as described in section 2.4.4.
In the presence of 12 mmol/1 deoxycholate, the electrophoretic mobilities, and
therefore the estimated values of the Peak 3 forms of yGT obtained from
liver microsomes, bile and serum were identical (Fig. 6.5). The Peak 4 forms
of yGT obtained from these three tissues also had identical mobilities (Band IV
(yGT)), and travelled just ahead of the Peak 3 forms (Fig. 6.5). The estimated
M values of the various fractions are shown in Table 6.1.
—r
Table 6.1




Gel chromatography Gradient electrophoresis
mean range mean range
Peak 3 16 1 000 157 000 - 165 000 130 000 125 000 - 135 000
Peak 4 115 000 - 104 000 98 000 - 110 000
These values are in agreement with those of other workers for the Peak 3 and
Peak 4 forms of yGT obtained from human liver (Huseby, 1977; 1978; Shaw et
al., 1978; Echetebu and Moss, 1982a), bile and serum (Huseby, 1978). The
slight differences between the values for the Peak 3 and Peak 4 forms
described here and those estimated by Sephacryl S300 gel chromatography
(Table 4.4) are well within the experimental error of the methods.
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Polyacrylamide gradient gel electrophoresis in 12 mmol/1
deoxycholate of concentrated pools from Peaks 3 and
4 (yGT) obtained after gel chromatography. 1, Peak
4 (yGT) serum; 2, Peak 4 (yGT) bile; 3, Peak 3 (yGT)
liver; 4, Peak 4 (yGT) liver; 5, Peak 3 (yGT) bile; 6,
Peak 4 (yGT) serum; 7, Peak 3 (yGT) serum.
2 3 4 5 6 7
<-Band III ( GT)
<-Band IV ( GT)
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6.2 INCUBATION OF LIVER TISSUE IN VARIOUS FLUIDS
The aim of these experiments was to test the theory of elution (Moss, 1980)
and attempt to reproduce the various yGT fractions observed in serum in liver
disease, by an extension of the initial jn vitro studies devised by Echetebu and
Moss (1979).
Human liver tissue (50 g) was obtained at post mortem from a patient with no
evidence of liver disease. The tissue was washed in ice-cold saline, cut into
1 g pieces and stored in plastic tubes at -60°C until required.
The incubation procedure was carried out largely according to Echetebu and
Moss (1979). 4 ml of the appropriate fluid was incubated with 1 g of thawed
liver tissue for 48 h at 37°C. At timed intervals, 0.2 ml aliquots were
removed, centrifuged for 10 min at 2500 x assayed for yGT activity and
stored at -60°C for electrophoretic studies. An equal volume of the fluid was
then added to the incubation to maintain a constant volume. Correction was
made for this addition when calculating the yGT activity. Sodium azide
(0.5 g/1) was added to each fluid, prior to the incubation procedure, to inhibit
bacterial growth. Sodium azide has been shown not to inhibit yGT activity
(Echetebu and Moss, 1979) and this was confirmed in the present study.
6.2.1 Incubation of liver tissue with a serum pool possessing 'normal' yGT
activity
A normal serum pool, with a yGT activity of 45 U/l, was incubated for 48 h
with liver tissue as described above. A control sample of the pool was also
incubated for 48 h at 37°C in the absence of liver tissue.
During the incubation procedure, a steady increase was observed in the yGT
activity of the liquid phase (Fig. 6.6).
At the end of the 48 h period, the liver-free supernatant and the control
incubation were both subjected to gel chromatography on a 95 x 2.6 cm column
of Sephacryl 5300 calibrated as described in section 2.3.3. Using the
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Figure 6.6 yGlutamyltransferase activity in the liquid phase after
incubation of liver tissue with various fluids with increasing
periods of time. The activity at time 0 was determined
immediately after the addition of each fluid to the tissue.
—•— , normal serum pool;--O- , abnormal serum pool; —O— ,
saline; —O— , 5 mmol/1 glycyochenodeoxycholate; ,






nomenclature described in section 4.3.1, the results (Fig. 6.7) show that the
increase in yGT activity, observed in the supernatant from the incubation with
liver tissue, is largely associated with an increase in Peak 1 (yGT), together
with a smaller increase in Peak 4 (yGT), when compared with the control
incubation. No apparent alteration in the amount of recovered activity of
Peak 2 (yGT) was observed but its elution profile changed from that of Peak
2A (yGT) to that of Peak 2B (yGT), when compared to the control incubation.
Electrophoresis of the supernatants on polyacrylamide gradient gels confirmed
the chromatographic findings. Incubation with liver tissue resulted, (1) in an
increase in the band of activity at the origin (Band I (yGT)) which corresponds
to Peak 1 (yGT) (section 4.4.1) and (2) in a decrease in the activity associated
with Bands IIA (yGT), which correspond to Peak 2A (yGT), together with the
appearance of Band IIB (yGT) which corresponds to Peak 2B (yGT)
(section 4.4.1) (Fig. 6.8).
6.2.2 Incubation of liver tissue with serum pool possessing raised yGT
activity
A serum pool, with a yGT activity of 402 U/l and containing approximately
equal amounts of Peak 2A (yGT) and Peak 2B (yGT) (section 4.3.2), was
obtained from patients with liver disease. This was incubated with liver tissue
as described above and a control sample of the pool was incubated for 48 h
without liver tissue.
Following incubation with liver tissue, a rise in the total yGT activity in the
liquid phase was noted, but this was not as great as that observed in the
normal serum pool (Fig. 6.6).
Gel chromatography on Sephacryl S300, of the liquid phase, obtained after 48 h
incubation with liver tissue, showed an increase in activity associated with
Peak 1 (yGT) compared with the control incubation (Fig. 6.9). This was
accompanied by a decrease in the amount of activity eluting as Peak 2A
(yGT).
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Figure 6,7 Elution profile on Sephacryl S300 of yGT in the supernatant
after incubation of normal serum pool with # , or without
O , liver tissue for 48 h at 37°C.
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Figure 6.8 Polyacrylamide gradient gel electrophoresis of yGT in the
supernatant obtained after incubation of a normal serum
pool at 37°C for 48 h with or without liver tissue. 1, with;
2, without,
1





Figure 6.9 Elution profile on Sephacryl S300 of yGT in the liquid phase
obtained after incubation of an abnormal serum pool with # ,
or without O , liver tissue for 48 h at 37°C.
Beak 1 Peak 2A Peak 2B Peak 4
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Electrophoresis of the 48 h supernatants on polyacrylamide gradients gave
results that were in agreement with the chromatographic findings. Incubation
with liver tissue resulted in an increase in the staining intensity associated
with Band I (yGT), a decrease in the staining intensity associated with Bands
IIA (yGT) and the appearance of a small zone of activity just ahead of Band IIB
(yGT) (Band IID (yGT) (Fig. 6.10).
6.2.3 Incubation of liver tissue with saline
During incubation of liver tissue in saline for 48 h, a steady rise in the activity
of the supernatant was observed (Fig. 6.6).
Gel chromatography of the supernatant on Sephacryl 5300 demonstrated that
the yGT released during the incubation procedure eluted as Peak 4 (yGT),
(Fig. 6.11).
Polyacrylamide gradient gel electrophoresis of the supernatant, obtained at 0,
24 and 48 h after addition of saline to the liver tissue, showed a gradual
increase in the intensity associated with Band IV (yGT) the eiectrophoretic
mobility of which corresponds to that of Peak 4 (yGT) (section 4.4.1)
(Fig. 6.12).
6.2.4 Incubation of liver tissue with 3 mmol/l qlycochenodeoxycholate
Addition of 5 mmol/l glycochenodeoxycholate to liver tissue resulted in the
immediate release into the liquid phase of more yGT activity than was evident
in any of the other fluids in the incubation experiments. The activity reached
a peak after 3 h and then fell to a slightly lower value for the remainder of the
incubation (Fig. 6.6). This observation is consistent with leaching of the yGT
from the plasma membrane into the liquid phase by the
glycochenodeoxycholate,with solubilisation being complete after about 3 h.
The fall in activity observed after this time may be due to slight instability of
the enzyme, when maintained at 37°C for long periods of time in an
environment deficient of protein.
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Figure 6.10 Polyacrylamide gradient gel electrophoresis of yGT in the
supernatant obtained after incubation of an abnormal serum
pool for different times at 37°C with or without liver tissue.








Figure 6.11 Elution profile on Sephacryl S300, of yGT in the liquid phase





Figure 6.12 Polyacrylamide gradient gel electrophoresis of Peak 4 (yGT)
and the supernatants obtained after incubation of liver
tissue in saline for 24 and 48 h. 1, 24 h; 2, 48 h; 3, Peak 4
(yGT).
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Gel chromatography of the 48 h supernatant in the absence of bile salts
revealed a broad peak of yGT activity, suggesting partial reaggregation of low
M. hydrophobic enzyme during chromatography. When chromatography was
repeated with 5 mmol/l deoxycholate in the elution buffer, a single peak of
low Mr was obtained corresponding to Peak 3 (yGT) (Fig. 6.13).
6.2.5 Incubation of liver tissue with human bile
Bile was obtained from a patient with 'T' tube drainage of the common bile
duct. The concentration of total conjugated cholate was 6.5 mmol/l and of
total conjugated chenodeoxycholate 1.5 mmol/l. The initial yGT activity was
439 U/l.
Following incubation of bile with liver tissue there was a steady decline in
yGT activity in the liquid phase (Fig. 6.6).
Gel chromatography of the liquid phase obtained after incubation for 48 h with
liver tissue revealed a decrease in activity of Peak 1 (yGT) compared to the
control that had been incubated for 48 h in the absence of liver tissue (Fig.
6.14). This was accompanied by the appearance of a large peak of activity
eluting immediately after Peak 1 (yGT). There was no apparent alteration in
the small amount of Peak 4 (yGT) present in the native bile. Although the
same volumes of 48 h supernatants were chromatographed, less activity was
recovered from the liver incubate than the control; 0.69 U and 0.84 U
respectively, with recoveries of applied activity of 87% and 95% respectively.
This observation is in agreement with the fall in activity of the supernatant
observed during the incubation procedure and suggests that yGT activity has
been lost in the liver incubate, a finding which is difficult to explain. One
possible explanation, advanced previously (section 6.2.4), is instability of yGT
at 37°C in the absence of protein. Another, for which there is no proof, is
that interaction of liver, or some component of liver, with biliary yGT
somehow results in its inhibition. Gel chromatography of the liquid phase
obtained after immediate mixing of the bile with the liver tissue revealed an
almost identical elution profile to the supernatant obtained after 48 h
incubation with the liver. The recovered activity of the former was greater,
however, due to the higher yGT activity of the sample.
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Figure 6.13 Gel chromatography of yGT in the supernatant, obtained
after incubation of liver tissue with 5 mmol/1
glycochenodeoxycholate for 48 h. O , no bile salts in the
elution buffer; • , 5 mmol/1 deoxycholate in the elution
buffer.
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When the 48 hour supernatant obtained after incubation with liver tissue was
chromatographed in the presence of 5 mmol/l deoxycholate, both Peak 1 (yGT)
and the peak eluting immediately after it disappeared, giving rise to Peak 3
(yGT) (Fig. 6.14).
6.2.6 Incubation of liver tissue with human albumin
It was noted that incubation of liver tissue with normal or abnormal serum, i.e.
solutions with high protein content, resulted in an increase in yGT activity
which eluted as Peak 1 (yGT). In contrast, incubation of liver tissue with a
protein-free solution, namely saline, resulted in release of activity which
eluted as Peak 4 (yGT). In an attempt to see if this difference was due to the
presence of protein in the incubation medium, a solution of 60 g/l albumin in
150 mmol/l NaCl was used in the incubation procedure.
The addition of the albumin solution to liver tissue caused the immediate
appearance of, and a further steady rise in, yGT activity in the liquid phase
(Fig. 6.6).
Gel chromatography of the 48 h supernatant on Sephacryl S300 revealed most
of the yGT activity eluting as Peak 4 (yGT) with a small quantity eluting as
Peak 1 (yGT) (Fig. 6.15).
Electrophoresis of the liquid phase on polyacrylamide gradient gels confirmed
the chromatographic findings. There was a steadily, increasing intensity of
Band IV (yGT) (Fig. 6.16).
6.3 DISCUSSION
The results of this preliminary study have confirmed the finding that yGT may
be released from human liver microsomes by the bile salt sodium deoxycholate
(Huseby, 1977, 1978; Shaw et al., 1978). In the presence of an adequate
concentration of bile salts, the enzyme exists as a low hydrophobic form
(Peak 3 (yGT)) which reaggregates when the bile salts are removed, as
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Figure 6.14 Gel chromatography on Sephacryl S300 of yGT in the liquid
phase obtained after incubation of hepatic bile with □ , or
without O , liver tissue for 48 h. ® , with liver but elution
buffer equilibrated with 5 mmol/1 sodium deoxychoiate.
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Figure 6.15 Elution profile on Sephacryl S300 of yGT in the liquid phase
obtained after incubation of liver tissue in 60 g/1 human
albumin for 48 h.
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Figure 6.16 Polyacryiamide gradient gel electrophoresis of yGT in the
liquid phase obtained after incubation of liver tissue in
60 g/1 human albumin at 37°C for different periods of time.
1, 0 h; 2, 12 h; 3, 24 h; 4, 48 h; 5, Albumin solution 48 h,
no liver.
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observed by others (Huseby, 1978; Echetebu and Moss, 1982a). In contrast, the
enzyme released by papain digestion (Peak 4 (yGT)), is hydrophilic in nature,
shows no tendency to reaggregate and is of lower M^ than the Peak 3 form. It
also appears to be produced by the action of trypsin on liver yGT (Shaw et al.,
1978; Echetebu and Moss, 1982b).
The Peak 3 forms of yGT from human liver, bile (Chapter 3) and serum
(Chapter 4) were all found to have identical electrophoretic and
chromatographic properties. Similarly, the Peak 4 forms of yGT from all
three tissues had identical physical properties. The implications of these
findings are considered and discussed later in Chapter 7.
Liver tissue, when incubated with serum containing normal or elevated yGT
activity, gave rise to yGT which was mainly in the Peak 1 (yGT) form and to
much smaller amounts of the Peak 4 (yGT) form, confirming the results of
Echetebu and Moss (1982a). In both these serum incubates there was a
decrease in the activity eluting as Peak 2A (yGT) and in the normal serum
incubate this was associated with an appearance of activity eluting as Peak 2B
(yGT). The pathological serum incubate gave rise to a new fraction detectable
only by electrophoresis (Band IID (yGT)) the significance of which is unknown
at present. These findings, however, are at variance to those of Echetebu and
Moss (1982a) who reported the complete disappearance of intermediate JM
yGT during the incubation procedure.
In contrast, incubation with a protein-free solution, such as saline, resulted in
the release of Peak 4 (yGT), again confirming the work of Echetebu and Moss
(1982a). However, incubation with protein-free or protein-deficient solutions
containing high concentrations of bile salts, such as bile or a solution of
glycochenodeoxycholate, resulted in the appearance in the liguid phase of yGT
of hydrophobic nature, which appeared to undergo varying degrees of
reaggregation during gel chromatography in the absence of bile salts.
The biochemical processes occurring during the incubation of liver tissue in
the various fluids may, in part, be explained as follows: Incubation with
protein-free solutions which are deficient in bile salts, such as saline or Ringer
solution (Echetebu and Moss, 1982a), result in the generation within the liver
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tissue of the hydrophilic Peak 4 form due to the action of intrinsic proteases.
This hypothesis is supported by the observations of Huseby (1982b) who
reported the conversion of hydrophobic yGT to a hydrophilic form during
incubation of liver homogenates for 24 h at pH 7.0. This conversion was, 1)
inhibited by the protease inhibitor diisopropylfluorophosphate, and 2)
stimulated by the protease (and thiol) activator glutathione. In contrast,
incubation with solutions deficient in protein, but containing high
concentrations of bile salts (such as hepatic bile or glycochenodeoxycholate
solution), result in the immediate release of the enzyme from the plasma
membrane into the liguid phase. Once in the liguid phase, the enzyme is no
longer in the environment of the proteases deep within the liver tissue and
therefore remains hydrophobic in nature.
The suggested mechanisms for the in vitro yGT release from liver outlined above
are in many ways incomplete. The in vivo mechanisms are even more obscure.
Echetebu and Moss (1982b) suggested that incubation of liver tissue in serum
results in the release of enzyme in complexed or particulate form, such as
membrane fragments. If this suggestion is correct, then some factor in serum
is able to stabilize these complexes and inhibit their hydrolysis by proteases.
The results of this preliminary study have shown that the factor is not albumin
and further studies are required to identify its exact nature and throw further




The principle objective of this thesis was to investigate the physical and
chemical nature of the multiple forms of yGT in human bile, serum and liver.
The main interest was to determine from these studies, a) the biological origin
and relationship to one another of these multiple forms and b) if their
measurement in serum was likely to be of diagnostic value.
The results have been discussed in detail already and compared in the relevant
chapters with similar experiments carried out by other authors. The aim in
this chapter is to consider the findings on a wider basis and thus to build a
unifying picture of the pathophysiological events occurring when yGT is
released from the diseased liver cell and subsequently reaches the circulation.
7.1 ISOENZYMES OR MULTIPLE FORMS?
By definition, true isoenzymes, as opposed to multiple forms of an enzyme, are
genetically different proteins. Multiple forms of an enzyme may arise, 1) by
post-translational changes within the cell such as the addition of sialic acid
residues to glycoproteins, 2) proteolytic modification after release from the
cell, 3) association with other molecules, and 4) polymerisation of enzyme
molecules. When the first description of yGT isoenzymes appeared, the
distinction between isoenzymes and multiple forms was less rigid and, in fact,
the authors may not have considered the point at all (Rutenburg et al., 1967;
Jacyszyn and Laursen, 1968; Patel and O'Gorman, 1973). However, their
findings must now be modified in the light of more recent work including that
described in the present study.
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7.1.1 Effect of detergents
Detergents have been used to solubilise membrane-bound proteins or protein
aggregates with the minimum of damage. They are amphiphilic molecules
composed of a hydrophilic head, which may be charged or neutral, and a
hydrophobic tail, which may be either aliphatic or aromatic in nature. They
are able to solubilise proteins because of their amphiphilic nature. Firstly, the
non-polar tails interact with the hydrophobic region of the protein (which may
itself be linked by hydrophobic interactions to the lipid-rich membrane).
Secondly, the polar heads are able to form strong non-covalent bands with the
surrounding water. These interactions result in an increase in entropy, making
solubilisation favourable (Helenius and Simons, 1975).
The high and intermediate hydrophobic forms of yGT in bile, serum and
liver are each converted by bile salts to low JM hydrophobic forms (Chapters
3, 4 and 6) (Peak 3 (yGT)). These low jv[ forms, irrespective of their source,
have similar chemical and physical properties and therefore there is strong
circumstantial evidence that they are, in fact, identical. Treatment of bile
(Chapter 3) or of serum (Huseby, 1978) with Triton-X 100 also converts the
hydrophobic forms of yGT to lower forms. All of these detergent-produced
low forms still possess hydrophobic properties and all reaggregate when in
an environment deficient in detergent. Because of this property, a valid
comparison of the yGT protein from the different tissues is not possible
without the use of detergents.
7.1.2 Effect of proteolytic enzymes
This study has shown that papain treatment converts yGT from human serum,
bile or liver to a low M hydrophilic form (Chapters 3, 4 and 6) (Peak 4 (yGT)).
This low form tends neither to aggregate nor to form complexes. Similar
results obtained after treatment of yGT with proteolytic enzymes have been
reported by others (Curthoys and Kuhlenschmidt, 1975; Huseby, 1977, 1978;
Tate and Ross, 1977; Echetebu and Moss, 1982b). The most likely explanation
of these findings is that hydrophobic forms of yGT possess a hydrophobic
domain on the molecule. This domain causes yGT to aggregate or to become
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attached to lipids. Removal of this domain by proteolytic enzymes renders the
molecule unable to undergo such hydrophobic interactions.
7.1.3 Effect of neuraminidase
The enzyme neuraminidase (EC 3.2.1.18) removes sialic acid residues from
glycoproteins. Electrophoresis of hydrophobic yGT from human serum, liver,
kidney and pancreas in the presence of detergents (for the reasons stated
above) showed that the mobility of the enzyme from liver is identical to that
from serum but differs from that of the enzyme from both kidney and
pancreas. After treatment with neuraminidase, however, the enzymes from
all of these tissues have identical electrophoretic mobilities (Huseby, 1981).
Electrophoresis of the hydrophilic forms of yGT obtained from human liver
and from kidney showed that they too have different electrophoretic
mobilities (Shaw et al., 1980). This finding is also consistent with each of
these forms of the enzyme containing different numbers of sialic acid residues
from one another.
7.1.4 Interaction of yGT with lectins
Lectins (Latin, leqere, to select or pick out) are carbohydrate-binding proteins
produced by plants. Broadly speaking, they may be divided into 4 groups
(Goldstein and Hayes, 1978), based upon their carbohydrate specificity:
1) D-Mannose (D-giucose)-binding lectins, e.g. concanavalin A of the
jack bean.
2) 2-Acetamido-2-deoxy-D-glucose-binding lectins, e.g. wheat germ
lectin.
3) 2-Acetamido-2-deoxy-D-galactose-binding lectins, e.g. soybean
lectin.
4) D-Galactose-binding lectins, e.g. castor bean lectin.
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To a certain extent, differences between glycoproteins can be characterised
by the lectin-binding properties of the glycoproteins. Studies with yGT from
liver, pancreas and kidney have shown that the lectin-binding properties of the
enzyme differ between tissues (Shaw and Petersen-Archer, 1979; Huseby,
1981). On the other hand serum yGT has similar lectin-binding properties to
those of liver yGT. These findings suggest that the differences in yGT that
exist between tissues are due in part, if not jn toto, to differences in sialic
acid content. Furthermore, they support the assumption that serum yGT is
derived from liver.
7.1.5 Kinetic studies
If the multiple forms of yGT studied in this thesis are, in fact, true
isoenzymes, i.e. forms which originate from separate structural genes, then it
is quite likely that they will exhibit quantitative differences in their catalytic
properties.
As a result of detailed initial-velocity kinetic studies, yGT preparations from
liver, kidney, pancreas and duodenum were all shown to have different kinetic
constants (Shaw et al., 1980). These authors proposed that their findings were
consistent with the idea that the various multiple forms each contained
different numbers of carbohydrate residues. In contrast, in the present study,
the kinetic constants of yGT in bile and in serum were shown not to differ
significantly (Chapter 4). Furthermore, in a similar study, the kinetic
constants of yGT in bile and in serum were shown to be the same as those of
the enzyme obtained from human liver (Echetebu and Moss, 1982a). These
findings, 1) support the concept that yGT from liver, bile and serum each
contain equal numbers of carbohydrate residues, and 2) provide further




The consensus of opinion in the literature is that the multiple forms of yGT
from human liver, kidney, pancreas and serum all contain the same antigenic
determinants. Szewczuk et al. (1977) prepared rabbit antiserum to human
kidney yGT, using highly purified kidney yGT as the antigen. They found that
the kidney antiserum inhibited kidney yGT activity by 77% and liver activity
by 57%, indicating a high degree of cross-reactivity. In similar studies, using
rabbit antisera towards human liver yGT, Shaw et al. (1980) noted that the
activities of yGT from human liver, kidney, pancreas and serum were inhibited
equally by the antiserum but that the activity of yGT from hog kidney was
inhibited to a smaller extent. Following double immunodiffusion against
antiserum raised against purified, papain-treated human liver yGT, Huseby
(1981) observed a reaction of identity between the enzyme from liver, serum,
kidney, urine and pancreas. However, in contrast to the above observations,
the yGT-antibody complexes were all enzymatically active. This finding is
consistent with the antibody being directed at an epitope far enough away
from the active site to avoid steric hindrance of the reaction process.
In conclusion, the evidence considered above is consistent with the idea that
the multiple forms of yGT in bile and in serum represent modifications, in one
form or another, of liver yGT.
7.2 THE HEPATOCYTE PLASMA MEMBRANE
The entire surface of the hepatocyte is covered by the liver cell membrane,
which is a complex organelle. When studied by transmission electron
microscopy, it appears as a three-layered structure, consisting of two
electron-dense lines between which is an area of low electron intensity. This
was interpreted by Davson-Danielle (1952) as being representative of a
phospholipid bilayer sandwiched between two protein layers. However, this
model has recently been replaced by the more dynamic concept of the cell
membrane, the fluid mosaic model (Singer and Nicholson, 1972). According to
this idea, the cell membrane consists of a double asymmetrical layer of
phospholipids with their polar heads orientated towards the outside and their
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hydrophobic tails towards the inside of the membrane. A large number of
membrane proteins and glycoproteins are arranged transversely across the
lipid bilayer in a highly specific configuration. There they are believed to
function as receptors, enzymes or trans-membrane carriers. There are two
important elements in the membrane concept, namely, the fluid state of the
phospholipid bilayer at body temperature and the lateral mobility of the
inserted protein molecules. The liver cell membrane should therefore be
considered to represent a continuously moving supramolecular complex rather
than a static structure.
Anatomically, the hepatocyte plasma membrane consists of biliary and
sinusoidal poles joined by a lateral region, which is contiguous with other
hepatocytes. The sinusoidal and biliary poles are interspersed with numerous
microvilli, whereas the lateral region is, on the whole, smooth although it does
possess desmosomes and gap junctions. The relative surface areas for the
sinusoidal, biliary and lateral surfaces have been estimated to be 72, 13 and
15% respectively (Blouin, 1977). The biliary pole, that forms part of the
biliary canaliculus, is competely surrounded by tight junctions, separating it
from the rest of the plasma membrane. The three anatomical areas of the
membrane each appear to have distinct physiological functions. The sinusoidal
surface is involved in the transport of metabolites to and from the circulation
together with the interaction of hormones responsible for the regulation of
hepatic function. The canalicular surface on the other hand is involved with
the transport of bile into the canalicular space whilst the lateral region is
largely concerned with intercellular communication (Evans, 1980).
y-Glutamyltransferase and the other glycoprotein enzymes LAP, ALP and
5'NT are believed to comprise a group of 'ectoenzymes' that are located on the
outer surface of the hepatocyte plasma membrane (Emmelot et al., 1968;
Evans and Gurd, 1973; Evans etal., 1973; Wacker, 1974; Trams and Lauter, 1974;
Gurd and Evans, 1974; Evans, 1974; Huseby, 1979). Although most
workers agree that the enzymes are membrane-bound, there is conflict as to
their location on the membrane surface. For example, in the rat, ALP has
been reported, on the one hand as having only a sinusoidal (Hagerstrand and
Norden, 1972) or, on the other hand, only a canalicular localisation (Ronchi and
Desmet, 1973). Similarly, Naftalin et al. (1969), reported yGT in normal
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human liver to be localised in the biliary canaliculi whereas Busachi et al.
(1977) reported it to be present only on the sinusoidal surface.
7.3 THE NATURE OF y-GLUTAMYLTRANSFERASE IN HUMAN BILE
Whereas many studies have been made of the content and output of bile salts,
cholesterol, phospholipids and pigments in mammalian bile, biliary proteins
and, in particular, biliary enzymes have aroused much less interest.
Electrophoretic and immunological studies of human bile have confirmed the
presence of many different proteins (Russell and Burnett, 1963; Wales et al.,
1969; Englert, 1970; Dive and Heremans, 1974). A significant proportion of
the biliary total protein is derived from serum proteins although biliary
proteins occur at lower concentrations than, and in different relative
proportions to, their concentration in serum (Mullock et al., 1978). On the
other hand, some proteins, e.g. polymeric IgA-bound secretory component, are
present at higher concentrations in bile than in serum. This bound polymeric
IgA, together with free secretory component, makes a substantial contribution
to the biliary protein profile (Lemaitre-Coelho et al., 1977; Mullock et al.,
1978).
Many of the enzymes believed to originate from the hepatocyte membrane
have been found in the bile of a large number of mammalian species
(Holdsworth and Coleman, 1973; Coleman et al., 1979; Godfrey et al., 1981;
Crofton and Smith, 1981a). In contrast, enzymes believed to originate from
the cytosplasm of the hepatocyte are not detectable, or are present in low
concentrations (Holdsworth and Coleman, 1975; Crofton and Smith, 1981a). It
should be noted that most of the analytical techniques, such as gel
chromatography or electrophoresis, used to study yGT and the other enzymes
in bile, involve considerable dilution of the samples in aqueous solution. This,
in effect, reduces the bile salt concentration in the solution containing the
yGT. Under such analytical conditions, yGT and the other enzymes are
present in solution as high M^ forms (Price and Sammons, 1974; Wenham et al.,
1978; Huseby, 1978; Crofton and Smith, 1981a; Echetebu and Moss, 1982a).
However, in the present study, it has been shown that if the analytical system
is set up so that the yGT is maintained in an aqueous solution containing
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physiological concentrations of bile salts, the enzyme is present as a low
form. Furthermore, the high and low forms of yGT are interconvertible,
depending on the bile salt concentration of the solution in which they are
present.
In an attempt to explain the mechanism for the appearance of plasma
membrane enzymes in bile, attention has long been centred on the possible
involvement of bile salts. After infusion of taurocholate into rats, the biliary
output of both 5'NT and ALP was increased (Javitt, 1965; Bode et al., 1973).
In contrast, dehydrocholate, which does not form micelles, and secretin, which
stimulates bile salt-independent bile flow, were less effective in increasing the
biliary output of the enzymes (Bode et al., 1973). Experiments on the effect
of various bile salts on human and sheep erythrocytes, and pig lymphocytes,
have demonstrated the release of plasma membrane materials from intact
cells before cell lysis (Holdsworth and Coleman, 1976; Billington et al., 1977;
Billington and Coleman, -1978). Extending these studies to isolated rat
hepatocytes, Billington et al. (1980) were able to release membrane-bound, but
not intracellular enzymes, by incubation in different bile salts. High speed
centrifugation of the incubation supernatant showed that, after incubation in
7 mmol/1 glycocholate, 75 - 91% of the released enzymes was particulate, but
when the glycocholate concentration was increased to 15 mmol/1, the
proportion of the released enzymes in a particulate form fell to 45 - 75%.
High speed centrifugation of rat bile results in 20 - 40% of plasma membrane
marker enzymes being sedimented (Godfrey £t al., 1981). Similar findings
were obtained in the present study (Chapter 3) where it was also shown that
the proportion of the plasma membrane enzymes sedimented fell with
increasing bile salt concentration.
When all of these factors are considered, the balance of the evidence favours
the following interpretation put forward by Simpson et al. (1984). At low bile
salt concentrations, plasma membrane may be released initially in the form of
small vesicles pinched off the tips of. the microvilli of the canalicular
membrane (Godfrey et al., 198 1). However, as the concentration of bile salts
in the biliary tract increases, the enzymes are leached from the particles and
pass into solution.
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7.4 HOW DOES SERUM yGT ACTIVITY RISE IN LIVER DISEASE?
The elevation of the serum activities of yGT and the other plasma membrane
enzymes are largely associated with cholestatic disease of one form or
another. Similar observations have been made in experimental animals, and, in
particular, it has been found that ligation of the common bile duct of rats is a
good model for cholestatic disease (Popper, 1968). Extensive studies have
therefore been made using rats and other small animals in attempts to
elucidate the mechanisms by which yGT and the other enzymes are released
into the circulation. Furthermore, whereas in human patients with
extrahepatic obstruction, interpretation may be made difficult because of
secondary damage, in animals, such problems may be avoided by studying the
changes that take place soon after obstruction. However, the results of
animal experiments must be viewed with caution since the mechanisms in such
experiments may differ from those in human disease.
Within 12 h of ligation of the bile duct of either rats or guinea pigs, the serum
activities of yGT, LAP, ALP and 5'NT are all increased (Kaplan and Righetti,
1970; Righetti and Kaplan, 1972; Kryszewski et al., 1973; Mullock et al., 1977;
Wooton^t al., 1977; Huseby and Vik, 1978). The peak rises in activities do not
all coincide with one another however. For example, in the study by
Kryszewski et al. (1973), whereas the serum yGT activity showed a steady rise
over 192 h, the rise in ALP activity peaked after 12 h and that of 5'NT after
24 h. It is difficult to decide, however, if these observations suggest different
underlying mechanisms for each of the enzymes, since the same enzyme, in
different studies, often took different times to reach the peak of its rise in
serum activity.
Within 12 h of occlusion of the common bile duct, there is a marked rise in the
specific activity of ALP in liver tissue (Kaplan and Righetti, 1970; Kryszewski
et al., 1973; Simpson et al., 1984). This increase, and the accompanying rise in
serum ALP activity described above, are largely, but not completely,
prevented by actinomycin D, which inhibits transcription of DNA to RNA, and
by cycloheximide, which inhibits the translation of messenger RNA into
protein (Kaplan and Righetti, 1970; Righetti and Kaplan, 1972; Kryszewski
et al., 1973; Huseby and Vik, 1978). In contrast, no significant changes in the
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specific activities of yGT and 5'NT occurred until between 48 h and 192 h
after ligation. Moreover, actinomycin D and cycloheximide did not affect the
rapid rise in serum activity of these enzymes. The animals, however, could
not be maintained long enough on these toxic compounds to study their effect
upon the delayed rise in liver activity of these enzymes (Kryszewski et al.,
1973).
The simplest interpretation of these findings is that increased synthesis of
liver ALP is the cause of all or part of the immediate rise in serum ALP
activity. However, Righetti and Kaplan (1972) also observed a small increase
in hepatic activity 2 - 3 h after occlusion, followed by a later increase in
serum activity, neither of which were prevented by cycloheximide. This
suggests that part of the increased ALP activity in the circulation following
bile duct ligation is not due to de novo protein synthesis.
In contrast to ALP, mechanisms other than protein synthesis appear to be
responsible for the rapid rise in serum yGT and 5'NT activities seen in the
period immediately following bile duct ligation in animals. One explanation
for this would be simple regurgitation of bile through the damaged bile
canaliculi or bile ducts (Popper, 1968). In the rat, after bile duct ligation, the
bile canaliculi are first distended, then become tortuous due to the pressure of
bile, resulting eventually in the opening up of canalicular-sinusoidal
connections (Birns et al., 1962). Mullock et al. (1977) observed that 5'NT, in
the bile and serum of bile duct-obstructed rats, bound to immobilised
antiserum to rat liver plasma membrane. Having excluded the presence of
plasma membrane fragments in the jaundiced sera, they concluded that the
changes in serum 5'NT activity were consistent with the direct leakage of bile
back into the circulation.
Membrane fragments, however, have been reported to be present in the
circulation of patients with cholestasis (De Broe at al., 1975). This finding is
also consistent with the occurrence of regurgitation, given that a significant
proportion of the plasma membrane enzymes in human bile is believed to be
present as a particulate form, with the remainder as a bile salt-solubilised, low
JM , hydrophobic Peak 3 form (section 7.3). The findings of the present study
do not exclude the occurrence of regurgitation of biliary yGT. Regurgitation
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of particulate yGT from bile could account for part of the rise in high yGT
activity observed in serum in cholestasis (Chapters 4 and 5). Similarly,
regurgitation of the Peak 3 form into the circulation, where the bile salt
concentration is an order of magnitude lower, would enable it to complex to
any circulating hydrophobic molecule.
Another possible explanation for the appearance of the plasma membrane
enzymes in the circulation in cholestasis is that it is due to soiubilisation by
bile salts. Righetti and Kaplan (1972) first suggested that the intrahepatic
accumulation of bile salts observed in cholestasis might cause m vivo
soiubilisation of the enzymes. Huseby and Vik (1978) found support for this
idea after noting that between 3 and 6 h after bile duct obstruction in the
guinea pig, the serum yGT and total bile salt concentration correlated with
one another. Furthermore, they calculated that the fall in specific activity of
hepatic yGT could be accounted for by elution of the enzyme from the liver
and passage into the circulation.
The results of the present investigation are consistent with the above
hypothesis. In the present study, the percentage of high yGT and of LAP
and of ALP correlated with one another (Chapter 5). Furthermore, the highest
levels of the high forms were found in patients with extrahepatic
obstruction, a group which also showed the highest serum levels of conjugated
bile salts. One possible explanation of these findings is that a hydrophobic, but
low form of yGT (and LAP and ALP), is eluted from the hepatocyte plasma
membrane by high intracellular concentrations of bile salts (Boyd al., 1966;
Greim et al., 1972). On passing into the circulation, where the concentrations
of bile salts are lower than in the liver cell, the yGT aggregates either with
itself or with other lipid containing particles (Huseby, 1982a). It has already
been shown in Chapter 3 of this thesis, that high concentrations of bile salts
are needed to maintain yGT in a hydrophobic low M form. The relatively
poor correlation between high yGT (%) and serum bile salt levels (Chapter
5) may be due to the fact that intracellular and serum bile salt concentrations
do not always parallel one another. Further support for this idea comes from
histochemical studies on human liver. In non-obstructive lesions (chronic
aggressive hepatitis, alcoholic liver disease) large amounts of yGT activity
were located in the bile ducts and canaliculi, but in severe cholestasis, few of
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the bile ducts and periportal canaliculi stained for the enzyme (Busachi et al.,
1977). Furthermore, these findings observed in cholestasis, could be
reproduced by incubating sections of liver, containing large amounts of yGT
activity, with increasing concentrations of bile salts.
This explanation is also consistent with the findings for high LAP (%) and
high M ALP % (Chapter 5). High Mr LAP (%) correlates well with high
yGT (%) and LAP is known to be readily accessible on the membrane surface,
whereas high _M ALP (%), which correlates poorly with high yGT (%), is
known to be less accessible to the dissociating action of, for example, papain,
than LAP or yGT (Crofton and Smith, 1981b). It is therefore quite likely that
ALP is much less accessible to the detergent action of bile salts than either
yGT or LAP.
The rise in serum yGT activity seen in patients on long term anticonvulsant
therapy or suffering from alcoholic liver disease, in contrast to those observed
in cholestasis, has long been thought to be due to enzyme induction (Rosalki et
al., 1971; Whitfield et al., 1973; Rosalki, 1976). Animal experiments have
also played a part in attempts to elucidate the mechanisms behind the rise
in serum yGT activity seen in these groups of patients. Administration of
ethanol or phenobarbitone to rats produces a significant increase in the
specific activity of yGT in hepatic tissues. These findings are consistent with
the theory that the induction of hepatic yGT synthesis causes the rise in serum
yGT activity observed in patients with alcoholic liver disease or on long term
anticonvulsant therapy (Ideo et al., 1971; Straus et al., 1978). However, the
induced enzyme is still largely present within the liver cell, attached to the
plasma membrane and microsomal fractions, and so a rise in serum yGT
activity will not be observed until the enzyme finds its way into the circulation
(Ratanasavanh et al., 1979). More recent work, also involving experiments on
animals, has suggested that this process may be facilitated by bile salts. After
administration of phenobarbitone to rabbits, Ratanasavanh et al., (1981, 1982)
reported a rise in both serum and liver yGT activity. However, no
rise in serum activity was seen until after 18 days of phenobarbitone
treatment, whereas a rise in liver activity was observed after 4 days. These
authors also observed that phenobarbitone administration also facilitated bile
salt-mediated release of yGT from isolated hepatocyte membranes
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m vitro and caused an increase in the sphingomyelin content and, as a result,
the phospholipid/cholesterol ratio of the membrane. Coleman et al. (1980) have
reported that when membranes were incubated in glycocholate, those with the
highest sphingomyelin/cholesterol ratio tended to lose more material in a
soluble rather than a particulate form. When considering the alcoholic patient
or the patient on long term anticonvulsant therapy, in the light of these
findings, the occurrence of two processes can be envisaged. Firstly, there
could be increased hepatic synthesis of the enzyme and secondly, an alternation
in the chemical composition of the membranes, rendering their constituents
more susceptible to bile salt-mediated release.
In conclusion, the above evidence is insufficient to confirm or exclude any of
the current theories for the increase in serum yGT activity in liver disease.
Although biliary regurgitation would be expected to contribute more towards
the rise seen in cholestatic than in non-cholestatic lesions, it does seem likely
that bile salts play an important role in determining the release of these
plasma membrane enzymes into the circulation in liver disease. The exact
processes, though, which facilitate the bile salt interaction with the
hepatocyte plasma membrane and its components, remain to be determined.
7.5 y-GLUTAMYLTRANSFERASE AS A LIVER FUNCTION TEST
The differential diagnosis of jaundice is a common diagnostic problem for the
practising clinician whether in a District General or in a Teaching Hospital.
Ideally, a test is required that is readily available, rapid, safe and accurate.
At present however, there is no single technique that satifies all of these
criteria.
The available techniques may be arbitrarily divided into two categories,
invasive and non-invasive. Among the former are included endoscopic
retrograde cholangiopancreatography, mini-laparotomy with cholangiography
and very fine needle percutaneous transhepatic cholangiography. Included on
the latter are scintography, sonography and computerised axial tomography as
well as serum enzyme measurements.
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The clinical study of the multiple forms of yGT described in Chapter 5 of this
thesis had two limitations shared by almost all other similar studies. Firstly,
it was not possible, in the limited period available, to follow the various
diseases over their natural clinical course. Secondly, the number of patients
suitable for study was limited by their availability and was therefore small.
Nevertheless, the study showed that the electrophoretic measurement of
serum Band IIB (yGT) was in most patients, able to distinguish extrahepatic
from intrahepatic cholestasis. From the clinician's view, serum yGT
electrophoresis, if provided as a service by the laboratory would be a safe,
non-invasive method of investigation which most laboratories would have little
difficulty in introducing.
In conclusion, serum yGT electrophoresis would be an extremely useful initial
test to carry out in these patients and could sometimes render the more
expensive and invasive tests unnecessary. However, it's exact place in the
diagnostic sequence requires further study and investigation.
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Summary
y-Glutamyltransferase has been studied in bile and sera from patients with extrahe¬
patic biliary obstruction. In both fluids y-glutamyltransferase activity is found
largely in the high molecular mass fraction present in the void volume following
G200 gel chromatography and which remains at the origin after 1% polyacrylamide
gel electrophoresis.
When bile, sera and liver microsomes are treated with deoxycholate, a different
form of y-glutamyltransferase, with an approximate molecular mass of 157000
estimated by gel chromatography and of 125 000 by gradient gel electrophoresis, is
obtained. After treatment with papain, all three types of specimen gave rise to a
form of y-glutamyltransferase with a molecular mass of 115 000 estimated by gel
chromatography and of 98000 by gradient gel electrophoresis. The possible relation¬
ship between these various forms of y-glutamyltransferase, and their relevance to the
increases in activity in serum seen in extrahepatic biliary obstruction, are discussed.
Introduction
Although large increases in serum y-glutamyltransferase (yGT; EC 2.3.2.2)
activity are known to occur in extrahepatic biliary obstruction [1,2], the mechanism
of the increases remains unknown. However, it has been generally assumed that in
these patients the obstruction to bile flow causes the regurgitation into the plasma of
the yGT normally present in bile.
It has been shown previously [3] that the increase in serum yGT activity in
patients with biliary obstruction is due to the appearance of a high molecular mass,
low density form of the enzyme. It has been suggested that this may represent either
a fragment of liver cell membrane or a complex between yGT and a plasma
lipoprotein, phenomena similar to those proposed for serum alkaline phosphatase in
patients with biliary obstruction [4-6].
* To whom correspondence should be addressed.
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In the present study further investigations have been carried out into some of the
properties of the yGT present in bile and sera from patients with biliary obstruction.
The yGT present in human liver microsomes has also been studied. The objective
was to gain further insight into possible mechanisms for the increased serum yGT
activity seen in patients with biliary obstruction.
Materials and methods
Sera with yGT activities varying between 192 U/l and 395 U/l were obtained
from patients with extrahepatic biliary obstruction. Specimens of hepatic bile with
yGT activity ranging from 250 U/l to 600 U/l were obtained from patients with
percutaneous or "T" tube drainage of the common bile duct.
Samples of human liver were obtained post mortem from patients with no
evidence or history of liver disease. The microsomal fraction of the liver homogenate
was obtained from the 100000 X g pellet after cell debris and mitochondria had been
removed by centrifugation at 3000 X g and 18 000 X g respectively.
Chemicals
y-Glutamyl ^-nitroanilide was obtained from Boehringer, Lewes, Sussex; y-
glutamyl a-naphthylamide from Koch Light, Colnbrook, Bucks, U.K.; sodium
deoxycholate, papain (twice crystallised) and Fast Blue B from Sigma Chemical
Company, Poole, Dorset, U.K.; Sephadex G200 from Pharmacia, Uppsala, Sweden;
acrylamide and bis-acrylamide from Eastman Kodak, Liverpool; carboxyl
[14C]sodium deoxycholate (52 jaCi/mmol) from the Radiochemical Centre,
Amersham, Bucks, U.K. All other chemicals were of analytical grade, purchased
from BDH. Poole, Dorset, U.K.
Papain treatment
Samples of bile, serum and liver microsomes were incubated with papain (1 g/10 g
protein) overnight at 20°C in the presence of 100 mmol/1 cysteine.
Deoxycholate treatment
Bile and sera were incubated with an equal volume, and liver microsomes with a
10-fold volume, of 25 mmol/1 sodium deoxycholate for 1 h at room temperature.
The liver microsomes were centrifuged for 1 h at 100 000 X g following incubation,
and the supernatant used.
7% Polyacrylamide gel electrophoresis
An RGA/500 electrophoresis apparatus (Raven Scientific, Haverhill, Suffolk,
U.K.) was used with vertical gel slabs (140 X 165 X 3 mm) and a discontinuous
buffer system of 180 mmol/1 Tris/HCl, pH 8.9, gel buffer and 50 mmol/1
Tris/glycine, pH 8.3, in the electrophoresis tanks.
Polyacrylamide gradient gel electrophoresis
The Uniscil electrophoresis apparatus (Universal Scientific Ltd., London, U.K.)
was used with preformed polyacrylamide gel slabs with 4- 30% gradient (Pharmacia,
Uppsala, Sweden) in a continuous buffer of 50 mmol/1 Tris/glycine, pH 8.3. Each




This was performed on Sephadex G200 using 20 mmol/1 Tris/HCl buffer, pH
8.0, containing 50 mmol/1 sodium chloride. A 650 X 26 mm column was used with
an upward flow rate of 15.6 ml/h. Fractions of 2.6 ml were collected. The column
was calibrated, for molecular mass determinations, using a mixture of proteins of
known molecular mass. A linear semilogarithmic plot of molecular mass versus
elution volume was obtained.
Localisation of yGT activity after electrophoresis
This was performed using y-glutamyl a-naphthylamide as substrate [8].
Estimation of yGT activity
This was measured in serum, bile and column effluents at 37°C on an LKB 8600
reaction rate analyser [9]. The serum reference range for this method was 6-31 U/l
for females and 8-49 U/I for males.
Results
Gel filtration chromatography
Depending upon the conditions of separation and on the type of sample applied
to the column, 4 elution peaks of yGT were observed: Peak 1 eluted with the void
volume, and therefore corresponds to a molecular mass greater than 600000; Peak 2
eluted at 115 ml, corresponding to a molecular mass of about 400000; Peak 3 eluted
at 145 ml, corresponding to a molecular mass of about 157000; and Peak 4 eluted at
155 ml, corresponding to a molecular mass of about 115000.
Bile and sera from the patients with extra-hepatic biliary obstruction both showed
an elution pattern in which Peak 1 predominated. Recovered activity was always
greater than 85% and the percentage of total activity recovered in Peak 1 from both
the bile and sera of patients with biliary obstruction ranged from 94% to 97% and
from 56% to 77% respectively. Both showed small amounts of activity in Peak 4
(3-21%). In the case of sera, a significant amount of activity (18-37%) also eluted in
Peak 2 (Fig. 1).
Following chromatography of deoxycholate-treated serum, bile and liver micro¬
somes, with varying concentrations of deoxycholate in the eluting buffer, the main
peak of yGT activity changed from Peak 1, when there was no deoxycholate in the
eluting buffer, to Peak 3 when the deoxycholate concentration was more than
7 mmol/1. However, at intermediate deoxycholate concentrations, a significant
amount of activity was present in Peak 2 with little or no activity in Peak 3 (Fig. 2).
After papain treatment, the specimens of serum, bile and liver microsomes all
showed a similar pattern after gel chromatography, namely over 95% of the yGT
activity eluted in Peak 4 (Fig. 3).
Papain treatment of the concentrated fractions from Peak 3 resulted in material
with an elution pattern similar to that seen after papain treatment of the native
samples, that is the activity was present in Peak 4. Treatment of any of the fractions
from Peak 4 with 12 mmol/1 deoxycholate did not result in any alteration in the
elution pattern.
116
peak 1 peak 2 peak 4
Fig. 1. Gel chromatography on Sephadex G200 of yGT present in serum from a patient with extra-hepatic
biliary obstruction (X X), and in hepatic bile (• •).
Fig. 2. Gel chromatography on Sephadex G200 of yGT in deoxycholate-treated hepatic bile; there were
increasing concentrations of deoxycholate in the eluting buffer. No deoxycholate, ▲ A; 1.2
mmol/1 deoxycholate, X X ; 7 mmol/1 deoxycholate, • •.
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Fig. 3. Sephadex G200 gel chromatography of papain-treated yGT present in hepatic bile and serum from
a patient with biliary obstruction and liver microsomes. Hepatic bile, • •: serum, X X;
and liver microsomes, ▲ ▲.
Polyaerylamide gel electrophoresis
The following results were obtained after electrophoresis in 7% polyacrylamide
gel slabs:
(1) Untreated serum and bile both showed a major band of activity at the origin
with a small amount of activity present in a band with 70% of the mobility of serum
■albumin. In serum, an additional band with mobility 50% of that of serum albumin
^and identical mobility to that of a concentrate of Peak 2 obtained after gel
chromatography) was also present (Fig. 4a), together with weakly staining zones of
activity of slower mobility. Occasionally in bile, a weak additional band of mobility
of 55% of serum albumin was observed.
(2) After treatment with deoxycholate, the results of electrophoresis depended on
whether or not 12 mmol/1 deoxycholate was also present in the gel buffer. When
there was no deoxycholate in the gel buffer, the specimens of bile showed one or two
additional bands with mobilities of 42% and 21% of that of albumin (Fig. 4b), and
serum showed a long smear of activity. In the presence of deoxycholate, electro¬
phoresis of specimens of liver microsomes, serum and bile, treated with deoxycho-
ate, yielded a major "fast" band with mobility 84% of that of albumin although
some activity remained at the origin (Fig. 5). The "fast" band had an identical
nobility to that of a concentrate from Peak 3 obtained from gel chromatography.
(3) Electrophoresis of the papain-treated samples yielded a single band of yGT
ictivity with mobility 70% of that of albumin (Fig. 5). This band had the same
nobility as a concentrated pool from Peak 4, obtained after gel chromatography.
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Fig. 4 (a and b). (a) Polyacrylamide slab gel electrophoresis of yGT in bile and serum from patients with
extrahepatic biliary obstruction. Left to right, bile, serum, bile, serum, bile, serum, bile. The dark band at
the lower (anodal) end of the serum samples is the albumin-bromophenol blue complex, (b) Polyacryla¬
mide slab gel electrophoresis of yGT in bile before (left) and after (right) deoxycholate treatment.
Fig. 5. Polyacrylamide slab gel electrophoresis in 12 mmol/1 sodium deoxycholate of yGT in deoxycho¬
late- and in papain-treated bile, liver microsomes and serum from a patient with extrahepatic biliary




Fig. 6. Polyacrylamide gradient gel electrophoresis in 12 mmol/1 deoxycholate of concentrated pools from
Peaks 3 and 4 obtained after gel chromatography. Left to right, Peak 4 serum, Peak 4 bile. Peak 3 liver,
Peak 4 liver, Peak 3 bile, Peak 4 serum, Peak 3 serum.
Polyacrylamide gel gradient electrophoresis
This yielded estimated molecular masses for Peaks 3 and 4 from gel chromatogra¬
phy of 125000 and 98000, respectively. It is noteworthy that, whereas Peak 4 had a
greater mobility than Peak 3 in the gradient gel, these findings were reversed in 7%
acrylamide gel. This suggests that the yGT in Peak 3 carries a much ?reater negative
charge than the yGT in Peak 4 (Fig. 6).
['4C]Sodium deoxycholate binding studies
These were restricted to bile, since'bile has a higher yGT activity/g protein than
serum. The experiments were designed to indicate whether bile salt binding to yGT
could account for the differences in molecular size and charge between the yGT in
Peaks 3 and 4.
(1) Neat bile (2 ml) was incubated for 1 h at room temperature with 5 p\ of a
solution containing 1 /xCi [l4C]deoxycholate (19.2 nmol). This mixture was then
chromatographed on Sephadex G200. Radioactivity (measured on a Packard Tri-
Carb Liquid Scintillation Counter [10]) was present only in the salt volume peak and
did not correspond with any of the peaks of the yGT activity.
(2) Bile was concentrated 20-fold on a Minicon macro solution concentrator
(Amicon, London, U.K.). The concentrated bile was then incubated for 1 h with
1 ju,Ci [14C]deoxycholate. Column chromatography of the mixture on Sephadex
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G200, which had been pre-equilibrated with [l4C]deoxycholate (5 /iCi/1), resulted in
three peaks of radioactivity. The first peak (A) co-eluted with the void volume, and
the majority of the yGT activity. The second peak (B) of radioactivity eluted at 175
ml, corresponding to a molecular mass of about 70 000 and the third peak (C) eluted
with the salt volume; there was no yGT associated with these peaks. The ratio of
radioactivity in Peak B to that in Peak A was 1.45 :1.
(3) The previous experiment was repeated using bile which had been treated with
papain. A similar elution pattern to that observed following deoxycholate treatment
was obtained, apart from a relatively greater amount of radioactivity appearing in
Peak B (ratio of Peak B to Peak A was 1.83 :1). The total amount of radioactivity in
Peak B was approximately the same in both experiments.
Incubation of Peak 4 with bile and serum
Samples of bile and serum, each containing 0.24 U of yGT activity, were added to
0.5 ml of concentrated Peak 4 eluate, also containing 0.24 U of yGT. The volumes
were made up to 2 ml with Tris/HCl buffer, pH 8.0, and the solutions incubated at
20°C for 6 h and 30 h. Following this, gel chromatography showed that the incuba¬
tion had not altered the chromatographic behaviour of Peak 4.
Discussion
The present study confirms previous reports [3,11-13] that the yGT present in
the sera of patients with biliary obstruction is mainly in a high molecular mass form,
but with some enzyme of an intermediate molecular mass of about 400000 (Peak 2)
and a small amount with a molecular mass of about 115 000 also present. Biliary
yGT showed similar properties on gel chromatography and polyacrylamide gel
electrophoresis, apart from the absence of Peak 2, suggesting that it too is mainly of
high molecular mass, in agreement with previous studies [14-15]. This conclusion
must be viewed with caution, however, since the yGT in bile has been shown in this
and in another study [16] to dissociate into a lower molecular mass form in the
presence of bile salts or other detergents. The results presented here suggest that a
bile salt concentration of about 7 mmol/1 or greater is required to achieve this effect.
Human bile has a much higher bile salt concentration than this, at least 10 mmol/1,
although much of the bile salt would be present in micellar form. There is, therefore,
a distinct possibility that the apparent high molecular mass of biliary yGT is an
artefact caused by reaggregation of the enzyme when removed into a solution
containing no bile salts.
Deoxycholate treatment of sera and bile from patients with extrahepatic biliary
obstruction, and of the liver microsomal preparations, caused the formation of yGT
with a molecular mass of 157000 when estimated by gel chromatography (Peak 3)
and of 125000 when measured by gradient gel electrophoresis. This discrepancy ir
molecular mass may arise (i) from the glycoprotein moiety of yGT conferring
anomalous behavioural properties on the enzyme towards gel filtration and electro
phoresis [17,18], or (ii) due to difference in salt concentration between the twc
buffers causing differences in the configuration of the molecule. In the absence o
bile salts, this molecule tended to reaggregate.
Papain treatment, on the other hand, caused the production of a yGT molecuk
which was smaller, with an estimated molecular mass of 115 000 by gel chromatogra
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phy (Peak 4) and of 98000 by gradient gel electrophoresis. This yGT also carried a
much smaller negative charge than the yGT resulting from deoxycholate treatment.
These findings are similar to those reported for yGT obtained from normal serum
and bile [16] and for partially purified liver yGT following papain [19] or trypsin
[20] treatment. Taken together, the findings in this paper are consistent with
explanations which have been advanced previously, namely that bile salt or deter¬
gent treatment of yGT complexes results in the formation of a yGT molecule
possessing a lipophilic area to which detergents may attach [16,21]. Papain treat¬
ment, on the other hand, may remove this lipophilic area, which is presumably a
peptide or peptides, causing formation of a yGT molecule which will not bind to bile
salts. It is perhaps not surprising that we were unable to confirm that radiolabeled
deoxycholate binds to the lipophilic form of the enzyme, since the molar concentra¬
tion of yGT in bile must be several orders of magnitude less than tlje concentration
of radiolabeled deoxycholate required to obtain sufficient counts.
The mechanism for the rise in yGT activity in the serum of patients with
extrahepatic biliary obstruction is uncertain. Firstly, low molecular mass (Peak 3)
yGT might be regurgitated from bile into plasma, where subsequent reaggregation
or binding to lipoproteins may occur. This is consistent with the previous finding
that, although both bile and serum may contain a high molecular mass yGT, the two
forms have different buoyant densities [3,15], Secondly, biliary yGT may be in the
form of membrane fragments which could be regurgitated into plasma in biliary
obstruction; the differences in buoyant density [3,15] make this explanation less
likely. Thirdly, the rise in bile salt concentration within the liver in cholestasis might
cause "solubilization" of membrane-bound yGT, which might then gain direct
access to the circulation and subsequently aggregate.
It seems much less likely that the elevated yGT activity found in serum during
biliary obstruction could arise by proteolysis as has been suggested for normal serum
[16,22], Proteolysis would be expected to release the lipophobic form of yGT, which
does not tend to aggregate, as shown by the experiments involving incubation of
Peak 4 with bile and serum.
The fact that an intermediate molecular mass yGT has been detected (Peak 2) in
sera from patients with obstructive jaundice could be taken as support for the thesis
that reaggregation does, in fact, play a role in the mechanism. Such a form of yGT is
not usually found in bile but does appear in the presence of relatively low
concentrations of bile salts—conditions in which partial reaggregation could occur.
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Summary
High molecular mass y-glutamyltransferase in human bile is converted by physio¬
logical concentrations of the bile salts glycocholate and glycochenodeoxycholate to a
form with a molecular mass estimated by gel chromatography to be 165000. A
molecule of intermediate molecular mass estimated to be 330000 is obtained
following treatment with the non-ionic detergent Triton X-100.
When human bile is centrifuged at 150000 Xg, between 25-73% of y-gluta¬
myltransferase activity is recovered in the supernatant. This proportion is increased
following prior addition of bile salts to the bile.
Analogous results are obtained for the high molecular mass enzymes alkaline
phosphatase and leucine aminopeptidase, present in human bile, and also considered
to originate from the hepatocyte plasma membrane. From these results it is sug¬
gested that these high molecular mass enzymes found in bile may, in part at least,
represent artefacts following aggregation of the enzymes in aqueous media contain¬
ing no bile salts.
Introduction
A number of enzymes such as y-glutamyltransferase (yGT, EC 2.3.2.2), alkaline
phosphatase (ALP, EC 3.1.3.1) and aminopeptidase (microsomal) (leucine amino-
peptidase, LAP, EC 3.4.11.2), which are usually considered to originate from the
hepatocyte membrane, are found in bile. However, the forms in which these enzymes
are present in bile and the exact means whereby they pass into the bile are uncertain.
Furthermore, it is not clear whether there is any relationship between the various
* To whom correspondence should be addressed.
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forms of these enzymes as they are found in bile and the forms of the same enzymes
found in increased amounts in the serum of patients with cholestasis.
Chromatography of bile on Sephadex G200 or similar materials demonstrates
that all three of the enzymes mentioned above are apparently present mainly in a
form with high relative molecular mass (Mx) [1-6]. However, it has been shown
previously that, if sodium deoxycholate is included in the chromatography buffer, a
low Mr form of yGT is recovered in the eluate [4,5], This raises the question as to
whether yGT (and also ALP and LAP) are present in bile in a low Mr form. It also
suggests that the complexes found on gel chromatography may merely represent
artefacts caused by aggregation of the enzymes in aqueous media in which no
detergent, i.e. bile salt, is present.
In a previous study [5], we used the bile salt sodium deoxycholate in the
chromatography buffer and studied only yGT. However, bile salts are normally
present in bile as glycine or taurine conjugates and cholate and chenodeoxycholate
conjugates are present in greater concentrations than those of deoxycholate. In order
to mimic physiological conditions in bile more closely, we have now studied the
effect of glycocholate and glycochenodeoxycholate on the elution pattern of yGT
from Sephadex G200. We have included ALP and LAP in our study to determine
whether our findings are more generally applicable, and have used electrophoresis,
ultracentrifugation and treatment with the non-ionic detergent Triton X-100 to gain
further insight into the nature of all of these enzymes in bile.
Materials and methods
Eight samples of hepatic bile were obtained from patients with 'T' tube drainage
of the common bile duct. The range of enzyme activities were as follows; yGT,
100-1540 U/l, ALP, 75-1150 U/l and LAP, 22-126 U/l.
Chemicals
y-Glutamyl-^-nitroanilide and p-nitrophenylphosphate were obtained from
Boehringer, Lewes, Sussex, UK; y-L-glutamyl-a-naphthylamide and L-leucyl-/?-naph-
thylamide from Koch Light, Colnbrook. Bucks, UK; sodium glycocholate, sodium
glycochenodeoxycholate, papain (twice crystallised), Fast Blue B. L-leucyl-p-
nitroanilide, a-naphthyl acid phosphate and 4-aminodiphenylamine diazonium
sulphate from Sigma Chemical Company, Poole, Dorset, UK; Sephadex G200 from
Pharmacia, Uppsala, Sweden; acrylamide and bis-acrylamide from Eastman Kodak,
Liverpool, UK. All other chemicals were of analytical grade, purchased from BDH.
Poole, Dorset, UK.
Papain treatment
This was performed as previously described [5].
Treatment with bile salts
Prior to gel chromatography or electrophoresis, bile salts, equal to the concentra¬
tion employed in the appropriate buffer, were added to bile. The bile was then
stored at 4°C for 12 h prior to further investigation.
305
7% Polyacrylamide gel electrophoresis
This was performed in vertical gel slabs (140 X 165 X 3 mm) in the RGA/500
electrophoresis apparatus (Raven Scientific, Haverhill, Suffolk, UK). Electrophoresis
of y-GT and LAP was carried out using a modification [5] of the method of
Azzopardi and Jayle [7]. Electrophoresis of ALP involved a modification [8] of the
method of Kaplan and Rodgers [9].
Polyacrylamide gradient gel electrophoresis
4-30% polyacrylamide gradients (Pharmacia, Uppsala, Sweden) were used with
the Uniscil electrophoresis apparatus (Universal Scientific Ltd., London, UK). A
continuous buffer system was always used, being 50 mmol/1 Tris/glycine, pH 8.3,
for yGT and LAP, and 370 mmol/1 Tris/borate, pH 9.5, for ALP.
Localisation of enzyme activities following electrophoresis
yGT was localised using y-glutamyl-a-naphthylamide as substrate [10], ALP with
a-naphthyl acid phosphate [6] and LAP with L-leucyl-/?-naphthylamide [6].
Gel chromatography
This was performed on a 650 X 26 mm column of Sephadex G200, calibrated with
proteins of known molecular mass, as previously described [5].
Ultracentrifugation
Samples of bile (before and after treatment with bile salts) (10 ml) were centri-
fuged at 2500 X g for 10 min. 8.5 ml of the supernatants were then centrifuged for a
further 1 h at 150000 X g. The supernatant was collected, the pellet washed with 1 ml
20 mmol/1 Tris/HCl buffer, pH 8.0, and then resuspended in 2 ml of the same
buffer. Enzyme activities were determined on all fractions.
Enzyme activities
These were estimated on a LKB 8600 Reaction Rate Analyser. The substrate for
measuring yGT activity was y-glutamyl-p-nitroanilide [11], for measuring ALP
activity, p-nitrophenylphosphate [12] and for measuring LAP activity, L-leucine-p-
nitroanilide [13]. The coefficients of variation were 5.2% within batch and 5.4%
between batch for yGT at a mean value of 135 U/l, 2.4% within batch and 3.0%
between batch for ALP at a mean value of 112 U/I and 3.9% within batch and 4.9%
between batch for LAP at a mean value of 185 U/l.
Enzyme activities of column fractions were estimated once on 0.5 ml of each
sample, the final reaction conditions being the same as those for enzyme activity
measurement in bile. Coefficients of variation were 2.5% within batch and 4.0%
between batch for yGT at a mean value of 7.6 U/l, 6.0% within batch and 6.5%
between batch for ALP at a mean value of 1.3 U/l and 5.7% within batch and 7.9%
between batch for LAP at a mean value of 3.8 U/l.
The enzyme fractions, represented by the peaks obtained by gel chromatography,
were measured by determining the peak areas and the problem of overlapping peaks
was overcome by extrapolation of the main peaks.
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Measurement of bile salt concentrations
The concentration of conjugated cholate and conjugated chenodeoxycholate in
bile was measured by radioimmunoassay [14,15]. Coefficients of variation were 7.0%
within batch and 8.0% between batch for both methods at a mean concentration of
3.0 /xmol bile salt/1.
Results
Effect of bile salts upon enzyme activities
Sodium glycocholate at concentrations up to 20 mmol/1 had no effect upon yGT
activity, whereas ALP activity appeared to be stimulated slightly. Sodium glyco-
chenodeoxycholate, on the other hand, did not alter the activity of either of these
enzymes at concentrations up to 10 mmol/1. Both bile salts significantly inhibited
LAP activity (Table I).
Effect ofpapain treatment
Digestion of hepatic bile with papain resulted in a slight decrease in yGT activity,
while the effect upon LAP activity was variable (Table II). In sharp contrast, ALP
activity was destroyed following papain treatment.
Gel filtration chromatography
A fairly clear pattern of results has emerged from these investigations. In order to
simplify the description, and agree with previous arbitrary nomenclature [5], we have
named the peaks separately in the order of their elution from the gel column:
TABLE I
ENZYME ACTIVITIES FOLLOWING ADDITION OF BILE SALTS TO HUMAN BILE
Percentage initial enzyme activity
yGT ALP LAP
Added glycocholate (mmol/l)
0 * 100 100 100
5 100 117 86
10 102 131 73
15 102 131 59
20 104 139 49
Added glycochenodeoxycholate (mmol/l)
0 * 100 100 100
1 95 92 83
3 94 97 68
5 94 108 59
10 93 110 42




ENZYME ACTIVITIES AFTER DIGESTION OF HUMAN BILE WITH PAPAIN
Percentage initial activity
yGT ALP LAP
Bile A 93 3 108
Bile B 78 0 74
Bile C 94 12 84
Peak 1: void volume for all enzymes.
Peak 2T (yGT), Peak 2T (ALP), Peak 2T (LAP): major intermediate Mr peaks
eluting when 0.1% (w/v) Triton X-100 is present in the elution buffer. See Table III
for estimated Mr values.
Peak 2T (iyGT), Peak 2T (ALP), Peak 2T (LAP): major intermediate Mr peaks
eluting when 0.1% (w/v) Triton X-100 is present in the elution buffer. See Table III
for estimated Mr values.
Peak 3 (yGT), Peak 3 (ALP), Peak 3 (LAP): major low Mr peaks eluting when
bile salts are present in the eluting buffer. These peaks reaggregate in the absence of
bile salts.
Peak 4 (yGT), Peak 4 (ALP), Peak 4 (LAP): minor peaks eluting after the
corresponding Peak 3 and found in small amounts in native bile, and in large
amounts (for yGT and LAP) in bile which has been previously treated with papain.
These peaks do not undergo reaggregation in the absence of bile salts.
TABLE III
ESTIMATED MOLECULAR MASSES OF THE ENZYME FRACTIONS OBTAINED FOLLOWING
GEL CHROMATOGRAPHY
Fraction Estimated molecular mass
gel chromatography gradient electrophoresis
yGT ALP LAP yGT ALP LAP
Peak 2T 333000 400000 430000 -
Peak 3 165000 290000 310000 135000 280000
Peak 4 115 000 200000 200000 110000 180000 177000
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Chromatography performed in the absence of bile salts
After gel chromatography of native bile, between 87 and 93% of yGT activity
eluted in the void volume, the remainder eluting as peak 4 (yGT), confirming our
previous findings [5], Similarly, both ALP and LAP eluted mainly as void volume
peaks (Fig. 1) comprising 83-98% and 61-76% respectively of total recovered
activity, the remainder eluting as Peak 4 (ALP) and Peak 4 (LAP). Recovery of yGT
and LAP ranged from 80-100% and for ALP from 100-220%. The high recovery for
ALP may possibly be due to the presence of low Mr inhibitors of ALP present in
native bile, but separated from the enzyme as it passes through the gel column.
Chromatography performed in the presence of bile salts
Gel chromatography with increasing concentrations of glycocholate in the elution
buffer resulted in a decrease in the amount of yGT eluting in the void volume, and
the appearance of a fraction eluting as Peak 3 (yGT). Between 41% and 56% of yGT
activity eluted as Peak 3 (yGT) (Fig. 2) when the elution buffer contained 20
mmol/1 glycocholate. At this concentration of glycocholate the proportion of ALP
activity eluting as Peak 3 (ALP) ranged from 32-45%. Results for LAP could not be
obtained because at high concentrations of glycocholate the enzyme was almost
completely inhibited during its passage through the column.
When glycochenodeoxycholate was included in the elution buffer, at increasing
concentrations, the main peak of activity changed from Peak 1 to Peak 3 for all three
enzymes. When the concentration was 5 mmol/1, 81-95% of yGT, 73-77% of ALP
and 63-87% of LAP activity eluted as Peak 3 (Fig. 3). At intermediate concentra¬
tions of glycochenodeoxycholate significant amounts of activity of all three enzymes
eluted as Peak 2, with little or no activity in Peak 3.
Chromatography performed in the presence of Triton X-100
2 vols, of bile were mixed with 1 vol. 0.3% (w/v) Triton X-100 and stored at 4°C




I LAP, ALP |
PEAK 4
(*GT)
o-U*f , , , „ c
80 90 100 110 120 130 140 150 160 170 180 190 200
ELUTION VOLUME (mil
Fig. 1. Elution profiles of high Mr enzymes in human bile following gel chromatography on Sephadex
G200. X X, yGT; ▲ A. ALP; • •. LAP.
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PEAK 1 PEAK 3
Fig. 2. Gel chromatography on Sephadex G200 of yGT in human bile with increasing concentrations of
glycocholate in the elution buffer. X X, 5 mmol/1 glycocholate; ▲ A, 10 mmol/1 glyco-
cholate; • •, 20 mmol/1 glycocholate.
the eluting buffer resulted in 90% of yGT, 84% of ALP and 71% of LAP eluting as
Peaks 2T. Small amounts of activity (6-11%) still eluted as Peak 1, with the
remainder as Peak 4.
Papain-treated bile
After papain treatment, gel chromatography in the absence of detergents resulted
PEAK 1 PEAK 3 PEAK 3
dSGT.LAP.AI.P) (ALP) (yGT)
PEAK 3
Fig. 3. Elution profiles of yGT, ALP and LAP following gel chromatography on Sephadex G200
containing 5 mmol/1 glycochenodeoxycholate in the elution buffer. X X, yGT; A A. ALP;
• •. LAP.
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in a decrease in yGT and LAP activity eluting in the void volume, together with an
increase in activity eluting as Peak 4. Since ALP activity was destroyed by papain a
study of this enzyme was not possible.
7% Polyaery lamide gel electrophoresis
Electrophoresis in 1% polyacrylamide gel equilibrated in both the gel and the
running buffer with 5 mmol/1 glycochenodeoxycholate showed that both native bile
and Peak 3 (yGT) contained a main zone of activity which migrated just ahead of
the zone due to Peak 4. Electrophoresis of bile. Peak 3 (ALP) and Peak 4 (ALP) in
the same concentration of bile salt, and stained for ALP activity, demonstrated a
single fast band of identical mobility in all three samples. The Peak 4 (ALP) was
obtained after gel chromatography of serum from a patient with liver disease. These
results suggest that the Peak 3 forms of yGT and ALP possess a greater negative
charge than the corresponding Peak 4 forms. Results for LAP could not be obtained
owing to its inhibition by bile salts.
Gradient gel electrophoresis
The estimated Mr values for the Peak 4 forms of yGT and ALP in untreated bile
were less than those for the corresponding Peak 3 forms (Table III) present in
5 mmol/I glycochenodeoxycholate.
Ultracentrifugation
Over 92% of the activity of all three enzymes was recovered from the supernatant
following centrifugation at 2500 X g. After a further centrifugation of this super¬
natant at 150000 Xg for 1 h, the percentage of enzyme activity recovered in the
supernatant ranged from 25-73% for yGT, 22-48% for ALP and 27-54% for LAP.
Addition of increasing concentrations of glycochenodeoxycholate to the bile prior to
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Fig. 4. Percentage recovery of enzyme activity in the supernatant following ultracentrifugation of bile at
150000Xg, plotted against initial conjugated chenodeoxycholate concentration. X X, yGT;
▲ ▲, ALP; • • LAP.
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150000 Xg supernatant. The increase in recovered supernatant activity was greater
in those samples obtained from patients in whom bile had been draining for several
days before the collection was made. They had a low concentration of bile salts due
to depletion of the bile salt pool (Fig. 4).
Discussion
It has previously been assumed that the liver membrane-associated enzymes,
yGT, ALP and LAP, are present in native bile as high Mr forms, possibly membrane
fragments, since, after exclusion chromatography on Sephadex G200 or Sepharose
6B, these enzymes elute in the void volume [1-6]. However, we have shown that, if
either glycocholate or glycochenodeoxycholate, at approximately physiological con¬
centrations, or the non-ionic detergent Triton X-100 are included in the gel buffer,
the elution patterns of the enzymes change markedly. The void volume peak
contains less of the enzyme activity and lower Mv forms of the enzymes appear (Peak
3, Peak 2T). These lower Mr forms reaggregate if they are rechromatographed in
detergent-free eluting buffer. The greater efficacy of glycochenodeoxycholate than
glycocholate in causing this change can readily be explained in terms of the greater
polarity of glycocholate.
The lower Mr forms of yGT, ALP and LAP which result from bile salt treatment
(Peak 3 forms) have been shown here to be quite distinct in molecular size, charge
and other properties from the low Mr forms found in untreated bile, or obtained
following treatment with papain (Peak 4). The Peak 4 enzymes do not tend to
aggregate, show no change of properties on the addition of bile salts, and have a
significantly smaller Mr than the Peak 3 enzymes (Table III). By analogy with other
membrane proteins, our results support previous suggestions [4.16] that the Peak 3
enzymes all contain a hydrophobic domain by which they are normally attached to
the membrane; enzyme molecules possessing this hydrophobic region will tend to
aggregate in aqueous solution unless an adequate concentration of detergent is
present. Papain treatment, on the other hand, removes this hydrophobic portion of
the molecule causing the difference in properties noted above. The three enzymes we
have studied are very similar to one another in respect to their behaviour with bile
salts and papain although the evidence is not quite complete since bile salts inhibit
LAP activity and papain destroys ALP.
The ultracentrifugation studies show that between 25 and 75% of yGT, ALP and
LAP activity in native bile is present in the 150000 X g supernatant. In samples in
which the bile salt concentration is low, such as those obtained after several days of
biliary drainage, the proportion of each of the enzymes present in the 150000 Xg
supernatant also tends to be low. We have obtained a similar effect in vitro by
adding glycochenodeoxycholate to bile and thereby increasing the amount of enzyme
present in the supernatant fraction. The simple interpretation of these findings is
that the 150000 X g sediment contains particles or aggregated enzyme and that bile
salts, whether endogenous or exogenous, will release the enzymes from these
complexes.
At present there are two theories to account for the nature of the high Mr
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enzymes in bile. One proposes that a low Mr enzyme is released into bile and forms
aggregates with biliary lipid and protein [1,4]. The other suggests that the aggregates
represent membrane fragments or small vesicles released by the hepatocyte or
pinched off from the tips of the microvilli [17-19]. Our findings do not exclude
either theory, nor do they exclude the possibility that both explanations might be
true. However, it does seem that complexes studied in vitro, using aqueous media in
which to separate and study the various forms, are very likely aggregates of the
enzymes with lipids and proteins of the native bile, since it is the aqueous environ¬
ment (i.e. without sufficient detergent action) that has caused the aggregation to
occur.
The relationship between the biliary and serum enzymes remains obscure, as does
the mechanism whereby serum enzyme activity rises in patients with cholestasis.
Each of the enzymes is present in both serum and bile in both high and low Mx
forms, the proportions of which vary depending on whether liver disease is present
and, if present, on its nature [1-6,20]. The low Mr forms in serum in general
resemble the enzymes which result from papain digestion of the enzymes in bile
(Peak 4) and seem unlikely to originate from bile, which contains the Peak 3 enzyme
but very little of the Peak 4 enzyme. We know too little about the high Mr forms of
the enzymes present in bile and serum to speculate on their relationship to one
another. One possibility, which fits most of the observed data, would be that in
cholestasis there is induction of the membrane-bound enzymes in the liver and these
are subsequently leached off the canalicular membrane by bile salts. An increased
amount of biliary enzyme (Peak 3) might then find its way into plasma, where it
would aggregate with lipids and possibly other proteins to yield a high MT form.
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Summary
Using gel chromatography on Sephacryl S300 we have separated serum y-gluta¬
myltransferase into three fractions with estimated relative molecular masses of (a)
greater than 1000000, (b) 250000-500000 and (c) about 120000. Similarly, serum
leucine aminopeptidase has been separated into three fractions. We have studied,
particularly, the y-glutamyltransferase fraction of intermediate relative molecular
mass (250000-500000) in serum from patients with a number of liver diseases. We
have shown, both by polyanion and immuno-precipitation, that it consists signifi¬
cantly of a complex between y-glutamyltransferase and high density lipoprotein. The
physical properties of this fraction, namely its mass and charge, can be altered by
incubating serum with either bile or bile salts.
Introduction
Several studies have reported the presence of multiple forms of y-gluta¬
myltransferase (yGT, EC 2.3.2.2) in the sera of patients with liver disease [1-5]. Gel
chromatography studies have confirmed the presence of three fractions of high,
intermediate and low relative molecular mass (A/r) [6-10]. Two of these forms have
been fairly well characterised. The form of high relative Mr is thought to consist of
complexes in which hydrophobic yGT is associated with lipids, lipoprotein-X and
other membrane enzymes, or membrane fragments [8,10-14], In contrast, the low Mr
form is hydrophilic and is thought to be produced by the action of neutral
* To whom correspondence should be addressed.
0009-8981/84/S03.00 © 1984 Elsevier Science Publishers B.V.
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endopeptidases upon the hydrophobic enzyme either before or after its release into
the circulation from the hepatobiliary tract. Only one detailed study, however,
appears to have been made on the intermediate MT forms with respect to their nature
or physical properties [10]. This investigation suggested that such intermediate Mr
forms consisted of complexes between yGT and high density lipoprotein (HDL).
The present study was undertaken to characterise the y-glutamyltransferases,
particularly those of intermediate Mr, and to compare their properties in patients
with a wide variety of liver diseases. The objective was two-fold. Firstly, to ascertain
whether any physical differences between the intermediate Mr forms in different
patients might suggest the basis for a useful diagnostic test of liver disease. Secondly,
to gain further insight as to possible mechanisms for the elevation of serum yGT
activity in liver disease.
Two other enzymes present on the hepatocyte plasma membrane, aminopeptidase
(microsomal) (leucine aminopeptidase, LAP, EC 3.4.11.2) and alkaline phosphatase
(ALP, EC 3.1.3.1) were included in the study, where we considered appropriate to
see if our findings were applicable on a wider basis to other membrane enzymes.
Materials and methods
Sera were obtained from 100 patients with liver disease and 10 apparently healthy
individuals in whom there was no clinical or biochemical evidence of hepatic
damage. The categories of liver disease included extrahepatic biliary obstruction,
alcoholic cirrhosis, primary biliary cirrhosis, chronic active hepatitis, haemochroma-
tosis, liver metastases and that due to anticonvulsant therapy.
Chemicals
Dextran sulphate (Mr = 15 000) was obtained from Sochibo, Boulogne, France;
antisera to human apolipoprotein A and apolipoprotein B from Hoechst, Hounslow,
Middlesex, UK; Sephacryl S300 from Pharmacia, Uppsala, Sweden; y-glutamyl-p-
nitroanilide and />-nitrophenyl phosphate from Boehringer, Lewes, Sussex, UK;
y-L-glutamyl-a-naphthylamide and L-leucyl-/?-naphthylamide from Koch Light, Col-
nbrook, Bucks, UK; sodium deoxycholate, sodium glycochenodeoxycholate. papain
(twice crystallised), Fast Blue B, L-leucine-p-nitroanilide, from Sigma Chemical
Company, Poole, Dorset, UK; acrylamide and bis-acrylamide from Eastman Kodak,
Liverpool, UK. All other chemicals were obtained from BDH, Poole, Dorset, UK,
and were of analytical grade.
Gel chromatography
This was performed on a 950 X 26 mm column of Sephacryl S300 equilibrated
with 20 mmol/1 Tris/HCl buffer (pH 8.0), containing 50 mmol/1 sodium chloride.
3.5-ml fractions were collected with an upward flow rate of 28 ml/h. The column
was calibrated for Mr determinations using a mixture of proteins of known Mr.
Polyanion precipitation
This was performed by the method of Burstein et al [15] using manganese
chloride-dextran sulphate to precipitate low density lipoprotein (LDL) and very low
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density lipoprotein (VLDL). After centrifugation, HDL was then precipitated by
increasing the concentrations of MnCl2-dextran sulphate. The lipoprotein precipi¬
tates were washed, then redissolved in a volume of 0.9% saline equal to the original
volume of serum used and kept for further study.
Incubation of serum with lipoprotein antisera
10 jitl serum was incubated with 50 jul antiserum to apolipoprotein A or apoli-
poprotein B or with 50 ;ul saline as a control, overnight at room temperature. 1 ml of
ammonium sulphate (270 g/1) was then added and the mixture centrifuged at
11000 X g for 10 min. yGT activity was determined on the supernatant.
For electrophoretic studies, 25 jul serum was incubated with 125 pi of antiserum
overnight at room temperature. 25 pi of 40% sucrose containing 0.1% bromophenol
blue was added to label the albumin, and 150 pi of the mixture subjected to
electrophoresis.
General methods
7% polyacrylamide gel electrophoresis, polyacrylamide gradient gel electrophore¬
sis, measurement of bile salt concentrations, localisation of enzyme activities after
electrophoresis and measurement of enzyme activities were performed as previously
described [16-22]. Reference ranges for serum from healthy adults were 6-31 U/l




Papain digestion of serum had little effect upon yGT activity, but 34% of LAP
activity and 43% of ALP activity was destroyed following papain treatment.
Gel chromatography
To agree with our previous arbitrary nomenclature [9,18], and simplify the
description, we have numbered the peaks in order of their elution from the gel
column (Figs. 1, 2). Quantitative differences in the relative sizes of the peaks were
noted, but here we were concerned with their physical properties:
Peak 1: void volume for all enzymes.
Peak 2 (yGT), Peak 2 (LAP): major peak of intermediate Mr (Table I). For yGT,
Peak 2 could take two forms (see below). No corresponding peak was present for
ALP.
Peak 3 (yGT), Peak 3 (ALP): peaks of intermediate Mr present in the eluate only
when bile salts are present in the eluting buffer. It is probable that the enzymes are
present in bile in this form [18], See Table I for estimated Mr values.
Peak 4 (yGT), Peak 4 (LAP), Peak 4 (ALP): peaks of low Mx (Table I)
representing a small fraction of serum yGT but a major proportion of serum LAP
and ALP activity. The size of this peak (for yGT and LAP) was increased greatly in
sera that had previously been treated with papain.
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Fig. 1. Elution profiles of hepatocyte plasma membrane enzymes following gel chromatography on
Sephacryl S300 of serum from a patient with extrahepatic biliary obstruction. O O, yGT;
• •, LAP; ■ ■. ALP.
Gel chromatography performed in the absence of bile salts
After gel chromatography of normal sera and sera from patients with liver
disease, varying amounts of yGT and LAP eluted as Peaks 1, 2 and 4 (Table II).
ALP on the other hand only appeared to exhibit activity in Peaks 1 and 4. Recovery
of enzyme activity was always over 80%.
The elution profile of the second peak of yGT activity from most of the patients





Fig. 2. Gel chromatography on Sephacryl S300 of hepatocyte plasma membrane enzymes in serum from a
patient with alcoholic cirrhosis. O O, yGT; • •, LAP; ■ ■, ALP.
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TABLE I
Estimated molecular masses of the enzyme fractions obtained following gel chromatography
Fraction Estimated molecular mass
gel chromatography gradient electrophoresis
yGT LAP ALP yGT LAP ALP
Peak 2A 325 000-500000 - _ 300000-710000 — _
Peak 2B 258000-295000 - - 180000-220000 - -
Peak 2 - 400000-610000 - - * -
Peak 3 175 000 - 280000 135 000 - 260000
Peak 4 118000 190000 200000 98000 170000 180000
* The staining of this fraction appeared too faint and diffuse to make an accurate estimation of
molecular mass.
with extrahepatic biliary obstruction (Peak 2B (yGT)) differed from that of most of
the other patients and normal individuals (Peak 2A (yGT)) (Figs. 1, 2). Peak 2B
(yGT) eluted later than Peak 2A (yGT) and was therefore of lower apparent Mr
than Peak 2A (yGT). Of the 25 patients with extrahepatic biliary obstruction
studied, 20 exhibited Peak 2B (yGT) activity only, three Peak 2A (yGT) activity
only, one approximately equal amounts of both and one neither peak activity.
All possessed variable amounts of Peaks 1 and 4 (yGT). It was noted that in
some jaundiced samples from patients with other pathologies, a shoulder was
observed on Peak 2A (yGT) in the position of Peak 2B (yGT). Analogous results
were obtained for LAP (Figs. 1, 2) except that Peak 2 (LAP) did not vary so much in
its elution profile, and appeared to constitute a smaller proportion of total activity in
those patients with obstructive jaundice compared to the rest. In contrast to both
yGT and LAP, ALP showed no intermediate Mv peaks (Figs. 1, 2).
Gel chromatography in the presence of bile salts
The fractions containing Peaks 1 and 2 obtained from gel chromatography were
TABLE II
Distribution of hepatocyte plasma membrane enzymes obtained after gel chromatography
Fraction Percentage of total recovered activity
mean range
Peak 1 (yGT) 27.3 6-82
Peak 2 (yGT) 57.4 0-83
Peak 4 (yGT) 15.3 2-58
Peak 1 (LAP) 18.5 3-60
Peak 2 (LAP) 22.5 0-53
Peak 4 (LAP) 59.0 27-91
Peak 1 (ALP) 14.0 2-54
Peak 4 (ALP) 86.0 46-98
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pooled, concentrated by ultrafiltration and rechromatographed in the presence of
either 12 mmol/1 glycochenodeoxycholate or 12 mmol/1 deoxycholate. Following
rechromatography, Peak 1 (yGT) and Peak 2 (yGT) disappeared, giving rise to Peak
3 (yGT). Peak 1 (ALP) similarly disappeared, giving rise to Peak 3 (ALP). No LAP
activity was recovered in the column eluate.
Papain-treated sera
Gel chromatography of papain-treated sera in the absence of bile salts resulted in
a decrease in yGT and LAP activity eluting as Peaks 1 and 2, together with an
increase in activity eluting as Peak 4. There was also a decrease in activity of Peak 1
(ALP), but no concomitant increase in activity associated with Peak 4.
Electrophoresis
Electrophoresis on 7% polyacrylamide gel showed two fairly distinct patterns of
yGT activity, according to patient group. In sera from patients with extrahepatic
biliary obstruction, two main bands of activity were seen, one at the origin (Band I
(yGT)), together with another of mobility 45-55% of albumin (Band IIB (yGT)
(Fig. 3)). Occasionally, smaller, minor zones of slower mobility were seen. The sera
from other groups of patients and the normal sera showed a smaller zone of activity
at the origin, with significant activity occurring in various zones (Bands IIA (yGT)
(Fig. 3)), with mobilities between 8 and 40% of that of albumin.
Minor zones were often present, corresponding to Band IIB (yGT) in abnormal
but not in normal sera. Sera from all patients showed a less intense zone of activity
(Band IV (yGT) (Fig. 3)), of mobility between 70 and 80% of that of albumin. This
zone was also present in normal sera and seemed to contribute a greater proportion
of total activity. Electrophoresis of concentrated pooled fractions corresponding to





Fig. 3. 1% polyacrylamide gel electrophoresis of yGT in sera from patients with liver disease. 1,
extrahepatic biliary obstruction; 2, blank; 3-7, alcoholic cirrhosis.
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Peak 2A (yGT) was heterogeneous, giving rise to several zones (Bands IIA (yGT)).
Peak 2B (yGT) on the other hand gave rise to an electrophoretically discrete band
(Band IIB (yGT)). Similarly, Band IV (yGT) was shown to have identical mobility
to concentrated pooled fractions corresponding to Peak 4 (yGT).
Analogous results were obtained for LAP. However, the bands of intermediate
mobility (between 5 and 35% of that of albumin) did not appear to display any
disease-specific distribution. The fraction corresponding to Peak 4 (LAP) obtained
from gel chromatography gave rise to two bands with mobility approximately 55 and
60% of that of albumin (Band IVA (LAP) and Band IVB (LAP)). Electrophoresis of
papain-treated sera yielded a single band of yGT activity with mobility identical to
that of Peak 4 (yGT). Similarly, a single band of LAP activity of equal mobility to
Band IVB (LAP) was obtained.
Polyacrylamide gradient gel electrophoresis
This confirmed the heterogeneity of Peak 2 for yGT (Table I).
Polyanion precipitation
Gel chromatography was performed on the redissolved lipoprotein fractions of
LDL and VLDL, and HDL. Between 40 and 75% of Peak 1 (yGT) activity
co-precipitated with the LDL and VLDL fraction, together with a much smaller
proportion of Peak 2A (yGT) (Fig. 4). Between 49 and 65% of Peak 2A (yGT) was
precipitated with the HDL fraction, whereas Peak 2B (yGT) did not co-precipitate
with any of the lipoprotein fractions.
These results with Peak 2A (yGT) provide circumstantial evidence that this yGT
PEAK 1 PEAK 2A PEAK 2B PEAK 4
(/GT) (/GT) (2GT) (rGT)
Fig. 4. Elution profile of yGT in serum and the lipoprotein fractions from a patient with alcoholic liver
disease before and after precipitation with polyanions. O O, whole serum; ■ ■. LDL,
VLDL; • •, HDL; □ □, supernatant after precipitation of LDL, VLDL and HDL.
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PEAK1 PEAK 2 PEAK A
(LAP) (LAP) (LAP)
ELUTION VOLUME (ml)
Fig. 5. Elution profile of LAP in serum from a patient with gallstones before and after precipitation of the
lipoprotein fractions with polyanions. O O, whole serum; ■ ■. LDL, VLDL; • •,
HDL; □ □, supernatant after precipitation of LDL, VLDL and HDL.
fraction is a part of HDL. Although it is possible that the polyanion precipitation
procedure coincidentally precipitates yGT protein, this was demonstrated to be
unlikely since: (1) polyanion precipitation of serum did not appreciably alter the
total recovered protein in the supernatant; and (2) the addition of polyanions to
Peak IV (yGT) diluted in serum (from which HDL had been removed, and using the
polyanion conditions suitable for HDL precipitation) did not precipitate any yGT.
Analogous results were obtained for LAP, with Peak 1 (LAP) co-precipitating
with LDL and VLDL, and Peak 2 (LAP) co-precipitating with HDL (Fig. 5). ALP
activity, however, only precipitated with the VLDL and LDL fractions.
Incubation with antisera
Sera from 69 patients were incubated with antiserum to apolipoprotein A; this




Fig. 6. Polyacrylamide slab gel electrophoresis of sera from patients with liver disease before and after
incubation with antiserum to apolipoprotein A. 1, 3, 5, 7, 9, before; 2, 4, 6, 8, 10, after; 11, antiserum to
apolipoprotein A.
1 2 3 4 5 6 7 8 9 10 11
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caused precipitation of a variable amount of yGT activity (mean 59.9%, range
8-92%). On the other hand, no yGT was precipitated either after incubation of the
sera with antiserum to apolipoprotein B, or when Peak 4 (yGT) was incubated with
antiserum to apolipoprotein A.
Electrophoresis of the mixtures of serum with apolipoprotein A antiserum re¬
sulted in a marked decrease in staining intensity of the bands of intermediate
mobility (Fig. 6). Inspection of the gels also suggested an increase in intensity of
staining at the origin for both yGT and LAP.
Immunoelectrophoresis of the LDL and VLDL fraction obtained by polyanion
precipitation, and of HDL-free serum against antiserum to apolipoprotein A did not
reveal the presence of any precipitin arcs when stained for protein. On the other
hand, immunoelectrophoresis of the HDL fraction against antiserum to
apolipoprotein A gave rise to a single precipitin arc in the a,-globulin region.
Incubation of sera with bile
Sera from patients that possessed Peak 2A (yGT) activity were incubated with an
equal volume of hepatic bile for 3h at 37 °C. The mixture was then subjected to gel
chromatography or electrophoresis.
Gel chromatography of the mixture revealed that the Peak 2A (yGT) activity
appeared to change to Peak 2B (yGT) activity (Fig. 7). Occasionally this change was
associated with an apparent increase in total activity recovered from the sera/bile
mixtures, possibly due to a matrix effect of the serum proteins on biliary yGT.
Electrophoresis of the mixture resulted in a marked decrease in intensity of Bands
IIA (yGT) and the appearance of a zone (Band IIC (yGT)) ahead of Band IIB
(yGT) (Fig. 8). Similarly, electrophoresis of bile-treated sera from patients with
obstructive jaundice possessing Band IIB activity resulted in the appearance of Band
IIC (yGT). Usually this was associated with a decrease in the intensity of staining of
Band IIB (yGT).
Fig. 7. Elution profile of yGT in the serum of a patient with alcoholic cirrhosis before and after






band IIC (7 GT)
band IY (tGT)
+
Fig. 8. Polyacrylamide slab gel electrophoresis of sera from patients with liver disease before and after
incubation with dialysed or undialysed hepatic bile. 1, undialysed hepatic bile; 2, dialysed hepatic bile; 3,
6, 9, sera + saline; 4, 7, 10, sera + undialysed bile; 5, 8, 11, sera + dialysed bile.
Incubation of the various bile-sera mixtures with antiserum to apolipoprotein A,
followed by electrophoresis, resulted in a decrease in intensity of staining of Band
IIC (yGT) as compared to mixtures that had been incubated with a saline control.
The ability of bile to effect these changes on Peak 2A (yGT) and Bands IIA
(yGT) and IIB (yGT) was removed by prior dialysis of the bile against 20 mmol/1
Tris/HCl buffer (pH 8.0) (Fig. 8).
Incubation of sera with bile salts
Patients' sera were incubated with an equal volume of glycochenodeoxycholate at
concentrations ranging from 10 /xmol/1 to 20 mmol/1 for 3 h at 37 °C. Electrophore¬
sis of the mixtures in either 1% polyacrylamide or 4-30% polyacrylamide gradient
gels showed that incubation with glycochenodeoxycholate at a concentration greater
than, or equal to 6 mmol/1 resulted in a decrease in intensity of Bands IIA (yGT)
and IIB (yGT). This phenomenon appeared to be independent of the initial
concentration of total conjugated chenodeoxycholate in the sera studied. For the
patients with extrahepatic biliary obstruction this was: mean 64 fxmol/1; range
9-229 jumol/1. For the others the mean was 12 fimol/1; range 0-113 jumol/1.
A sample of serum from an alcoholic patient containing Peak 2A (yGT) activity
was incubated with an equal volume of 20 mmol/1 glycochenodeoxycholate for 3 h
at 37 °C. Gel chromatography of the mixture revealed a shift in the elution profile of
Peak 2A (yGT) to that approximating to Peak 2B (yGT). No change in the elution
profile of Peak 1 (yGT) was observed.
Effect of dialysis and freezing and thawing
Dialysis against 20 mmol/1 Tris-HCl (pH 8.0), or freezing to — 60 °C, followed
by thawing at 37 °C, had no effect either upon the elution patterns of the enzymes
from the Sephacryl column or on their electrophoretic mobility.
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Studies on Peak 3 (yGT)
Gel Chromatography was performed on a patient's serum containing Peaks 2A
(yGT) and 2B (yGT), in the presence of 12 mmol/1 deoxycholate and the Peak 3
(yGT) obtained was pooled, concentrated and dialysed against 20 mmol/1 Tris/HCl
(pH 8.0). Peaks 2A (yGT) and 2B (yGT) were also obtained by performing gel
chromatography in the absence of bile salts and a single concentrated pool obtained.
The original serum, and each of the two concentrated pools (Peak 3 (yGT)), and
Peaks 2A (yGT) and 2B (yGT) were then incubated overnight at room temperature
with an equal volume of antiserum to apolipoprotein A and saline as a control. The
mixtures were then subjected to electrophoresis and stained for yGT activity. A
decrease, compared to a saline control, in enzyme staining in the areas correspond¬
ing to Bands IIA (yGT) and IIB (yGT) was observed in the original serum and the
Peaks 2A (yGT) and 2B (yGT) pool after incubation with antiserum. No such
decrease in intensity of staining was observed in the sample representing Peak 3
(yGT).
The two pools representing the combined Peaks 2A (yGT) and 2B (yGT) and
Peak 3 (yGT) were then incubated overnight at room temperature with an equal
volume of a normal serum prior to incubation with antiserum, and subjected to
electrophoresis. On staining for yGT activity, a decrease in staining intensity of the
zones of intermediate mobility was observed in all of the incubations with antiserum
as compared to a saline control.
Discussion
Our present study confirms previous reports [6-11,23] that yGT is present in
normal sera and in sera from patients with liver disease in high, intermediate and
low Mt forms. We have also shown that another hepatocyte plasma membrane
enzyme, LAP, is present in high, intermediate and low Mr forms, unlike ALP which
does not possess the intermediate Mx form.
The high Mr forms of all three enzymes co-precipitated with VLDL and LDL
after treatment with polyanions. This is consistent with previous reports that they
may consist of complexes of the enzymes with lipoproteins or lipoprotein-X
[8,10,12,24,25].
In contrast, varying amounts of the intermediate Mr enzymes with the notable
exception of Peak 2B (yGT), co-precipitated with HDL, confirming the findings of
Huseby [10]. On the other hand, all of the intermediate Mx enzymes including Peak
2B (yGT), were shown to bind to antiserum to apolipoprotein A but not to
antiserum to apolipoprotein B. Taken together, these findings strongly suggest that
the intermediate Mr forms of both yGT and LAP consist of complexes of the
enzymes with HDL. Their estimated molecular mass (Table I) is consistent with the
attachment of a single molecule of yGT or LAP onto an HDL particle whose
molecular mass may range from 180000 to 350000 [10]. However, the wide range of
molecular mass, particularly in Peak 2A (yGT), does not preclude the attachment of
more than one enzyme molecule per HDL particle. Up to 30% of the intermediate
Mv enzymes also co-precipitated with LDL and VLDL (Figs. 4, 5). This suggests
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either that the presence of the intermediate Mr enzymes on the HDL complexes may
have altered the behaviour of some of the complexes with polyanions or that the
enzymes may have been associated with LDL or VLDL. The latter possibility is
rendered unlikely by the fact that these intermediate Mr enzymes were not precipi¬
tated by antiserum to apolipoprotein B. The reason for Peak 2B (yGT) not
precipitating with polyanions is unclear to us. It is possible, although we have no
evidence of this, that the presence of high concentrations of bile salts in the serum of
these patients may have altered the precipitation characteristics of these particles.
The mean bile salt concentration in the serum of patients with obstructive
jaundice were over five times those of the other groups. Consequently, in an attempt
to mimic the serum abnormalities found in obstructive jaundice, sera containing
Peak 2A (yGT) were incubated with hepatic bile. After incubation Peak 2A (yGT)
was converted to a peak with an elution pattern similar to that of Peak 2B (yGT).
The ability of bile to effect this change was (a) removed by prior dialysis of the bile,
and (b) reproduced by incubation with glycochenodeoxycholate. These results
suggest that the conversion of Peak 2A (yGT) to Peak 2B (yGT) was caused by the
bile salts present in the bile. Electrophoresis of the bile/bile salt/sera mixtures
however, showed the presence of Band IIC (yGT), not previously detected in any
sera. This would suggest that factors, other than bile salt concentrations, are
involved in the formation of Peak 2B (yGT) in the sera of patients with obstructive
jaundice. This is supported by the fact that dialysis appeared to have no effect upon
Peak 2B (yGT) in terms of its Mr or total recovered activity.
When gel chromatography was performed in the presence of bile salts, the Peak 3
forms of the enzymes were obtained. These peaks are identical to those already
described in hepatic bile and sera [9,11,18,23,25], although the picture is incomplete
because bile salts inhibited serum LAP activity. Unlike the hydrophilic Peak 4
forms, observed in untreated sera, or obtained following treatment with papain, the
Peak 3 forms were hydrophobic in nature and readily re-aggregated if the bile salt's
were removed by dilution or dialysis.
The inability of antiserum to apolipoprotein A to bind Peak 3 (yGT) suggests
that the yGT-HDL complex had either been dispersed or radically altered in its
properties. In an attempt to reform the complex, Peak 3 (yGT) was incubated with
normal serum, after which the antiserum appeared able to bind to the yGT in the
serum-Peak 3 (yGT) mixture. These findings imply that the yGT-HDL interaction is
hydrophobic in nature and that it can form spontaneously in serum in vitro. The
complex also appears to have a stable physical configuration since freezing and
thawing had no noticeable effect.
The mechanism whereby serum yGT activity rises in patients with liver disease
remains obscure. The serum enzyme activity is elevated to varying extents in many
disease states. This elevation appears to be due to the presence of so many different
physico-chemical forms [1-10] that it is difficult to envisage a single unifying
hypothesis that would explain all of the observed elevations. What is probable is that
the Peak 3 (yGT) described here, and previously proposed [18] to be the major
component of yGT in bile (where there is a high concentration of bile salts), is in
some way involved. This molecule is hydrophobic in nature and readily re-aggregates
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in the absence of bile salts. Biliary obstruction, liver cell damage, alcohol excess or
drug therapy may cause induction of this enzyme form, which may be leached off
the plasma membrane by bile salts, and subsequently released into the circulation.
Once in the circulation, and consequently in an environment of lower bile salt
concentration, the enzyme would be free to re-aggregate with itself or to form
complexes with one or other of the lipoprotein fractions present in the plasma. The
lipoprotein fractions to which it complexes would depend upon the disease process
which is occurring. However, the factors which dictate the particular lipoprotein
fractions with which the enzyme associates remain unknown.
Finally, our finding that Peak 2B (yGT) is found in large amounts only in
patients suffering from extrahepatic obstructive jaundice suggests that measurement
of this fraction might be of clinical and diagnostic value.
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